<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by bert vorstman on Medium]]></title>
        <description><![CDATA[Stories by bert vorstman on Medium]]></description>
        <link>https://medium.com/@bvorstman?source=rss-cf8cbd15bcb6------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*lTQwf66aUrx9qbNlHfLXEA.jpeg</url>
            <title>Stories by bert vorstman on Medium</title>
            <link>https://medium.com/@bvorstman?source=rss-cf8cbd15bcb6------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 09:55:14 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@bvorstman/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[THE GREAT PROSTATE CANCER SCAM: When Doctors Betray And Harm Patients]]></title>
            <link>https://bvorstman.medium.com/the-great-prostate-cancer-scam-when-doctors-betray-and-harm-patients-45fcbee122bb?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/45fcbee122bb</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Tue, 03 Nov 2026 15:12:06 GMT</pubDate>
            <atom:updated>2026-11-03T15:12:06.686Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*FKJnft-xpILdqBh1" /></figure><p>Bert Vorstman MD, Ron Piana</p><p>The prostate cancer industry makes many bold claims about the benefits of PSA screening, cancer detection, and cancer treatments. But there are some very serious concerns about these claims. Many prostate cancers are simply outlived, yet countless men are unnecessarily treated. Treatments are often associated with potentially devastating, life-altering complications.</p><p>Cancer treatments commonly fail, cancers recur, and additional treatments are frequently required. Treatments are also commonly needed to fix complications caused by previous treatments, sometimes generating even more complications requiring further treatment. Wives and partners are also impacted because sexual intimacy is often destroyed in the process. Unsurprisingly, treatment regret is significant, while decades of prostate cancer screening and treatment have failed to demonstrate a clear overall-survival benefit.</p><p>Nevertheless, countless men continue to be steered into the prostate cancer screening, detection, and treatment money-making machine despite the lack of reproducible scientific evidence that these interventions save substantial numbers of lives.</p><h3>1. THE PROSTATE CANCER DECEPTION: ONE LABEL FOR VASTLY DIFFERENT DISEASES</h3><p>The belief that prostate cancer is one dangerous, potentially deadly disease is simply untrue. The fundamental problem is that the prostate cancer label lumps together cancers of vastly different biological aggressiveness — as though they are all equally dangerous. Many have little or no lethal potential and are simply outlived, while a minority are aggressive and potentially deadly.</p><ul><li>One label, vastly different cancers. Prostatic adenocarcinoma accounts for approximately 95–99% of diagnosed prostate cancers, yet these cancers vary enormously in biological aggressiveness. Many are slow-growing and unlikely to threaten life, while a minority are potentially deadly.</li><li>Prostate cancer is extraordinarily common in older men. Autopsy studies reveal unsuspected areas of prostate cancer in older men, at <a href="https://www.cancer.org/cancer/types/prostate-cancer/key-statistics.html">about 60%</a> in those over 65. Many lived normal lifespans without ever knowing these cancers existed.</li><li>Some cancers take 40 years or more to develop. Certain low-risk prostate cancers have cell-division times of approximately <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">479 ± 56 days</a>. This means that some may take 40 years or longer to reach 1 cm in size, meaning a cancer detected today may have existed for decades without causing harm.</li><li>Most men die with prostate cancer, not from it. Because prostate cancer commonly presents later in life, competing illnesses such as heart disease and stroke frequently determine survival. Many men simply outlive their prostate cancer.</li><li>Only a minority of cancers are highly aggressive. Approximately <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4508854/">10–15%</a> of prostate cancers are high-grade, potentially deadly cancers that account for a disproportionate share of the approximately <a href="https://www.cancer.org/cancer/types/prostate-cancer/key-statistics.html">35,000</a> annual U.S. prostate cancer deaths.</li></ul><p>The fundamental deception is treating prostate cancer as one uniformly dangerous disease when many cancers are simply outlived. Prostate cancer is not one disease, yet most if not all screening and treatment studies routinely commingle cancers of vastly different Gleason grades, tumor volumes, and biological aggressiveness as though they were identical — delivering fundamentally misleading conclusions and exaggerated claims of benefit that no amount of randomization, peer review, or statistical manipulation can scientifically overcome.</p><h3>2. THE PROSTATE EXAM DECEPTION: AN UNRELIABLE TEST THAT CANNOT DISTINGUISH CANCER FROM NO CANCER</h3><p>There’s a belief that the digital rectal examination (DRE), or prostate exam, is a reliable and useful screening test. But the facts show otherwise. The DRE is an unreliable screening tool that cannot reliably distinguish cancer from non-cancer, frequently misses aggressive cancers, and lacks reproducible evidence of a significant life-saving benefit.</p><ul><li>Only a small portion of the prostate can be examined. The examining finger reaches only the posterior surface of the prostate adjacent to the rectum, leaving much of the gland — including deep anterior regions — beyond examination. The procedure can also be uncomfortable or painful, particularly in men with hemorrhoids, anal fissures, or anal stenosis.</li><li>Small aggressive cancers frequently escape detection. Prostate cancers generally must become sufficiently large or anatomically accessible before producing palpable abnormalities. A normal examination cannot exclude clinically significant or potentially deadly cancer.</li><li>Most suspicious abnormalities are not cancer. Benign prostate enlargement, nodules, fibrosis, inflammation, and calcification can mimic cancer, generating false alarms, unnecessary anxiety, and further investigations.</li><li>The examination depends heavily on subjective judgment. Interpretation varies with the physician’s experience, tactile perception, and clinical judgment. Different examiners may reach different conclusions about the same prostate, and the DRE cannot reliably distinguish harmless cancers from aggressive ones.</li><li>No demonstrated significant life-saving benefit. The ultimate benchmark of a useful screening test is improved health and reduced mortality — not simply finding more abnormalities. Routine DRE screening has not demonstrated reproducible evidence of a significant reduction in prostate cancer deaths, yet suspicious findings can funnel men toward unnecessary, invasive prostate needle biopsies.</li></ul><p>The fundamental problem: The DRE cannot reliably detect the aggressive cancers that matter most, a normal examination cannot rule out cancer, and the test has no established significant life-saving benefit as a screening tool.</p><h3>3. THE PSA SCREENING DECEPTION: AN UNRELIABLE BLOOD TEST THAT CANNOT DISTINGUISH CANCER FROM NO CANCER</h3><p>There’s a belief that PSA (prostate-specific antigen) screening can reliably identify prostate cancer and save lives. But the facts reveal a deeply flawed screening test. PSA is an enzyme produced primarily by the prostate to liquefy semen — not a cancer-specific marker. Its levels cannot reliably distinguish benign prostate conditions from harmless cancers or potentially deadly cancers, yet millions of men are steered into further investigations and treatments based on this unreliable test.</p><ul><li>The misleading “prostate-specific” label. PSA is not specific for prostate cancer and can also be found in other bodily tissues and fluids, including female bodily fluids. The conventional PSA range of 0–4 ng/mL is an arbitrary threshold based largely on statistical convention and medical consensus rather than a definitive biological distinction between cancer and no cancer. An elevated PSA does not necessarily mean cancer, and a normal PSA does not exclude it — making any rigid dividing line between cancer and no cancer fundamentally unreliable.</li><li>False positives, false reassurance, and missed aggressive cancers. The PSA has about a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3183963/">75%</a> false positive rate. Some biologically aggressive cancers produce <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.29691">little or no PSA</a> and may escape detection, while microscopic cancer cells may already have <a href="https://www.sciencedirect.com/science/article/pii/S0304383521004985">disseminated</a> from high-grade cancers before the primary tumor becomes clinically detectable.</li><li>PSA levels are distorted by numerous unrelated factors. Benign prostate enlargement, inflammation, urinary infections, ejaculation, and recent prostate manipulation can elevate PSA, while obesity-related hemodilution and medications — including finasteride and dutasteride, thiazide diuretics, anti-inflammatory medications, metformin, and certain supplements may lower measured PSA without eliminating an existing cancer. When these medications are stopped, PSA may rise again — not necessarily because a new cancer appeared, but because an artificially suppressed laboratory value returned toward its untreated level. Also, the PSA level undergoes normal daily biological fluctuations that further complicate interpretation.</li><li>More sophisticated testing does not eliminate the fundamental problem. PSA density, PSA derivatives, PSA velocity, additional biomarkers, genomic panels, MRI, and newer diagnostic algorithms may improve risk assessment, but none can reliably identify every potentially deadly cancer or guarantee that screening will prevent metastatic disease. More accurate detection does not automatically translate into substantial life-saving benefits.</li><li>An unreliable test created an enormous healthcare industry. During the late 1980s and early 1990s, PSA evolved from a tool for monitoring prostate cancer into widespread population screening before convincing mortality evidence was available. This expansion helped create a multibillion-dollar machinery of repeated testing, biopsies, imaging, treatments, surveillance, and follow-up — despite persistent concerns about overdiagnosis, overtreatment, and the modest absolute mortality benefit demonstrated in subsequent trials.</li></ul><p>The fundamental problem: PSA fails to meet the criteria for being a useful cancer screening marker. PSA cannot reliably distinguish cancer from no cancer, harmless cancer from aggressive cancer, or identify every cancer that threatens life. PSA screening has not established a clear overall-survival benefit. Finding more prostate cancers is not the same as saving substantial numbers of lives.</p><h3>4. THE PROSTATE MRI DECEPTION: SOPHISTICATED IMAGING THAT CANNOT REVEAL THE WHOLE TRUTH</h3><p>There’s a belief that early prostate cancer detection using MRI saves lives. But the facts reveal significant detection limits, false positives, false negatives, and interpretation errors. Small, biologically aggressive cancers can remain invisible, while harmless abnormalities can be mistaken for cancer, funneling men toward unnecessary biopsies and treatments. A sophisticated MRI image does not necessarily reveal the biological truth about the prostate.</p><ul><li>Significant detection limits leave cancers invisible. Multiparametric MRI (mpMRI) has difficulty reliably identifying small cancers, particularly those under approximately 5 mm. Some anterior tumors and very small high-grade cancers remain MRI-invisible regardless of reader experience. Generally, cancers need to be about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7815233/">5 mm or larger</a> in order to be detected.</li><li>Slow-growing cancers may have existed for decades before detection. Some low-risk prostate cancers grow so sluggishly that they may have been present for 20–40 years before becoming detectable. Finding these cancers earlier does not necessarily mean preventing death, while small aggressive cancers may already have developed the ability to disseminate to the bone marrow before becoming visible.</li><li>False positives trigger unnecessary investigations. Benign prostate enlargement, inflammation, granulomatous prostatitis, scarring, and previous trauma can mimic cancer on MRI. Suspicious findings may lead to anxiety, invasive needle biopsies, overdiagnosis, and potentially unnecessary treatment.</li><li>PI-RADS formalizes subjective judgment — not certainty. Radiologists use the Prostate Imaging Reporting and Data System (PI-RADS), assigning scores from 1 to 5 to estimate the likelihood of clinically significant cancer. Interpretation remains dependent on image quality, equipment, technique, experience, and subjective judgment, producing meaningful variability between radiologists and institutions.</li><li>Multifocal cancers make MRI even less reliable as a complete assessment. Prostate cancers are multifocal in <a href="https://www.nature.com/articles/s41467-020-14657-7">80–90%</a> of cases, arising in two or more separate areas of the gland, with different sizes and Gleason grades. Different Gleason grades <a href="https://www.modernpathology.org/article/S0893-3952(22)04406-4/fulltext">may exist</a> within the same single cancer growth. Detecting one suspicious lesion does not exclude a smaller (5 mm or less) elsewhere in the prostate, and a negative MRI cannot guarantee the absence of potentially deadly disease.</li></ul><p>The fundamental problem: Prostate MRI cannot reliably detect every aggressive cancer, distinguish every harmless abnormality from malignancy, or reveal the complete biological truth inside the prostate. Growths less than 5 mm commonly go undetected. Its diagnostic limitations remain significant, and earlier MRI detection alone is not proof that substantial numbers of lives are saved.</p><h3>5. THE PROSTATE NEEDLE BIOPSY DECEPTION: SAMPLING A FRACTION OF THE GLAND AND CLAIMING TO KNOW THE WHOLE TRUTH</h3><p>There’s a belief that the prostate needle biopsy, whether random or MRI-targeted, transrectal or transperineal, reveals the biological truth about prostate cancer. But the facts show that this is simply untrue. Even sophisticated MRI/ultrasound fusion biopsies and in-bore MRI-guided biopsies remain subject to significant detection limits, massive sampling errors, false negatives, and the multifocal and multigrade nature of prostate cancer. The needle biopsy examines only tiny fragments of a large, biologically diverse gland, yet its findings are commonly treated as though they accurately define the grade, volume, distribution, and aggressiveness of the cancer throughout the entire prostate. As well, the biopsy itself also carries real risks, including anxiety, pain, bleeding, infection, occasionally life-threatening sepsis, urinary retention, and possible sexual difficulties. False-negative findings can provide misleading reassurance, while the detection of sluggish-growing cancers can funnel men toward overdiagnosis, unnecessary treatment, and potentially devastating complications.</p><ul><li>Detection limits mean aggressive cancers can be missed altogether. MRI-targeted biopsies depend upon a cancer first being visible and correctly interpreted on MRI. Cancers smaller than approximately 5 mm are particularly difficult to detect, while some small, biologically aggressive cancers remain MRI-invisible. If a cancer cannot be seen, it cannot be specifically targeted, and even a successfully targeted biopsy samples only fragments of the growth — not the entire lesion.</li><li>Massive sampling errors make the biopsy inherently unreliable. A standard 12-core prostate needle biopsy may sample only approximately <a href="https://www.medscape.com/viewarticle/945928#vp_2">0.1–0.6%</a> of the prostate by volume, depending upon needle size and prostate volume. Even doubling the number of cores from 12 to 24 leaves approximately 98% or more of the gland unexamined. Yet physicians frequently rely upon this microscopic sample to make potentially life-altering decisions about the entire prostate.</li><li>The multifocal nature of prostate cancer compounds the problem. More than 80–90% of prostate cancers are multifocal, meaning cancers arise in two or more separate areas of the prostate, often with vastly different sizes, Gleason grades, and biological aggressiveness. Detecting one low-grade cancer does not exclude a separate, smaller, potentially deadly high-grade cancer elsewhere in the gland that the biopsy simply missed.</li><li>The multigrade nature of individual cancers creates even more uncertainty. Even within the same cancer growth, different areas may contain different Gleason grades. A needle may pass through a lower-grade portion while missing the highest-grade component only millimeters away. Consequently, the reported Gleason score may underestimate the true grade of the sampled lesion, creating false reassurance and potentially inappropriate management.</li><li>What is called cancer progression or upgrading may simply be delayed detection of cancer that was already there. During active surveillance or following focal therapy, a repeat biopsy showing a higher Gleason grade is frequently interpreted as evidence of disease progression. But given the substantial detection limits, sampling errors, and multifocal and multigrade nature of prostate cancer, the higher-grade cancer may have existed all along and simply escaped the original biopsy. Many low-risk prostate cancers grow extraordinarily slowly, with some estimated to take 40 years or more to reach 1 cm in size. The biology of most low-risk prostate cancers does not support rapid progression. A newly detected higher-grade component does not necessarily mean that a previously low-grade cancer suddenly became aggressive.</li></ul><p>The fundamental deception is treating a needle biopsy that samples only about 0.1–0.6% of the prostate as though it reveals the biological truth about your cancer or the remaining 99% or more of the gland. It does not. Prostate cancer is typically multifocal, meaning two or more areas of cancer within the prostate, often of different sizes, multi-grade with various Gleason grades, and biological aggressiveness. Growths smaller than approximately 5 mm may escape MRI detection and therefore cannot be reliably targeted.</p><p>Furthermore, the Gleason score is a pathologist’s interpretation of the two most common microscopic patterns of cancer grades in a minute sample of prostate tissue, with the score representing the sum of those two grades. Clearly, cancers that were never detected, sampled or misinterpreted mean that your prostate cancer diagnosis does not necessarily reflect the biological truth about your entire prostate.</p><p>One possible explanation for multigrade cancers within a single growth is the phenomenon of field effects, or field cancerization, in which genetically or epigenetically altered, seemingly normal prostate tissue may give rise to multiple independent cancers. The collision or merging of adjacent, independently developing cancer cell lines of different Gleason grades within tissue affected by field effects may contribute to a single mixed-grade growth, although this explanation remains a hypothesis.</p><p>The bottom line is that a tiny biopsy sample cannot reveal the full biological complexity of multifocal, multigrade prostate cancer — and presenting its findings as the definitive biological truth about the entire gland is scientifically indefensible.</p><h3>6. THE PROSTATE PATHOLOGY DECEPTION: YOUR GLEASON SCORE DOES NOT REVEAL THE WHOLE BIOLOGICAL TRUTH</h3><p>There’s a belief that your prostate needle biopsy and pathology report represent the biological truth about everything going on inside your prostate. But the facts show that this is absolutely untrue. The pathologist examines only the tiny fragments of tissue selected by an already unreliable MRI and needle biopsy process, both associated with significant detection limits and sampling errors. Even perfect pathological interpretation cannot reveal cancers that were never sampled. In fact, there is a distinct possibility that your pathology report does not reflect the most aggressive cancer existing in your prostate.</p><ul><li>Detection limits mean the most aggressive cancer may never be sampled. Prostate cancers commonly arise in two or more separate areas of the gland, often with different sizes and degrees of aggressiveness. MRI has difficulty reliably detecting cancers smaller than approximately 5 mm, making these lesions difficult to target with a needle biopsy. Consequently, a small, potentially deadly cancer may remain undetected while a larger, less aggressive cancer is sampled and reported.</li><li>Gleason grading depends upon subjective judgment. Dr. Donald Gleason developed a grading system based upon five architectural patterns of prostate cancer cells, numbered 1 through 5, with higher patterns reflecting increasingly disorganized and aggressive disease. But different pathologists can interpret the same tissue differently, particularly when distinguishing Gleason Pattern 3 from Pattern 4. These disagreements can change a man’s Gleason score and Grade Group — and determine whether he is monitored, irradiated, hormonally treated, or surgically altered.</li><li>Benign tissue can mimic cancer, while cancer can be underestimated. Atrophy, adenosis, crowded benign glands, inflammation, and certain normal anatomical structures can resemble malignancy. Technical artifacts, tissue fragmentation, compression, poor orientation, and multiple biopsy cores placed in the same container can further compromise interpretation. These limitations may produce diagnostic uncertainty, overcalls, undercalls, or findings such as atypical small acinar proliferation (ASAP) and high-grade prostatic intraepithelial neoplasia (PIN).</li><li>Individual prostate cancers can contain several different Gleason grades. Even more problematic is the fact that a single prostate cancer growth may contain areas of varying biological aggressiveness. Because the needle biopsy samples only a fraction of that growth, it may pass through a lower-grade area while missing the most aggressive component only millimeters away. Your reported Gleason score may therefore underestimate the highest grade present in that particular cancer.</li><li>A pathology report cannot establish the biological truth about the entire prostate. A standard needle biopsy samples only approximately 0.1–0.6% of the gland, while prostate cancers are frequently multifocal and multigrade. Even an accurately interpreted pathology report describes only the tissue actually examined. It cannot guarantee that a more aggressive cancer was not missed, that the reported Gleason score represents the highest grade present, or that the cancer’s future biological behavior can be predicted with certainty.</li></ul><p>The fundamental deception is treating a pathology report based upon a few microscopic tissue fragments as though it reveals the complete biological truth about the entire prostate. It does not. Detection limits, massive sampling errors, multifocal and multigrade disease, and subjective Gleason grading mean that even a technically accurate pathology report may fail to identify the most aggressive cancer present. The entire screening and detection paradigm is therefore burdened by substantial uncertainty, yet its findings are routinely used to justify potentially life-altering treatments and provide assurances that the evidence cannot guarantee.</p><h3>7. THE GLEASON 6 DECEPTION: A PSEUDO-CANCER LABELED AS A DANGEROUS DISEASE</h3><p>There’s a belief that Gleason 6 is a true prostate cancer, but the facts raise serious questions about whether this extraordinarily common, low-risk prostate disease deserves the cancer label at all. Its classification was originally based upon low-power microscopic appearances rather than demonstrated lethal biological behavior.</p><p>More importantly, pure Gleason Pattern 3 within Gleason 3+3=6 behaves fundamentally differently from Pattern 4 and 5 cancers. The biological mechanisms responsible for cancerous behavior appear to be absent or inactive in pure Pattern 3 disease, raising the question of whether Gleason 6 should be regarded as a pseudo-cancer rather than a potentially deadly malignancy.</p><ul><li>A cancer label based upon microscopic appearances rather than demonstrated lethal behavior. Gleason 6 was classified as cancer based upon architectural abnormalities observed under low-power microscopy, including loss of the basal cell layer, subtle glandular changes, and sometimes perineural invasion. These microscopic features and biochemical changes can also occur in benign prostate tissue.</li><li>The biological mechanisms for aggressive cancerous behavior are largely inactive or absent. Pure Gleason Pattern 3 <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">differs fundamentally</a> from higher-grade Pattern 4 and 5 disease in the molecular pathways associated with aggressive growth, invasion, and metastasis. Although Gleason 6 has low-risk malignant microscopic features, it does not demonstrate the biological hallmarks associated with prostate cancer. This is the central argument for calling pure Gleason 6 a pseudo-cancer: it carries the cancer label but rarely, if ever, demonstrates the capacity to behave as cancer when rigorously confirmed as pure Pattern 3 disease.</li><li>No verified deaths attributable to rigorously confirmed pure Gleason 6 disease. Studies of carefully characterized pure Gleason 3+3=6 cancers have found no reproducible evidence of prostate cancer deaths. There are no convincingly documented deaths attributable to rigorously verified pure Gleason 6 disease without a higher-grade component, raising serious questions about the continued use of terminology that places it alongside potentially deadly cancers.</li><li>Apparent upgrading may simply reflect detection limits and sampling errors. Prostate cancers are commonly multifocal and multigrade, while MRI frequently misses lesions smaller than about 5 mm and needle biopsies examine only a tiny fraction of the gland. An individual cancer growth may also contain different Gleason grades. Consequently, when a repeat biopsy identifies Pattern 4 or higher-grade disease, this does not necessarily mean that Gleason Pattern 3 biologically transformed into a more aggressive cancer. The higher-grade component may have existed all along but escaped detection because of MRI limitations and needle-biopsy sampling errors.</li><li>The inappropriate cancer label generates unnecessary fear and treatment. Despite its extraordinarily indolent biological behavior, the Gleason 6 diagnosis continues to cause enormous anxiety, unnecessary fear, repeated PSA testing, MRI examinations, invasive needle biopsies, and, in some cases, unnecessary surgery or radiation. These treatments can produce potentially devastating complications, including urinary incontinence, erectile dysfunction, loss of sexual intimacy, and significant treatment regret.Sadly, these men are survivors of their treatment and not survivors of the Gleason 6 disease.</li></ul><p>The fundamental deception is labeling pure Gleason 6 as cancer while failing to adequately distinguish its biological behavior from genuinely aggressive prostate cancers. If the mechanisms required for lethal cancerous behavior are absent or inactive, if rigorously confirmed pure Gleason 6 has no convincingly demonstrated lethal potential, and if apparent upgrading can be explained by detection limits and sampling errors, why should men continue to be frightened by the same cancer label applied to potentially deadly disease? Especially when most prostate cancers are outlived. The failure to resolve this terminology problem continues to expose countless men to unnecessary fear, investigations, overtreatment, and life-altering complications.</p><h3>8. THE PROSTATE CANCER STAGING DECEPTION: A NEGATIVE SCAN DOES NOT MEAN YOUR CANCER HAS NOT SPREAD</h3><p>There’s a belief that prostate MRI and PSMA PET scans can accurately determine whether your prostate cancer is localized to the prostate or has already spread elsewhere in the body. But the facts show that this belief is unreliable. These sophisticated imaging studies are routinely used to determine whether cancer remains confined to the prostate, has invaded adjacent structures, or has disseminated. Yet both MRI and PSMA PET scans have significant physical detection limits, false positives, and false negatives. Consequently, a negative scan cannot establish that a cancer is truly localized or that microscopic dissemination has not already occurred.</p><ul><li>Prostate MRI has significant detection limits. Multiparametric MRI frequently struggles to identify cancers smaller than approximately 5 mm, while cancers that grow diffusely between normal prostate tissue rather than forming a distinct solid growth may also escape detection. A normal MRI cannot reliably exclude small, biologically aggressive cancers or microscopic extension beyond the prostate.</li><li>PSMA PET scans also have substantial detection limits. Standard PET scanners have a spatial resolution of approximately <a href="https://link.springer.com/article/10.1007/s00259-021-05501-1">4–5 mm</a>, making very small cancer deposits difficult to identify. Detection also depends upon the biological characteristics of the cancer and the PSA level. For example, when PSA is below 0.2 ng/mL following treatment, PSMA PET scans frequently fail to identify recurrent disease. False-negative and false-positive findings further undermine certainty, and some prostate cancers express little PSMA, making them especially difficult to detect.</li><li>Aggressive cancers may have already disseminated before becoming detectable. Even more concerning is the possibility that some high-grade prostate cancers may have already seeded disseminated cancer cells (DCCs) into the bone marrow while the primary growth in the prostate is 5 mm or smaller and undetectable on MRI. These microscopic cancer cells are also beyond the detection capabilities of conventional MRI and PSMA PET imaging.</li><li>Disseminated cancer cells may remain dormant for years or decades. Microscopic cancer cells that have escaped the prostate may remain dormant in the bone marrow for years or even decades before some eventually become active and develop into detectable metastatic disease. Consequently, removing or irradiating what appears to be a localized prostate cancer cannot guarantee that disseminated cancer cells were not already present, potentially creating a temporary semblance of cure.</li><li>Negative imaging does not prove localized disease or guarantee a cure. Although prostate MRI and PSMA PET scans are valuable modern staging tools, neither can identify every microscopic cancer deposit or establish with certainty that disease has not spread. Early detection of a prostate cancer does not necessarily mean early detection of its biological dissemination, and finding and treating the primary cancer cannot reverse metastatic events that may have already occurred.</li></ul><p>The fundamental deception is treating a negative MRI or PSMA PET scan as though it proves that prostate cancer is confined to the prostate. It does not. A cancer may appear localized simply because its microscopic spread remains below the detection limits of modern imaging. The absence of visible metastases is not proof of the absence of disseminated cancer cells, and early detection has not been shown to reliably exclude or prevent metastatic disease in every patient.</p><h3>9. THE PROSTATE CANCER TREATMENT DECEPTION: A SMORGASBORD OF TREATMENTS, BUT WHERE IS THE SUBSTANTIAL LIFE-SAVING BENEFIT?</h3><p>There’s a belief that having numerous prostate cancer treatment choices, whether whole-gland or focal therapy, allows doctors to guide patients toward the best treatment for their particular cancer. But the facts raise serious questions about this belief. The extraordinary variety of treatments for localized prostate cancer underscores the absence of one universally accepted treatment for every patient, while the continuing expansion of treatment options reflects, in part, the search for alternatives to the potentially devastating complications of open and robotic prostatectomy. Despite impressive technological advances, the fundamental scientific question remains: Where is the reproducible evidence that these treatments save substantial numbers of lives rather than simply destroy cancer tissue, lower PSA levels, or delay progression?</p><ul><li>A smorgasbord of prostate cancer treatments. Men are offered an extraordinary menu of whole-gland, focal, and other treatment options, including open radical prostatectomy, laparoscopic prostatectomy, robotic-assisted radical prostatectomy, external-beam radiation therapy, IMRT, IGRT, SBRT/CyberKnife, brachytherapy, proton-beam therapy, androgen deprivation therapy (ADT), high-intensity focused ultrasound (HIFU), cryotherapy, irreversible electroporation (NanoKnife®), focal laser ablation (FLA), transurethral ultrasound ablation (TULSA), vascular-targeted photodynamic therapy (VTP), and combinations of these approaches. Active surveillance and watchful waiting are also offered as alternatives to immediate treatment. When treatments fail or cancers recur, men may face yet another menu of salvage surgery, salvage radiation, cryotherapy, HIFU, ADT, and other interventions.</li><li>More treatment choices do not necessarily mean better outcomes. Many newer treatments have limited long-term comparative evidence demonstrating durable safety, meaningful clinical benefits, and substantial life-saving ability. Although treatments can destroy localized cancer, lower PSA levels, and delay progression, these outcomes should not automatically be interpreted as proof that the treatment prolongs life or prevents metastatic disease. Furthermore, the treatment recommended may depend heavily upon the specialist consulted: see a surgeon and surgery may be recommended; see a radiation oncologist and radiation may be recommended.</li><li>Treatments can become accepted practice before their full benefits and harms are established. Historically, many prostate cancer treatments began with the belief that destroying or removing the cancer should improve survival. They subsequently became accepted practice, standard practice, and eventually standard of care, without randomized evidence demonstrating a substantial overall-survival advantage for the particular technique. H.H. Young MD claimed early diagnosis and radical cure with his <a href="https://www.hopkinsmedicine.org/-/media/brady-urology-institute/documents/historical-research-papers/1905b.pdf">new surgical</a> technique and of its “simplicity, effectiveness and remarkably satisfactory functional results furnished.” In contrast, there was zero evidence for early diagnosis and no evidence for radical cure. Two patients died, and the other two were left with lifelong urinary incontinence after prolonged hospitalizations. Technological sophistication and widespread adoption are not substitutes for reproducible scientific evidence of meaningful patient benefit.</li><li>Standard of care does not automatically mean scientifically proven to save lives. The term <em>standard of care</em> describes the level of care reasonably expected of clinicians under prevailing professional and legal standards. It does not, by itself, establish that a treatment has been supported by rigorous, reproducible evidence demonstrating substantial life-saving benefits. A treatment can be commonly practiced, professionally endorsed, and highly profitable without having demonstrated that it substantially prolongs overall survival in every group of patients receiving it.</li><li>Robotic surgery is not minimally invasive in its biological consequences. Robotic prostatectomy is commonly marketed as minimally invasive because it uses smaller abdominal incisions. But the operation still removes the entire prostate and can damage the urinary and sexual mechanisms, producing potentially life-altering complications. After a low level <a href="https://wayback.archive-it.org/7993/20170404123010/https:/www.fda.gov/ohrms/dockets/ac/99/transcpt/3523t1.pdf">clinical study</a> in Mexico, the robotic device was FDA approved for use in gallbladder surgery in 1999 despite the robotic device failing to demonstrate clear benefits for cholecystectomy. Robotic systems for radical prostate cancer surgery entered clinical practice in 2000 through medical-device regulatory pathways, including FDA 510(k) <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K011002">clearances</a> for applicable devices, rather than trials delivering reproducible evidence that robotic prostatectomy was safe, effective and saved significant numbers of lives. Smaller incisions and sophisticated robotic technology do not make removal of an entire organ a minor procedure, nor do they establish superior cancer survival.</li></ul><p>The fundamental deception is presenting an ever-expanding smorgasbord of prostate cancer treatments as though more choices, more sophisticated technology, and the label “standard of care” automatically translate into more lives saved. They do not. Some treatments have implied benefits in poorly designed studies that fail to compare like with like, but reproducible substantial overall-survival advantages for prostate cancer treatments remain unproven. Destroying cancer, lowering PSA, or achieving local tumor control is not the same as proving that a treatment saves substantial numbers of lives — particularly when the treatment itself can produce devastating complications and generate the need for even more treatment.</p><h3>10. THE PROSTATE CANCER TREATMENT DECEPTION: A TROVE OF POTENTIALLY DEVASTATING, LIFE-ALTERING COMPLICATIONS</h3><p>There’s a belief that prostate cancer treatments are safe and effective, but the facts reveal a troubling reality. Prostate cancer treatments, whether whole-gland or focal therapy, are associated with an extraordinary range of potentially devastating, life-altering complications involving urinary, sexual, hormonal, cardiovascular, metabolic, and psychological functions. Many men experience more than one complication, and treatments intended to fix complications caused by previous treatments can generate even more complications requiring further treatment. For many men, the initial prostate cancer treatment is not the end of their treatment journey — it is only the beginning.</p><ul><li>Treatments commonly generate more treatments — and even more complications. Initial treatments may fail, cancers recur, and men may require salvage radiation, hormonal therapy, salvage surgery, artificial urinary sphincters, penile prostheses, urethral reconstruction, medications, rehabilitation, and repeated procedures to manage complications caused by previous interventions. Each additional treatment carries its own risks. When treatment failure generates more treatment, and complications generate further complications, the patient bears the consequences.</li><li>ADT adds an extraordinary burden of potentially lifelong complications. Approximately 50% of prostate cancer patients may receive androgen deprivation therapy (ADT) or hormonal therapy during their disease course, depending on the population studied. Testosterone suppression is one of the most physiologically disruptive cancer treatments, affecting virtually every organ system. Complications include loss of libido, erectile dysfunction, genital shrinkage, hot flashes, night sweats, breast enlargement, weight gain, muscle wasting, osteoporosis, fractures, diabetes, adverse lipid changes, fatigue, cognitive difficulties, depression, anemia, and increased cardiovascular risk in susceptible men. Although ADT can extend survival in selected patients with metastatic disease, it is not curative because cancer cells that are insensitive to testosterone suppression can survive, multiply, and eventually produce treatment-resistant metastatic disease.</li><li>Urinary and sexual complications can devastate patients and their partners. Stress urinary incontinence, urge incontinence, bladder-neck contractures, urethral narrowing, anastomotic strictures, urinary leakage, and urinomas can follow prostate cancer treatments. Sexual complications include erectile dysfunction, loss of ejaculation, altered orgasm, penile shortening, corporal fibrosis, penile curvature, and diminished sexual function. Even meticulous nerve preservation cannot guarantee normal erections or urinary control. Wives and partners are also impacted because sexual intimacy is often profoundly altered or destroyed in the process.</li><li>Robotic surgery adds another list of potential complications without eliminating those of open surgery. Although robotic prostatectomy generally reduces blood loss, transfusion requirements, and hospital stays, it does not eliminate urinary incontinence, erectile dysfunction, strictures, or other major complications. Robotic surgery also introduces risks associated with trocar-related vascular and bowel injuries, electrical current arcing, rare gas embolism, nerve and muscle compression, and eye injuries from prolonged surgical positioning. Furthermore,surgery whether open or robotic is associated with <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">positive surgical margins</a> (persistent cancer) occur in approximately 11–48% of patients, while <a href="https://www.nature.com/articles/s41391-023-00712-z">biochemical recurrence</a> or rising PSA (recurrent cancer) rates may reach 20–50% within 10 years of any treatment. These findings can lead to additional salvage treatments and further complications.</li><li>Decades of surgical refinements have not eliminated complications, treatment regret, or financial burdens. Physicians recognized the severity of these complications and developed numerous operative modifications to reduce hemorrhage, urinary leakage, and erectile dysfunction. Yet complications persisted, contributing to an entire prosthetic industry producing artificial urinary sphincters and penile implants, along with urinary and sexual rehabilitation programs and shared decision-making tools intended to manage patient expectations. Treatment <a href="https://www.sciencedirect.com/science/article/abs/pii/S2588931123000378">regret</a> has been reported in approximately 20% of men in some studies. Repeated medical appointments, imaging, PSA monitoring, medications, prosthetic devices, revision procedures, lost productivity, anxiety, relationship difficulties, and sometimes PTSD-like symptoms can impose enormous emotional and financial burdens for years.</li></ul><p>The fundamental deception is presenting prostate cancer treatments as safe and effective while minimizing the extraordinary burden of complications, treatment failures, cancer persistence and recurrence, and additional treatments needed to fix the damage caused by previous interventions. Removing the prostate, destroying cancer tissue, or lowering PSA does not automatically establish that a particular treatment substantially prolongs life.</p><p>When treatment failure generates more treatment, complications generate more complications, and every additional intervention generates further healthcare spending, the medical industry continues to benefit financially while patients and their families bear the physical, emotional, and economic consequences. The ultimate measure of successful prostate cancer treatment should be longer life and better health — not simply more treatments, more technology, and more medical procedures.</p><h3>11. THE PSA SCREENING DECEPTION: MORE CANCERS DETECTED, BUT WHERE ARE THE LIVES SAVED?</h3><p>There’s a belief that PSA screening saves significant numbers of lives, but the facts raise serious questions about this claim. Despite more than three decades of widespread use, major randomized trials and long-term follow-up studies have failed to consistently demonstrate that population-wide PSA screening substantially improves overall survival. Although some studies report small reductions in prostate cancer deaths, these assumed benefits must be weighed against poor quality study design, the enormous burden of false positives, overdiagnosis, unnecessary treatments, and potentially devastating complications.</p><ul><li>Decades of screening have failed to demonstrate substantial overall-survival benefits. Major studies, including the European Randomized Study of Screening for Prostate Cancer <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2503223">(ERSPC)</a>, the PLCO Cancer <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">Screening</a> Trial, the <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9275849/">Göteborg</a> Trial, Cochrane systematic <a href="https://www.cochrane.org/evidence/CD004720_blood-test-psa-effective-screening-method-prostate-cancer">reviews</a>, and <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/">analyses</a> published in JAMA, have produced varying results. Some demonstrate modest reductions in prostate cancer-specific mortality, but none has established a substantial overall-survival advantage from population-wide PSA screening. Finding more prostate cancers does not necessarily mean saving more lives.</li><li>PSA is an unreliable marker for prostate cancer. It is not cancer-specific and cannot reliably distinguish cancer from benign conditions, indolent cancers from aggressive ones, or identify every potentially life-threatening cancer. Approximately 70–75% of men biopsied following an elevated PSA may have no cancer detected, depending upon the screening threshold and population. Meanwhile, some biologically aggressive, high-grade cancers produce little or no PSA and can escape detection altogether. An elevated PSA does not necessarily mean cancer, and a normal PSA does not exclude it.</li><li>False positives, overdiagnosis, and overtreatment expose countless men to unnecessary harm. Because PSA cannot reliably distinguish harmless cancers from potentially deadly cancers, screening detects large numbers of slow-growing cancers that men would otherwise simply outlive. The resulting anxiety, repeated PSA testing, MRI examinations, invasive needle biopsies, unnecessary surgery, radiation, and hormonal treatments can produce potentially devastating, life-altering complications. The assumption that earlier cancer detection automatically means cure is scientifically unjustified.</li><li>Prostate cancer studies can create misleading impressions of benefit. Urologists are well aware that prostate cancer is not one disease, yet they continue to repeat one of the most elementary mistakes in scientific study design: failing to compare like with like. Instead, studies routinely combine patients with vastly different Gleason grades, scores, tumor volumes, and biological aggressiveness — as though slow-growing cancers that men would simply outlive were comparable to the minority of potentially deadly cancers. This commingling of biologically different diseases can distort study results and create a misleading semblance of benefit from screening or treatment. Randomization, peer review, and statistical significance do not automatically overcome these shortcomings or establish that substantial numbers of lives have been saved. Bad study design risks delivering misleading conclusions, false hope, and false promises — not reproducible scientific proof of meaningful life-saving benefits.</li><li>More sophisticated screening and AI-generated detection improvements are meaningless without meaningful life-saving benefits. PSA derivatives, additional biomarkers, MRI, genomic testing, and AI-assisted diagnostic technologies may improve cancer detection and risk assessment. But all the pontification about earlier screening, more accurate detection, and increasingly sophisticated technology misses the fundamental issue: Unless screening leads to treatments that reproducibly prevent substantial numbers of deaths while minimizing harm, detecting more cancers is not proof of better healthcare.</li></ul><p>The fundamental deception is promoting PSA screening as a major life-saving intervention when decades of research have demonstrated questionable reductions in prostate cancer-specific mortality without a clearly established overall-survival benefit. Meanwhile, false alarms, overdiagnosis, unnecessary biopsies, overtreatment, and potentially devastating complications continue to impose substantial burdens upon countless men.</p><p>The ultimate benchmark of a worthwhile screening program is not how many cancers are detected, how early they are found, or how sophisticated the technology becomes. It is whether substantial numbers of lives are saved without exposing even greater numbers of men to unnecessary harm. Finding more prostate cancers is not the same as saving more lives.</p><h3>12. THE PROSTATE CANCER TREATMENT DECEPTION: DECADES OF TREATMENTS, BUT WHERE ARE THE LIVES SAVED?</h3><p>There’s a belief that prostate cancer treatments save significant numbers of lives, but the facts raise serious questions about this claim. Despite decades of increasingly sophisticated surgery, radiation, hormonal treatments, and focal therapies, reproducible evidence demonstrating substantial overall-survival benefits for many treatments of localized prostate cancer remains limited. Major studies extending approximately <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15</a>, and <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20</a> years have shown that treated and untreated patients had similar survival rates. If treatments cannot demonstrate substantial life-saving benefits, then no amount of screening, earlier detection, sophisticated MRI, biomarkers, or AI-generated diagnostic improvements can automatically make the entire screening and treatment enterprise worthwhile.</p><ul><li>Long-term studies challenge the assumption that treatment saves substantial numbers of lives. Major trials, including PIVOT, ProtecT, and long-term Scandinavian studies, have questioned the magnitude of survival benefits from treating localized prostate cancer. At approximately 15 years, the ProtecT trial found similar prostate cancer-specific survival among men assigned to surgery, radiation, or active monitoring, despite differences in metastases and disease progression. Other studies have demonstrated benefits in selected patients, but the fundamental question remains whether aggressive treatment provides enough additional survival benefit to justify its potentially devastating complications. Typically, these studies can’t be believed as they are corrupted by the inclusion of various Gleason grades and tumor volumes in the study group and not comparing like with like.</li><li>Treatments became standard practice without uniform evidence of substantial life-saving ability. Open radical prostatectomy, robotic prostatectomy, radiation therapy, proton therapy, brachytherapy, ADT combinations, HIFU, cryotherapy, NanoKnife, TULSA, and other focal treatments have entered clinical practice with widely varying levels of long-term scientific evidence. Many began with the belief that removing or destroying cancer should save lives, then became accepted practice, standard practice and eventually standard of care. But standard of care does not automatically mean that every treatment has demonstrated reproducible evidence of safety, meaningful benefit, and substantial life-saving ability.</li><li>Many treatments are directed toward cancers that men would simply outlive. Most prostate cancers exhibit remarkably slow biological behavior, and some low-risk cancers may take 40 years or more to reach approximately 1 cm in size. Yet men undergo irreversible surgery, radiation, and other treatments for cancers that may never have threatened their lives. Because prostate cancer commonly presents later in life, competing illnesses such as heart disease and other age-related conditions frequently determine survival. Treating a cancer that would never have caused harm is not a life saved — it is potentially unnecessary treatment with potentially life-altering consequences.</li><li>Treatments cannot guarantee elimination of aggressive disease that has already spread. MRI and PSMA PET scans cannot reliably exclude microscopic cancer dissemination, while some aggressive cancers may have acquired metastatic potential before the primary tumor becomes clinically detectable. Removing or irradiating the prostate cannot necessarily eliminate cancer cells that have already migrated into the bone marrow or elsewhere. Furthermore, residual cancer and rising PSA remain significant concerns, with some patients requiring salvage radiation, salvage surgery or ADT. About <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7242115/">45–50%</a> of prostate cancer patients will eventually receive ADT, despite substantial metabolic, cardiovascular, skeletal, cognitive, sexual, and quality-of-life consequences. Destroying the visible primary cancer does not guarantee that the patient has been cured or that metastatic disease has been prevented.</li><li>Failure to compare like with like can create misleading impressions of treatment benefit. Prostate cancer studies frequently include patients with vastly different Gleason grades, scores, tumor volumes, and biological aggressiveness. Sound study design demands comparing like with like. The inclusion of large numbers of various Gleason grades and slow-growing cancers can distort interpretation and exaggerate apparent benefits. Studies must demonstrate meaningful improvements in survival and quality of life — not merely lower PSA levels, fewer positive biopsies, or delayed progression. Poorly designed studies founded upon questionable assumptions can produce misleading conclusions that are subsequently repeated as established medical facts.</li></ul><p>The fundamental deception is promoting prostate cancer treatments as reliably life-saving while failing to adequately distinguish the many cancers that men simply outlive from the minority of aggressive cancers that threaten life. Long-term evidence does not demonstrate significant reductions in metastasis or prostate cancer deaths between treated and untreated patients.</p><p>All the pontification about PSA screening, early detection, sophisticated imaging, genomic testing, and AI-generated improvements becomes meaningless if the cancers being detected would never have caused harm or if the treatments offered cannot demonstrate meaningful life-saving benefits. The ultimate benchmark is not how many cancers are found, how many prostates are removed, or how many PSA levels decline. It is how many men actually live longer, healthier lives because of these interventions — and how many suffer unnecessary, potentially devastating complications in the process.</p><h3>13. THE ACTIVE SURVEILLANCE DECEPTION: MONITORING CANCER WITH UNRELIABLE TESTS AND FALSE ASSURANCES</h3><p>There’s a belief that active surveillance is safe and reliable, but the facts reveal significant limitations and uncertainties. Active surveillance arose because physicians were fully aware of the potentially devastating, life-altering complications associated with prostate cancer treatments and recognized that many prostate cancers grow extraordinarily slowly and are simply outlived. Rather than subject every man to surgery or radiation, a monitoring option was developed using repeated PSA testing, prostate MRI, and needle biopsies.</p><p>But active surveillance is only as reliable as the tests used to monitor the cancer, and these tests have substantial detection limits, false positives, false negatives, sampling errors, and subjective interpretation. Although active surveillance can spare men unnecessary treatment, it cannot guarantee that an aggressive cancer will be detected before it becomes dangerous.</p><ul><li>Active surveillance arose because many treatments cause more harm than the cancers being treated. Physicians recognized that many prostate cancers grow sluggishly and may never threaten life, while surgery, radiation, and hormonal treatments can produce devastating urinary, sexual, and other complications. Active surveillance was therefore developed to avoid or delay unnecessary treatment. But simply avoiding treatment of a cancer that would never have caused harm should not be confused with demonstrating that surveillance itself saves lives.</li><li>Active surveillance depends upon the questionable assumption that earlier detection will lead to effective life-saving treatment. The fundamental justification for surveillance is that a potentially dangerous cancer can be identified in time for treatment to prevent death. Yet treatments are not supported by reproducible evidence of substantial life-saving ability. Monitoring only has a life-saving purpose if detecting a dangerous change leads to an intervention that meaningfully improves survival.</li><li>PSA, MRI, and needle biopsies cannot reliably reveal the complete biological truth about the prostate. PSA cannot distinguish harmless cancers from aggressive cancers, MRI may miss small high-grade lesions, and needle biopsies sample only approximately 0.1–0.6% of the prostate in a typical 12-core procedure. Prostate cancers are frequently multifocal and multigrade, meaning separate growths and even different areas within the same growth may contain different Gleason grades. Detection limits, false negatives, false positives, observer variability, and massive sampling errors mean that a reassuring PSA, MRI, or needle biopsy cannot guarantee that a potentially deadly cancer has not been missed.</li><li>Aggressive cancer cells may have already disseminated before surveillance detects them. Some biologically aggressive prostate cancers may acquire the ability to disseminate microscopic cancer cells into the bone marrow or elsewhere before the primary cancer becomes detectable by MRI or needle biopsy. These disseminated cancer cells may remain invisible to MRI and PSMA PET scans and can remain dormant for years before developing into detectable metastatic disease. Consequently, finding a higher-grade cancer during surveillance does not guarantee that its metastatic potential has been identified in time to prevent dissemination.</li><li>Field cancerization creates another major uncertainty for active surveillance and focal therapy. Genetically altered tissue elsewhere in the prostate — the so-called <em>field effect</em> or <em>field cancerization</em> — may provide an environment in which additional, independent cancers develop over time. While many remain low-grade and indolent, a minority may be aggressive. A man undergoing surveillance for one known low-risk cancer may develop or already harbor a separate, undetectable high-grade cancer elsewhere in the prostate. The same concern applies to men undergoing focal therapy, because substantial prostate tissue remains untreated and potentially capable of harboring or developing additional cancers.</li></ul><p>The fundamental deception is presenting active surveillance as though repeated PSA testing, MRI imaging, and needle biopsies can reliably identify every dangerous cancer before it threatens life. They cannot. Active surveillance can substantially reduce unnecessary treatment and its complications, and long-term evidence supports conservative management for appropriately selected men. Active surveillance cannot eliminate the enormous uncertainty created by multifocal and multigrade prostate cancers, unreliable screening and detection methods, sampling errors, possible field effects, and microscopic cancer dissemination. Because screening, detection, and treatments remain error-prone, while reproducible evidence of safety, meaningful benefits, and substantial life-saving ability remains scant, men still die from prostate cancer despite reassuring screening results, active surveillance, and aggressive treatments for supposedly localized disease. The uncomfortable reality is that a reassuring test result does not guarantee the absence of deadly cancer, and treating what appears to be localized disease does not guarantee that potentially deadly cancer cells have not already spread.</p><p>Active surveillance was developed largely because so many prostate cancers are simply outlived and the treatments themselves are often worse than the disease. Yet the same unreliable screening and detection machinery is repeatedly used to reassure men that potentially deadly disease will be found in time. Avoiding unnecessary treatment is a genuine benefit — but surveillance cannot guarantee that aggressive cancer will be detected early enough to save a life. And, if a more aggressive cancer was detected there’s no reproducible evidence that treatments save substantial numbers of lives.</p><h3>14. THE PROSTATE CANCER TREATMENT DECEPTION: HAVING NOTHING BETTER DOES NOT MEAN CURRENT TREATMENTS ARE GOOD ENOUGH</h3><p>There’s a belief that we should continue using unreliable PSA-based screening and prostate cancer treatments simply because we have nothing better. But the absence of a better treatment option does not constitute scientific evidence that current treatments are effective, safe, or save substantial numbers of lives. Medical recommendations should rest upon reproducible scientific evidence demonstrating that benefits clearly outweigh harms — not historical practice patterns, theoretical expectations, or the belief that doing something must be better than doing nothing. Doing something does not justify indiscriminate screening, unnecessary treatment of cancers that men would simply outlive, or the idea that every accepted treatment substantially prolongs life.</p><ul><li>Having nothing better is not scientific justification for ineffective screening or treatment. PSA screening, MRI imaging, needle biopsies, surgery, radiation, hormonal treatments, and focal therapies have significant limitations and widely varying levels of evidence for life-saving benefits. A treatment should not be defended simply because it is commonly practiced, labeled standard of care, or because no better alternative exists. The fundamental question remains whether its demonstrated benefits outweigh its potentially devastating complications.</li><li>Metastatic prostate cancer does not automatically mean imminent death. Although metastatic disease remains serious and potentially deadly, advances in systemic therapies allow many men to live for years, sometimes with acceptable quality of life. Estimates suggest that approximately <a href="https://www.sciencedirect.com/science/article/abs/pii/S146238891470002X">10–20% of men</a> may present with metastatic disease at diagnosis, while approximately 20–30% of men initially diagnosed with localized disease may eventually develop metastases, depending upon the population, cancer aggressiveness, and follow-up. Portraying immediate treatment of every localized prostate cancer as the only alternative to possible catastrophic suffering ignores the vastly different biological behavior of these cancers.</li><li>Castration may delay prostate cancer progression, but it does not cure metastatic disease. Medical castration using androgen deprivation therapy (ADT), including GnRH injections and other testosterone-suppressing medications, or surgical castration by removing the testicles, can suppress testosterone-sensitive cancer cells and extend survival in selected patients. But cancer cells that are insensitive to testosterone suppression may survive, multiply, and eventually produce treatment-resistant disease. Approximately 45–50% of prostate cancer patients receive ADT in some studied populations, exposing many men to potentially devastating hormonal, metabolic, cardiovascular, sexual, and psychological complications. Adding ADT to another treatment should not automatically be confused with proof of cure — more treatment does not necessarily mean more lives saved.</li><li>Men still die despite screening, early detection, and active surveillance. PSA testing, prostate MRI, PSMA PET scans, and needle biopsies have substantial detection limits, false negatives, false positives, and sampling errors. Small, biologically aggressive cancers may escape detection, while some may have already disseminated microscopic cancer cells into the bone marrow before the primary tumor becomes clinically visible. These disseminated cancer cells can remain dormant for years or even decades before becoming active and causing metastatic disease. Finding and treating a cancer that appears localized cannot guarantee that microscopic dissemination has not already occurred.</li><li>We need better tests and treatments that actually work against aggressive prostate cancer. The priority should be developing reliable methods to distinguish harmless cancers from potentially deadly cancers, detect aggressive disease before clinically important dissemination, and provide treatments with reproducible evidence of meaningful survival benefits and acceptable harms. There are numerous other cancers in medicine for which satisfactory screening or treatment options remain unavailable. The absence of an effective solution is a reason to pursue better science — not to exaggerate the benefits of existing interventions or minimize their complications.</li></ul><p>The fundamental deception is using the argument that “we have nothing better” to justify continued reliance upon imperfect screening, detection, and treatment methods without demanding convincing evidence that their benefits outweigh their harms. As well, there’s no reproducible evidence that treatments save significant numbers of lives.</p><p>The medical profession should not confuse doing more with doing better. More PSA tests, more MRI scans, more biopsies, more prostate removals, more radiation, and more hormonal treatments do not automatically translate into more lives saved. Until we develop better methods to identify and successfully treat the minority of biologically aggressive prostate cancers, the priority must be reproducible scientific evidence, honest disclosure of uncertainty, and protection of men from unnecessary, potentially life-altering harm.</p><h3>15. THE PROSTATE CANCER INFORMATION DECEPTION: HOW FEAR, MEDICAL DOGMA, AND FINANCIAL INTERESTS PERPETUATE A FALSE NARRATIVE</h3><p>There’s a belief that the prostate cancer narrative and its public messaging are founded upon sound scientific evidence, but the facts raise serious questions about that belief. Bad science delivers bad results, and bad messaging delivers false hope and false promises. Prostate cancer information is drowning in beliefs, opinions, assumptions, questionable studies, and recycled misinformation, often promoted by physicians, medical institutions, and an industry that benefits financially from more screening, detection, and treatment. Meanwhile, frightened, confused, and vulnerable men diagnosed with cancer are confronted with complex medical jargon and reassuring promises without always being told how limited the actual life-saving benefits are.</p><ul><li>Bad science delivers misleading results. Prostate cancer studies are frequently complicated by unreliable screening and detection methods and by combining men with vastly different Gleason grades, scores, tumor volumes, and biological aggressiveness. Failing to adequately compare like with like can distort findings and exaggerate apparent benefits. The fundamental question is not whether a study produces a favorable statistic, but whether its findings demonstrate meaningful benefits for the men being tested and treated.</li><li>Physician beliefs, herd mentality, and the standard-of-care label perpetuate questionable practices. Once medical beliefs become accepted dogma, they are repeated in guidelines, medical journals, professional meetings, and clinical practice, sometimes without adequate scrutiny. Financial incentives can reinforce this process. Meanwhile, the <em>standard of care</em> label can create an impression of scientific certainty even though it does not guarantee that every accepted intervention has demonstrated substantial life-saving benefits. Medical consensus is not a substitute for reproducible scientific evidence.</li><li>Prostate cancer awareness campaigns can become powerful vehicles for fear and false hope. Foundations, advocacy organizations, support groups, and men’s health campaigns repeatedly promote slogans such as “early detection saves lives” without always explaining the absence of a clearly demonstrated overall-survival advantage of PSA screening, or the substantial risks of overdiagnosis and overtreatment. Prostate cancer awareness campaigns exploit September to amplify fear-based messaging, exaggerated promises, celebrity diagnoses, and emotional survivor stories that overshadow scientific evidence. Movie-star diagnoses and former President Joe Biden’s metastatic prostate cancer have fueled the familiar slogan “early detection saves lives”, although no celebrity diagnosis proves that earlier PSA screening would have prevented metastatic disease or death. Survivor stories are equally misleading when men may simply have outlived slow-growing cancers that never threatened their lives. Even high-risk populations are targeted for earlier, intensified PSA screening despite a lack of reproducible evidence that this strategy substantially improves overall survival. Age, family history, inherited mutations, and ancestry may increase risk, but greater risk does not automatically establish greater screening benefit. Celebrity diagnoses are not scientific evidence, surviving treatment does not prove a life was saved, and targeting higher-risk men does not substitute for reproducible proof of substantial life-saving benefits.</li><li>Industry funding raises serious conflicts of interest. Pharmaceutical companies, medical-device manufacturers, biotechnology firms, and other commercial interests fund medical societies, research, educational initiatives, and patient advocacy organizations. Because these businesses may benefit from increased testing, imaging, biopsies, and treatments, their financial relationships deserve transparent disclosure and independent scrutiny. Governments, hospitals, corporations, and public-health organizations should not amplify medical claims simply because they are popular, professionally endorsed, or politically appealing. When increased medical intervention generates increased revenue, protecting patients must take priority over protecting the industry.</li><li>WHAT GOOD IS AI-ENHANCED PROSTATE CANCER DETECTION WITHOUT REPRODUCIBLE EVIDENCE THAT THE RESULTING TREATMENTS SAVE SUBSTANTIAL NUMBERS OF LIVES? AI cannot turn detection into salvation. Worse still, AI trained on medical literature, guidelines and institutional consensus can recycle misinformation, flawed assumptions and commercially influenced narratives with greater speed and apparent authority. AI cannot turn consensus into scientific truth or manufacture life-saving benefits. Without reproducible evidence of substantial survival benefits and fewer devastating complications, AI risks becoming another sophisticated vehicle for false hope, false promises and overtreatment — betraying the very patients it is supposed to help.</li></ul><p>The fundamental deception is allowing beliefs, professional consensus, commercial interests, and relentless awareness campaigns to substitute for the scientific evidence patients deserve. Neither PSA screening or treatments have delivered reproducible data for substantial life-saving benefits. Instead, the messaging exaggerates benefits, minimizes complications and commonly treats every prostate cancer diagnosis as an impending death sentence.</p><p>We do not need more fear, more slogans, more awareness for awareness’s sake, or more AI-generated repetition of questionable medical claims. We need sound science, honest messaging, independent regulatory oversight, and a determined focus on identifying and successfully treating the minority of aggressive prostate cancers that actually threaten men’s lives. Above all, we must keep asking the question the prostate cancer industry should never be allowed to avoid: WHERE IS THE REPRODUCIBLE SCIENTIFIC EVIDENCE THAT THESE TESTS AND TREATMENTS ARE SAFE, BENEFICIAL, AND SAVE SUBSTANTIAL NUMBERS OF LIVES?</p><h3>16. THE DECEPTION ABOUT PROSTATE CANCER CRITICS: WHEN CHALLENGING MEDICAL DOGMA BECOMES HERESY</h3><p>There’s a belief that outspoken critics challenging the established prostate cancer narrative are misguided or wrong, but the facts show that challenging medical dogma is essential to scientific progress. Medicine has repeatedly witnessed so-called standard-of-care treatments exposed as ineffective, harmful, or both. Those defending the status quo often respond aggressively, ridiculing or alienating their critics. Yet when rigorous scientific evidence overturns accepted medical practices, the phenomenon is known as medical reversal. Research suggests that approximately 40% of established practices examined in certain studies were reversed when subjected to rigorous testing. The prostate cancer narrative deserves similar scrutiny concerning reproducible evidence of safety, benefits, and substantial life-saving ability. Standard of care does not necessarily mean scientifically proven, safe, effective, or life-saving.</p><ul><li>The USPSTF challenged the prostate cancer screening establishment. In 2012, the United States Preventive Services Task Force recommended against routine PSA-based screening, concluding that its potential harms outweighed its benefits. This challenged decades of widespread screening practices and exposed the serious consequences of overdiagnosis and overtreatment. However, following intense lobbying by those in the business of prostate cancer, the <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening">USPSTF</a> subsequently watered down its recommendations to an individualized decision-making process for men aged 55–69, despite the absence of reproducible evidence that this change would save substantial numbers of lives.</li><li>Dr. Anthony Horan exposed the prostate cancer industry’s uncomfortable realities. A urologist and outspoken critic, Horan challenged the conventional prostate cancer narrative in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em>. He argued that widespread PSA screening and aggressive treatment had created a financially rewarding system of overdiagnosis, unnecessary intervention, and potentially devastating complications. His central challenge was whether the prostate cancer industry could justify its practices with reproducible evidence of substantial life-saving benefits.</li><li>Dr. Richard Ablin challenged the misuse of his own discovery. Ablin, whose research contributed to the discovery of PSA, became one of the most outspoken critics of its widespread use as a population screening test. In <em>The Great Prostate Hoax</em>, written with Ronald Piana, he argued that PSA screening had been profoundly misused, generating unnecessary biopsies, overdiagnosis, overtreatment, and substantial healthcare expenditures. Few criticisms are more compelling than a scientist warning that his own discovery has been promoted far beyond its demonstrated clinical value.</li><li>Dr. Otis W. Brawley warned that more screening does not necessarily mean better healthcare. As former Chief Medical Officer of the American Cancer Society, Brawley repeatedly challenged the exaggerated promises of routine PSA screening. He emphasized its inability to reliably distinguish harmless cancers from potentially deadly cancers and warned about the psychological, physical, and financial consequences of unnecessary diagnosis and treatment. His message challenged the seductive but scientifically questionable assumption that finding more cancers automatically means saving more lives.</li><li>Dr. Laurence Klotz challenged the biological meaning of Gleason 6 cancer. Klotz questioned whether rigorously confirmed Gleason 3+3 disease should continue carrying the emotionally devastating label of cancer when its metastatic and lethal potential appears absent or at best, extraordinarily low. His work on active surveillance helped demonstrate that many men with low-risk prostate cancer can safely avoid or defer aggressive treatment. Although Gleason 6 remains histologically classified as adenocarcinoma based mostly on microscopic appearances and not biological behavior, his challenge exposes the harm that can arise when a frightening cancer label fails to communicate the remarkably indolent behavior of the disease.</li></ul><p>The fundamental deception is portraying physicians and scientists who challenge the prostate cancer narrative as misguided simply because their conclusions contradict established beliefs, professional consensus, or financially rewarding practices. Physician beliefs in the hopeful-sounding promises of prostate cancer screening and treatment became so deeply entrenched that they too often overpowered critical scientific thinking and the willingness to challenge accepted medical dogma. Medical history is littered with reversals in which treatments once celebrated as standard of care were subsequently abandoned after rigorous scientific evidence exposed their ineffectiveness or unexpected harms. Beliefs, opinions, assumptions, and professional consensus do not qualify as scientific proof — and defending medical dogma in the face of contradictory evidence is not good medicine.</p><p>Scientific progress does not come from blindly parroting established dogma. It comes from questioning beliefs, challenging assumptions, demanding reproducible evidence, and having the courage to acknowledge when medicine has been wrong. These outspoken critics deserve to have their arguments judged by the quality of their evidence — not by how uncomfortable their conclusions make the prostate cancer establishment.</p><h3>17. THE PROSTATE CANCER RESEARCH DECEPTION: BAD SCIENCE, FALSE PROMISES, AND COUNTLESS MEN BETRAYED</h3><p>There’s a belief that information from prostate cancer studies is trustworthy, but the facts raise serious questions about the scientific credibility of many published conclusions. Prostate cancer is not one disease, yet studies routinely combine different Gleason grades, scores, tumor volumes, and biological behaviors — mixing slow-growing cancers that men would simply outlive with potentially deadly aggressive cancers. Failure to adequately compare like with like can skew results toward an exaggerated semblance of screening or treatment benefit. Even major studies, including the 20-year Scandinavian trial, ProtecT, and ERSPC, deserve scrutiny over how differences in cancer biology affect their conclusions. No amount of randomization, peer review, or statistical interpretation can rescue fundamentally flawed study design.</p><ul><li>Bad science delivers misleading results. Mixing biologically different prostate cancers without adequately controlling for their differences risks producing unreliable conclusions about screening and treatment benefits. Dr. John Ioannidis famously <a href="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020124">challenged</a> the reliability of most published medical research, while other research has highlighted uncertainty about the effectiveness of about 50% of <a href="https://theincidentaleconomist.com/wordpress/half-of-medical-treatments-of-unknown-effectiveness/">established</a> medical treatments. A statistically significant result does not automatically mean substantial numbers of lives have been saved.</li><li>Beliefs, opinions, and assumptions do not qualify as science. Many prostate cancer treatments began with the belief that removing or destroying cancer should save lives, progressing into accepted practice, standard practice, and eventually standard of care. Yet the strength of reproducible evidence for safety, meaningful benefits, and substantial life-saving ability remains unproven primarily because of study design. Standard of care does not automatically mean scientifically proven, safe, effective, or life-saving.</li><li>False hope and false promises carry potentially devastating consequences. Prostate cancer screening and treatments can produce overdiagnosis, overtreatment, urinary incontinence, sexual dysfunction, hormonal complications, psychological distress, and significant treatment regret. Treatments may fail, cancers may recur, and additional treatments may be required to manage recurrence or correct complications — sometimes generating still more complications. When treatment failure generates more treatment, the healthcare financial engine keeps turning while patients and their partners pay the price.</li><li>Men still die despite screening, active surveillance, and aggressive treatment. PSA testing, MRI, needle biopsies, and imaging cannot reliably reveal every potentially deadly cancer or exclude microscopic dissemination. Meanwhile, many indolent cancers are detected and treated unnecessarily. More cancers detected and more treatments delivered do not necessarily mean more lives saved. The absolute number of prostate cancer deaths in the United States has hovered right around 35,000 per year.</li><li>WHAT GOOD IS AI-ENHANCED PROSTATE CANCER DETECTION WITHOUT REPRODUCIBLE EVIDENCE THAT THE RESULTING TREATMENTS SAVE SUBSTANTIAL NUMBERS OF LIVES? AI cannot turn detection into salvation. Worse still, AI trained on medical literature, guidelines and institutional consensus can recycle misinformation, flawed assumptions and commercially influenced narratives with greater speed and apparent authority. AI cannot turn consensus into scientific truth or manufacture life-saving benefits. Without reproducible evidence of substantial survival benefits and fewer devastating complications, AI risks becoming another sophisticated vehicle for false hope, false promises and overtreatment — betraying the very patients it is supposed to help.</li></ul><p>The fundamental deception is presenting questionable research conclusions, professional beliefs, and accepted medical practices as though they constitute irrefutable scientific proof. The prostate cancer narrative has become a gigantic, money-making public-health hoax, fueled by exaggerated fear-based messaging, false hope and false promises sold to vulnerable and unwitting men. Despite the well-known detection limits, sampling errors and observer variability of PSA screening, MRI and needle biopsies — and the fact that only a minority of prostate cancers are aggressive and potentially deadly — the screening, detection and treatment machinery has flourished. The result has been massive overdiagnosis, overtreatment and enormous healthcare expenditures, exposing countless men to treatments without reproducible evidence of substantial life-saving benefits, while leaving many with residual cancer, rising PSA levels and other potentially life-altering complications affecting both patients and their wives or partners.</p><p>Physicians, researchers, medical institutions and the American healthcare regulatory apparatus must be held accountable for the recommendations they promote, the harms they minimize and the exaggerated promises they perpetuate. Scientific truth — not fear, bad science, financial incentives or entrenched medical dogma — must determine the standard of care.</p><p>And to everyone determined to defend the established prostate cancer narrative, one fundamental question remains: WHERE IS THE ROBUST, REPRODUCIBLE SCIENTIFIC EVIDENCE THAT THE TEST OR TREATMENT YOU ARE PROMOTING IS SAFE, EFFECTIVE, AND SAVES SUBSTANTIAL NUMBERS OF LIVES — WITH BENEFITS THAT CLEARLY OUTWEIGH THE HARMS?</p><h3>READ MORE</h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/ref=sr_1_1?crid=1GHHMCYQM7IQT&amp;dib=eyJ2IjoiMSJ9.AVXCAxuTQodCbGaBBNAy8YbNL5RuhvgkjTL4AcxIK5IP9hu_URAWhg8omq-iVTkH.eOnEQO325p4ZykHPXfDjdaMddNqI7dkeaHrIjfNHFtE&amp;dib_tag=se&amp;keywords=the+rise+and+fall+of+the+prostate+cancer+scam&amp;nsdOptOutParam=true&amp;qid=1792514978&amp;s=books&amp;sprefix=the+rise+and+fall+of+the+prostate+cancer+scam%2Cstripbooks%2C149&amp;sr=1-1">THE RISE AND FALL OF THE PROSTATE CANCER SCAM</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/ref=sr_1_1?crid=WCJMH2MNH710&amp;dib=eyJ2IjoiMSJ9.bpc-XXjnmPsZcceGXYRwcpaz96bvvsHaIyWSsUSxgqh9pcFpd6dnOqzJO582irYgLwWZgkKfWUeRMyqqEJlzCo9n7pLhEgCFZBp3hBBW8SqgnwwGC01wKkxxkOoTS1oyG8eCpO25HMkvoOYh0LSr8RZwKlNHioVbD5Xnvm7laSXEkdBhqpUvyYA5xcXsWi5sIVQH9pMsmU4z81RA8iVatA.lTGIU-xg0ebUD8LCx0nOELC6z9E_foZfAmQdpoz-ANI&amp;dib_tag=se&amp;keywords=the+great+prostate+hoax&amp;qid=1792515510&amp;s=books&amp;sprefix=the+great+prostate+hoax%2Cstripbooks%2C136&amp;sr=1-1">THE GREAT PROSTATE HOAX</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-deception-how-psa-screening-men-vorstman-md-xajie/">THE GREAT PROSTATE CANCER DECEPTION: How PSA Screening and Treatments Betrayed Countless Men</a></p><p><a href="https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/">https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/</a></p><p><a href="https://www.linkedin.com/pulse/great-obesity-denial-epidemic-hiding-plain-sight-bert-vorstman-md-iehge/">https://www.linkedin.com/pulse/great-obesity-denial-epidemic-hiding-plain-sight-bert-vorstman-md-iehge/</a></p><h3>Discover the YouTube HEALTHdrum channel where medical fact is separated from medical fiction.</h3><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/great-prostate-cancer-scam-when-doctors-betray-harm-bert-vorstman-md-ontve/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=45fcbee122bb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[THE GREAT OBESITY DENIAL: An Epidemic Hiding in Plain Sight]]></title>
            <link>https://bvorstman.medium.com/the-great-obesity-denial-an-epidemic-hiding-in-plain-sight-fb5fdfc8f703?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/fb5fdfc8f703</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Tue, 29 Sep 2026 14:09:00 GMT</pubDate>
            <atom:updated>2026-09-29T14:09:00.546Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*NAJ2iaNMocQYQ8V6" /></figure><p>Bert Vorstman MD</p><p>About 75% of U.S. adults meet the criteria for obesity under a new definition that goes beyond traditional BMI measures, while other data show that only about 12% are metabolically healthy. The economic consequences are staggering: obesity drains the U.S. economy by an estimated $1.4 trillion annually when direct healthcare spending is combined with broader corporate and workplace costs, including lost productivity, absenteeism and disability. The price of obesity is therefore measured not only in deteriorating health and preventable disease, but in an enormous economic burden ultimately carried by individuals, employers, healthcare systems and society.</p><p>Yet as obesity balloons in children and adults, the debate is increasingly diverted toward stigma and fat-shaming rather than prevention and the causes driving the epidemic. We can continue spending fortunes treating obesity after it develops — or confront it before the medical bills arrive. Obesity cannot defy the laws of energy. The mystery isn’t how we got here; the question is why we remain so reluctant to confront it.</p><h3>OBESITY: WHAT ARE WE ACTUALLY TALKING ABOUT?</h3><ul><li>Obesity is the excessive accumulation of body fat to a level that threatens health. It is not simply a question of appearance, clothing size or society’s changing perception of what constitutes a “normal” body.</li><li>Traditionally, obesity in adults has been screened using <a href="https://www.cdc.gov/bmi/adult-calculator/index.html">Body Mass Index</a> (BMI). A BMI of 25–29.9 is classified as overweight, 30–34.9 as Class I obesity, 35–39.9 as Class II obesity, and 40 or greater as Class III obesity.</li><li>BMI is an imperfect measurement — not an excuse to ignore obesity. It cannot distinguish muscle from fat or reveal where fat is stored, which is why waist circumference, body composition and metabolic measurements can provide important additional information.</li><li>Where the fat accumulates matters. Excess abdominal and visceral fat carries particularly important metabolic consequences and is associated with diabetes, cardiovascular disease, fatty liver disease and other disorders.</li><li>The definition may be debated and the measurements refined, but the underlying problem cannot be defined away. When excessive body fat accumulates to the point that it damages health, arguing endlessly over terminology does nothing to make the consequences disappear.</li></ul><h3>OBESITY CANNOT DEFY THE LAWS OF ENERGY</h3><ul><li>The First Law of Thermodynamics is not a theory about obesity — it is a <a href="https://www.britannica.com/science/laws-of-thermodynamics">fundamental law</a> of physics. Energy cannot be created or destroyed; it can only be transferred or transformed. The human body is biologically complicated, but it is not exempt from this law.</li><li>For body weight, the principle is expressed through energy balance: energy consumed versus energy expended. Energy enters principally through food and beverages and is expended through basal metabolism, digestion, physical activity and other physiological processes.</li><li>When food intake chronically exceeds energy expenditure (overeating), that excess energy has to go somewhere and becomes fat. Some can be stored as glycogen or incorporated into lean tissue, but sustained positive energy balance ultimately increases stored body energy, predominantly as adipose tissue — and continuing accumulation of excess body fat produces obesity.</li><li>The reverse is equally fundamental: a sustained energy deficit forces the body to draw upon stored energy. Metabolism can slow, hunger can intensify and maintaining weight loss can become extraordinarily difficult, but those adaptations change the size of the energy deficit — they do not abolish the underlying energy equation.</li><li>This is where the obesity debate too often becomes needlessly confused. Genetics, hormones, medications, psychology, food environment, sleep and socioeconomic circumstances can influence appetite, calorie consumption and energy expenditure; they help explain why positive energy balance occurs. But none provides an escape from energy conservation: biology can influence the equation — it cannot repeal the laws of energy.</li></ul><h3>THE OBESITY EPIDEMIC IS A MODERN PHENOMENON</h3><ul><li>The roots of the <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4923953/">modern obesity crisis</a> took hold in the late 1970s, but the epidemic began to explode statistically in the early 1980s. Before then, little obesity existed..</li><li>Human genetics did not suddenly change in a decade. What changed dramatically was the environment surrounding the same human biology — food availability, portion sizes, eating habits, transportation, work and lack of physical activity.</li><li>The food supply was transformed. Cheap, calorie-dense, ultra-processed foods, refined carbohydrates, sugary beverages, fast food and endless snacks became increasingly abundant and accessible.</li><li>At the same time, everyday energy expenditure was disappearing. Desk jobs, automobiles, automation, elevators, television and labor-saving technology progressively replaced walking and routine physical work.</li><li>The timing should be a wake-up call: the environment changed, calorie consumption became easier, energy expenditure declined — and obesity exploded. The modern obesity epidemic did not require a mysterious new human biology; it emerged alongside a radically different way of eating and living.</li></ul><h3>IF OBESITY WERE SIMPLY INEVITABLE, WHY IS IT SO UNEVENLY DISTRIBUTED?</h3><ul><li>Obesity is strikingly uneven across occupations and lifestyles. Physicians, surgeons, dentists and other highly educated health-related professions have been reported among occupational groups with comparatively low obesity prevalence — people who are disciplined and understand particularly well what obesity does to the human body.</li><li>Competitive athletics provides an even more dramatic contrast. Distance runners, cyclists, triathletes, soccer players and many combat-sport athletes like those in rugby and ice hockey (many American football players are obese) maintain low body-fat levels because excess fat directly compromises speed, endurance, agility and mechanical efficiency.</li><li>Weight-class sports make the relationship impossible to ignore. Wrestlers, boxers and other combat athletes must continuously control body weight because excess weight can determine whether they are even permitted to compete in a particular division.</li><li>These populations are not exempt from human genetics, hunger hormones or metabolic adaptation. What differs dramatically are their environments, incentives, physical demands, dietary behaviors and consequences for gaining excess weight.</li><li>That contrast should be another wake-up call. Where maintaining lower body weight carries immediate professional or performance consequences, obesity can be substantially less prevalent — powerful evidence that environment and behavior matter enormously even though biology influences how difficult weight control is.</li></ul><h3>WE SUPERSIZED THE FOOD — THEN ACTED SURPRISED WHEN PEOPLE GOT BIGGER</h3><ul><li>Portions expanded dramatically. Restaurant meals, snacks and beverages became far larger or <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4105580/">supersized</a> than what previous generations considered normal.</li><li>Sugary drinks became enormous. A beverage that once accompanied a meal could become hundreds of rapidly consumed calories.</li><li>Calorie-dense snacks became omnipresent. Gas stations, pharmacies, offices and checkout counters became extensions of the food marketplace.</li><li>Even the visual definition of a serving changed. Giant plates, oversized sandwiches and cookies approaching the size of Frisbees increasingly stopped looking extraordinary.</li><li>The environment changed the baseline. When “large” becomes common and ordinary, excess consumption, larger clothes, larger chairs and larger wheelchairs become ordinary with it.</li></ul><h3>HOW DO PEOPLE GET FAT? BITE BY BITE, SNACK BY SNACK, PORTION BY PORTION</h3><ul><li>People do not become obese because fat mysteriously appears — they become obese when excess energy (food) repeatedly enters the body and is stored. The modern food environment makes that extraordinarily easy: calorie-dense meals, oversized portions, sugary drinks and snacks are available virtually everywhere, all day long.</li><li>The type of food matters because some foods make overconsumption remarkably easy. Many ultra-processed foods combine refined carbohydrates, fats, salt and intense flavors in highly palatable, energy-dense packages that can deliver enormous numbers of calories before comparable fullness is achieved.</li><li>Then comes the endless snacking. Eating is no longer confined to three meals: snacks, desserts, sweetened drinks, drive-through food and distracted eating in front of screens can turn much of the waking day into another opportunity to consume calories.</li><li>Portion size compounds the damage. Restaurant meals, fast food, sugary beverages and packaged snacks have conditioned consumers to regard portions that were once exceptional as ordinary — and a single energy-dense meal can contain an extraordinary fraction of an individual’s daily caloric requirement.</li><li>Put it together and the mechanism is hardly mysterious: calorie-dense foods make excessive calories easy to consume, oversized portions deliver more of them, and constant snacking provides more opportunities to consume them. Repeat that pattern day after day and year after year and the surplus has to go somewhere. The body stores it. The waistline expands. Eventually, the result is obesity and you are fat.</li></ul><h3>WHEN OVEREATING BECOMES SELF-DESTRUCTIVE</h3><ul><li>Self-destructive behavior is behavior that repeatedly causes physical, psychological or emotional harm — and chronic overeating can become exactly that. Impulsive eating, compulsive eating and binge eating exist along a spectrum in which repeated excessive caloric intake can continue despite mounting damage to health, mobility and quality of life.</li><li>The contradiction becomes increasingly difficult to ignore as obesity becomes severe. Many people recognize that they are substantially overweight and know about familiar risks such as diabetes and heart disease, yet the eating behaviors contributing to excess weight may continue even after breathlessness, painful joints, impaired mobility, sleep apnea or metabolic disease appear.</li><li>The damage is often much greater than people realize. Obesity is associated not merely with diabetes and cardiovascular disease but with fatty liver disease, sleep apnea, kidney disease, osteoarthritis and increased risk of numerous cancers — many of which can progress silently long before their consequences become obvious.</li><li>But calling these behaviors self-destructive does not mean they are always deliberate or simply a failure of willpower. Depression, anxiety, trauma, binge-eating disorder, compulsive behavior and highly reinforcing food environments can create a vicious cycle in which eating becomes a coping mechanism even while excessive consumption contributes to worsening obesity and distress.</li><li>Recognizing a destructive behavioral pattern is not “fat shaming” — it is recognizing a dangerous cycle that demands intervention. When repeated excessive caloric intake is contributing to progressive obesity and serious medical harm, compassion should mean helping interrupt that behavior rather than normalizing its consequences. A behavior does not become harmless simply because it is difficult to change.</li></ul><h3>THE FOOD INDUSTRY DISCOVERED THAT MORE CONSUMPTION MEANS MORE PROFIT</h3><ul><li>Food companies compete for repeat consumption. Taste, texture, convenience, packaging and marketing are deliberately optimized to make products appealing.</li><li>Ultra-processed foods can combine refined carbohydrates, fats and salt in intensely palatable formulations. Such foods can be consumed rapidly and may encourage greater calorie intake.</li><li>The commercial incentive is obvious. A company selling food benefits when consumers purchase its products repeatedly.</li><li>Addiction-like eating behavior is reported in some people. Whether “food addiction” should be considered a formal addiction remains debated, but cravings and loss of control are real clinical phenomena.</li><li>Ancient appetite has collided with modern food engineering. Human biology evolved under scarcity; it now operates inside an environment selling calories everywhere.</li></ul><h3>BIOLOGICAL COMPLEXITY DOES NOT REPEAL PHYSICS</h3><ul><li>Obesity has genuine biological contributors. Genetic susceptibility, appetite signaling, sleep, medications and metabolic adaptation can materially influence weight.</li><li>Rare genetic disorders can produce extreme hunger from childhood. Mutations involving pathways such as MC4R or POMC demonstrate how powerful appetite biology can be.</li><li>Epigenetic and developmental influences may also affect later susceptibility. They can alter metabolism and appetite without changing the underlying DNA sequence.</li><li>But susceptibility is not an independent energy source. Several hormonal and endocrine disorders can cause or contribute to significant weight gain and obesity and these conditions can profoundly influence how easily weight is gained and how difficult it is to lose — but they still operate within the body’s energy system rather than creating an exception to it.</li><li>Complexity explains why obesity develops more easily in some people than others. It does not demonstrate that accumulated body fat appeared without excessive energy intake.</li></ul><h3>WHEN “COMPLEXITY” BECOMES A DISTRACTION FROM THE FUNDAMENTALS</h3><ul><li>Modern obesity literature increasingly describes obesity as a complex chronic neuroendocrine disease governed by genetics, hormones, brain circuitry and metabolic adaptation. Much of that biology is real — but describing the forces controlling appetite and metabolism does not invalidate the fundamental requirement for positive energy balance to accumulate excess body energy.</li><li>The hypothalamic “set point,” starvation defenses and metabolic adaptation help explain why losing weight can be difficult and why the body may resist maintaining weight loss. They do not demonstrate that body fat can be created without an energy source. When sustained energy intake falls sufficiently below expenditure, stored energy must be mobilized.</li><li>Leptin resistance, ghrelin, GLP-1 signaling and so-called “food noise” can powerfully influence hunger and the drive to eat. But notice what these mechanisms ultimately influence: food intake and energy expenditure. They help explain <em>why someone may overconsume calories</em>; they do not make caloric intake irrelevant.</li><li>Genetic susceptibility is equally important — but susceptibility is not destiny. Hundreds of genetic variants may influence appetite, satiety, food preference, metabolism and fat distribution, yet the modern obesity epidemic developed far faster than the human genome could have fundamentally changed. Genes can load the biological gun; an environment of abundant, inexpensive, calorie-dense food can help pull the trigger.</li><li>The danger comes when scientific complexity is translated into public messaging that makes obesity sound mysterious, inevitable or disconnected from food intake–the scientifically defensible message is much simpler: biology can make controlling energy intake extraordinarily difficult, but it cannot make energy balance irrelevant. Complexity explains the struggle — it does not repeal physics.</li></ul><h3>THE BODY TRIES TO FIGHT WEIGHT LOSS</h3><ul><li>Weight loss itself triggers biological resistance. Energy expenditure can decline as body mass falls.</li><li>Hunger frequently increases. Hormonal and neurological responses can make maintaining a reduced calorie intake increasingly difficult.</li><li>Satiety can simultaneously weaken. The person who has lost substantial weight may therefore experience stronger biological pressure to regain it.</li><li>This helps explain why long-term weight maintenance is difficult. Regaining weight should not automatically be interpreted as laziness or moral weakness.</li><li>But difficult is not impossible. Metabolic adaptation changes the magnitude of the energy equation; it does not abolish the energy equation.</li></ul><h3>CHILDHOOD OBESITY CAN BECOME A LIFELONG BIOLOGICAL BURDEN</h3><ul><li>Childhood is a critical period for fat development. Excess energy causes their fat cells to enlarge and multiply contributing to expansion of adipose tissue.</li><li>Obesity established early often persists into adulthood. Childhood obesity therefore should never be dismissed simply as harmless “baby fat.”</li><li>Children do not control the food environment surrounding them. Adults largely determine what food enters the home, how it is prepared and what portions are served. Unhealthy food promotes childhood obesity.</li><li>Prevention must therefore begin with parents, schools and the food environment. Waiting until severe obesity is established means confronting a far harder problem.</li><li>The most humane obesity treatment may be preventing childhood obesity in the first place. Prevention avoids decades of struggling against an established condition.</li></ul><h3>FAT IS NOT JUST STORAGE — IT BECOMES AN ACTIVE ORGAN</h3><ul><li>Adipose tissue is metabolically active. It produces several hormones and signaling molecules that affect physiology throughout the body.</li><li>Excess and dysfunctional adipose tissue promotes inflammation. Chronic low-grade inflammatory signaling accompanies many forms of severe obesity.</li><li>Insulin sensitivity can deteriorate. This creates fertile ground for metabolic dysfunction and type 2 diabetes.</li><li>The liver and cardiovascular system can suffer as well. Excess adiposity is strongly associated with fatty liver disease and cardiovascular disease.</li><li>Obesity therefore becomes more than accumulated calories. Once established, excessive adipose tissue can participate directly in the disease processes that follow.</li></ul><h3>OBESITY DOESN’T JUST CHANGE THE WAISTLINE — THE BODY BEGINS TO SHOW THE STRAIN</h3><ul><li>The most obvious sign is excessive body fat, particularly around the abdomen — but the consequences quickly extend beyond appearance. Increasing waist circumference and abdominal fat can signal increasing metabolic risk, while stretch marks, heavy sweating and skin irritation in deep body folds can become increasingly common.</li><li>Breathing can become harder because simply moving a larger body requires more work. Walking short distances or climbing stairs may produce breathlessness and fatigue, while obesity can contribute to asthma and obstructive sleep apnea, with loud snoring and repeated interruptions of breathing during sleep.</li><li>The skeleton eventually pays for carrying the additional load. Knees, hips and the lower back absorb increased mechanical stress day after day, contributing to pain, impaired mobility and osteoarthritis — and reduced mobility can then make weight control still more difficult.</li><li>The skin and circulation can begin displaying warning signs. Rashes develop where skin folds trap moisture and friction; lower legs and ankles may swell; and dark, velvety patches known as <em>acanthosis nigricans</em> can accompany insulin resistance.</li><li>These are not merely cosmetic inconveniences — they can be warning lights that the body is struggling under an excessive physiological and mechanical burden. When breathlessness, sleep apnea, painful joints, declining mobility and metabolic abnormalities appear together, obesity has moved far beyond a number on a bathroom scale.</li></ul><h3>THE REAL DANGER OF OBESITY IS WHAT COMES NEXT</h3><ul><li>Obesity can become a whole-body assault. It is associated with hypertension, abnormal blood lipids, coronary heart disease, heart failure and stroke — the cardiovascular machinery is being asked to function in an increasingly unfavorable metabolic environment.</li><li>Metabolic damage can become profound. Excess adiposity is strongly associated with insulin resistance and type 2 diabetes, while fat accumulation in the liver can progress from metabolic dysfunction-associated steatotic liver disease (MASLD) to inflammation, fibrosis and, in some patients, cirrhosis.</li><li>The consequences extend from the kidneys to the gastrointestinal system. Obesity is associated with chronic kidney disease, gallstones, gallbladder disease and gastroesophageal reflux, while hypertension and diabetes can compound damage to vulnerable organs.</li><li>Cancer belongs on the obesity warning list as well. Excess body weight is associated with increased risk of numerous cancers, including prostate (tends to be more aggressive and advanced), colorectal, postmenopausal breast, endometrial, kidney and pancreatic cancers — another reminder that excessive adiposity is biologically active tissue, not simply stored padding.</li><li>This is why the obesity epidemic demands far more than arguments about terminology, appearance or stigma. When excessive body fat is accompanied by breathlessness, immobility, sleep apnea, diabetes, fatty liver disease, cardiovascular disease, joint destruction and increased risks of several cancers, the expanding waistline is no longer the story — it is the warning sign.</li></ul><h3>SURGERY BECOMES HARDER WHEN THE PATIENT BECOMES LARGER</h3><ul><li>Airway management and ventilation can become more difficult. Severe obesity creates important challenges for anesthesia.</li><li>Operative exposure becomes considerably harder. Greater tissue depth can make reaching and visualizing surgical anatomy more demanding and sutures are difficult to tie.</li><li>Positioning becomes more complicated. Very high body mass can increase pressure-related and positioning risks.</li><li>Perioperative and postoperative complications can increase. Bleeding during surgery is more difficult to control while thromboembolism, pulmonary complications, wound problems and infections deserve particular attention.</li><li>For the surgical team, severe obesity is not an abstract social construct. It can materially alter the technical difficulty and risk of an operation.</li></ul><h3>MORBID OBESITY: WHEN EXTREME OBESITY BECOMES DEPENDENT ON OTHERS</h3><ul><li>Morbid obesity — now generally termed Class III obesity — is the extreme end of excessive body-fat accumulation. It is conventionally defined as a BMI of 40 or greater, and it carries major risks of immobility, diabetes, cardiovascular disease, respiratory problems and premature disability.</li><li>A profoundly obese body requires continuing energy to maintain its enormous mass. Genetics, hormones, psychological disorders and metabolic adaptation may influence appetite and susceptibility, but they cannot supply the calories required to sustain extreme body weight.</li><li>Eventually, severe obesity can destroy the very mobility needed to obtain food independently. Some individuals become confined to a chair or bed and dependent upon family members or caregivers for shopping, cooking, food delivery and basic activities of daily living.</li><li>This is where the uncomfortable issue of the “enabler” must be confronted. When an immobile person cannot independently obtain excessive quantities of food, another person may sustain the behavior by purchasing it, preparing it and repeatedly bringing it to the bed or chair — sometimes out of love, guilt, fear of confrontation, codependency or a misguided desire to protect.</li><li>Compassion must not become participation in self-destruction. Caring for an immobile person means providing nutrition, dignity and essential assistance; it does not require continuously supplying the excessive calories that help maintain life-threatening obesity. At the extreme, confronting enabling behavior may need to become part of confronting obesity itself.</li></ul><h3>EXERCISE IS ESSENTIAL FOR HEALTH — BUT IT CANNOT CANCEL UNLIMITED CALORIES</h3><ul><li>Exercise improves cardiovascular health, insulin sensitivity, strength and psychological well-being. Its medical benefits are unquestionable.</li><li>Exercise also contributes to energy expenditure. It is especially important for maintaining weight loss and preserving functional capacity.</li><li>But ordinary exercise can be overwhelmed by excessive calorie consumption. It is much easier to consume several hundred calories than to deliberately expend them through exercise.</li><li>Weight can fall without exercise when caloric restriction is sufficient. Conversely, highly active people can gain weight if energy intake persistently exceeds expenditure.</li><li>“Move more” is therefore only part of the answer. Controlling excessive caloric intake remains central to controlling body weight.</li></ul><h3>THE BEST TREATMENT FOR OBESITY IS NOT NEEDING TREATMENT IN THE FIRST PLACE</h3><ul><li>Medicine has allowed the obesity discussion to become dominated by how to treat obesity after it has already developed. The more important public-health question is how to prevent millions of children and adults from accumulating the excess body fat that eventually requires lifelong medical attention.</li><li>Prevention begins with controlling the side of the energy equation we can most directly influence: food intake. Portion size, calorie density, sugary beverages, constant snacking and highly palatable processed foods matter because relatively small daily caloric surpluses, repeated for years, can become substantial weight gain.</li><li>Exercise is enormously important for cardiovascular fitness, metabolic health, muscle preservation and weight maintenance — but it should not become a distraction from excessive caloric intake. It is generally far easier to consume hundreds of calories than to exercise them away, making nutrition fundamental to preventing weight gain.</li><li>The time to intervene is before 20, 40, 80 or 100 excess pounds have accumulated. Physicians should identify rising weight and waist circumference early, discuss eating patterns directly, review medications that promote weight gain and intervene before obesity becomes accompanied by diabetes, sleep apnea, fatty liver disease, immobility and cardiovascular disease.</li><li>Prevention is not glamorous, patentable or technologically exciting — but it attacks the epidemic upstream. Every case of obesity prevented means one fewer person potentially requiring decades of medications, repeated medical visits, treatment of obesity-related diseases or bariatric surgery. Preventing obesity should therefore be the first objective of obesity medicine — not its forgotten afterthought.</li></ul><h3>PHYSICIANS SHOULD INTERVENE BEFORE THE PRESCRIPTION PAD BECOMES THE ANSWER</h3><ul><li>Once obesity is present, “eat less and exercise more” is not an adequate medical program. Physicians should help patients create a structured, measurable caloric deficit using nutritional counseling, food and weight monitoring, behavioral strategies and realistic goals rather than vague advice to “try to lose some weight.”</li><li>Behavioral intervention should identify exactly where excess calories are coming from. Food diaries, portion awareness and recognition of environmental or emotional eating cues can turn an abstract weight problem into identifiable behaviors that can actually be changed.</li><li>Nutrition and physical activity have different but complementary jobs. Dietary energy reduction drives much of the initial weight loss, while regular aerobic activity and resistance training improve cardiovascular health, preserve lean mass and become particularly important for maintaining lost weight.</li><li>Medications and bariatric procedures have legitimate roles when appropriately indicated — but they should not erase prevention from the conversation. Anti-obesity medications can substantially reduce appetite and weight, and metabolic surgery can produce major benefits in severe obesity, but both intervene after excessive weight has already become a significant medical problem.</li><li>Medicine should stop waiting for obesity to become severe enough to require rescue. Detect the trajectory early, confront excessive caloric intake directly, help patients change the environment that promotes overeating and escalate treatment when necessary. The greatest victory in obesity medicine is not successfully treating 100 pounds of excess weight — it is preventing those 100 pounds from accumulating in the first place.</li></ul><h3>GLP-1 DRUGS ARE POWERFUL TOOLS — NOT MAGIC</h3><ul><li>Semaglutide, tirzepatide and related drugs can produce substantial weight loss. They represent an important advance in obesity medicine.</li><li>One of their major effects is reducing appetite and calorie consumption. Their success therefore does not disprove energy balance — it demonstrates how powerful appetite control can be.</li><li>They also carry adverse effects and medical considerations. Nausea, vomiting, constipation and other gastrointestinal effects are common, with rarer serious complications such as temporary vision shifts and optic nerve conditions requiring clinical attention.</li><li>Stopping therapy frequently produces weight gain. Pharmacological appetite suppression does not necessarily permanently eliminate the biological and environmental pressures favoring weight gain.</li><li>Medication can treat obesity without explaining away its origins. Society still needs to ask why unprecedented numbers of people require appetite-suppressing drugs in the first place and why prevention failed.</li></ul><h3>BARIATRIC SURGERY CAN WORK — BUT LOOK AT WHAT OBESITY HAS FORCED MEDICINE TO DO</h3><ul><li>Sleeve gastrectomy permanently removes much of the stomach. Gastric bypass reconstructs gastrointestinal anatomy.</li><li>These operations can produce profound weight loss and metabolic improvement. For appropriately selected patients, their benefits can be substantial.</li><li>But surgery introduces operative and lifelong nutritional considerations. Patients require continuing medical surveillance.</li><li>Its success again does not repeal energy balance. Surgery works partly through profound changes in intake, satiety, gastrointestinal physiology and nutrient handling.</li><li>A society performing major gastrointestinal surgery on a massive scale should be asking why primary prevention failed long before the operating room became necessary.</li></ul><h3>EVERY TREATMENT HAS A PRICE</h3><ul><li>Anti-obesity medications have adverse effects. Some are minor and transient; others can require discontinuation or medical intervention.</li><li>Procedures and operations carry risks. Complications must be balanced against the considerable risks of untreated severe obesity.</li><li>Rapid weight loss can also reduce lean tissue. Nutrition and resistance exercise become important components of treatment.</li><li>Long-term therapy can become expensive. Medications, physician visits, monitoring and procedures all consume healthcare resources.</li><li>Preventing severe obesity avoids an entire cascade of treatment. That makes prevention of overeating not merely medically desirable but economically rational.</li></ul><h3>THE HEALTHCARE SYSTEM IS PAYING AN ENORMOUS PRICE</h3><ul><li>Obesity-associated diseases require enormous healthcare resources. Diabetes, cardiovascular disease, sleep apnea, orthopedic disease and other complications generate continuing expenditures.</li><li>The expense extends beyond physician visits. Prescription drugs, diagnostic testing, hospitalization, surgery and long-term management all contribute.</li><li>Modern anti-obesity drugs add another potentially substantial expenditure. Their downstream savings and long-term cost-effectiveness will depend on patient selection, durability and health outcomes.</li><li>Insurance spreads these costs across populations. The financial consequences therefore extend beyond the individual receiving treatment.</li><li>The obesity epidemic is simultaneously a medical problem and an economic problem. Ignoring overeating prevention guarantees that both bills continue growing.</li></ul><h3>INSURANCE DOESN’T MAKE THE COST DISAPPEAR — IT REDISTRIBUTES IT</h3><ul><li>Insurance pools medical risk. Obesity-related healthcare costs are spread across the insurance pool, meaning those making good lifestyle choices help pay the premiums and medical costs of those not making good lifestyle choices.</li><li>More obesity-related disease means more claims. Chronic illness generates repeated medical utilization rather than a single expense.</li><li>Current U.S. rules generally prevent individual health-insurance premiums from being determined simply by a person’s obesity. That protects access to insurance but does not eliminate the underlying healthcare expenditure.</li><li>Those costs must still be financed. Higher utilization ultimately appears somewhere in premiums, employer spending, government expenditure, taxes or reduced resources elsewhere.</li><li>There is no free healthcare. Every unnecessary disease burden, especially those that can be prevented consumes resources that could have been used elsewhere and those making good life-style choices bear the burden.</li></ul><h3>BODY POSITIVITY SHOULD NEVER BECOME MEDICAL DENIAL</h3><ul><li>No human being deserves ridicule because of body size. Humiliation is neither treatment nor prevention.</li><li>Body positivity correctly challenged cruelty and the idea that human worth depends upon appearance. That was a legitimate social correction.</li><li>But dignity and physiology are different questions. Respecting a person does not require declaring every physical condition healthy.</li><li>A dangerous condition does not become benign because it becomes common. Hypertension would remain dangerous if nearly everyone developed it.</li><li>Respect the individual completely — but confront the health consequences of overeating honestly.</li></ul><h3>“FAT SHAMING” CANNOT BECOME A VETO OVER MEDICAL REALITY</h3><ul><li>Weight stigma can harm people. It can produce psychological distress and discourage patients from seeking healthcare.</li><li>Physicians should therefore discuss obesity professionally rather than contemptuously. There is no medical justification for humiliation.</li><li>But legitimate discussion of obesity’s health consequences is not automatically shaming. Medicine routinely warns patients about modifiable risks.</li><li>The language debate must not consume the disease debate. Perfect terminology will not reverse diabetes, fatty liver disease or cardiovascular risk.</li><li>Eliminate the humiliation — not the conversation about prevention and diet.</li></ul><h3>COMMON DOES NOT MEAN HEALTHY</h3><ul><li>As larger bodies become more prevalent, they inevitably become more visually familiar. Human perception adjusts to whatever surrounds it.</li><li>Commercial culture reflects that change. Clothing, advertising and entertainment appropriately serve and represent consumers of many body sizes.</li><li>But commercial representation is not medical evidence. A product market cannot determine whether a physiological condition increases disease risk.</li><li>Prevalence is not health. A condition can become extraordinarily common while remaining medically undesirable.</li><li>When abnormality becomes commonplace, society must be especially careful not to confuse familiarity with harmlessness and prevention.</li></ul><h3>TYPE 2 DIABETES AND FATTY LIVER SHOULD BE GIANT WARNING LIGHTS</h3><ul><li>Excess adiposity is a major modifiable driver of insulin resistance and type 2 diabetes. Weight reduction can substantially improve glycemic control.</li><li>Fatty liver disease is likewise closely associated with obesity and metabolic dysfunction. Significant weight reduction can markedly reduce liver fat and improve disease markers.</li><li>These diseases are not inevitable consequences of aging. Many cases are strongly influenced by modifiable metabolic and lifestyle factors.</li><li>Medication may still be necessary. But treating the downstream disease without confronting excess weight and weight control leaves a major upstream driver untouched.</li><li>An elevated HbA1c or fatty liver should not merely trigger another prescription — it should trigger a serious examination of the metabolic circumstances producing it and targeting preventive measures.</li></ul><h3>SOCIAL MEDIA CAN TURN IGNORANCE INTO AUTHORITY</h3><ul><li>Everyone can now broadcast an opinion to millions of people. Expertise is no longer required to achieve enormous reach or broadcast ignorance.</li><li>Repetition can make unsupported claims feel true. Viral popularity is easily mistaken for scientific validation.</li><li>Algorithms reward attention rather than accuracy. Outrage, certainty and emotionally satisfying narratives often travel farther than cautious evidence.</li><li>Artificial intelligence can reproduce the same problem. If the underlying information environment contains repeated assumptions, weak studies or commercial messaging, AI can amplify rather than independently prove them.</li><li>Scientific truth is not determined by likes, followers, influencers, repetition or algorithms. It is determined by evidence.</li></ul><h3>THE REAL FAILURE IS WAITING UNTIL OBESITY NEEDS LIFELONG TREATMENT</h3><ul><li>Once severe obesity is established, losing weight and maintaining that loss can become biologically difficult. Prevention therefore has an enormous advantage over rescue.</li><li>Childhood should be the first battlefield. Preventing excessive weight gain before decades of metabolic dysfunction develop offers potentially enormous benefits.</li><li>The food environment must also be confronted. Endless access to oversized, calorie-dense food cannot be treated as irrelevant to population obesity.</li><li>Drugs and surgery should remain available when medically appropriate. But an expanding treatment industry is not evidence that prevention has succeeded.</li><li>The ultimate measure of progress should not be how many people we can medicate for obesity — it should be how many people never become severely obese in the first place.</li></ul><h3>THE OBESITY BILL HAS ARRIVED — AND EVERYONE IS PAYING IT</h3><ul><li>Obesity is not only expanding waistlines — it is expanding America’s healthcare bill. The total economic and healthcare impact of obesity in the United States has been estimated to exceed $1.4 trillion annually when direct medical treatment and broader indirect costs, including workplace productivity losses, are included. Obesity is no longer merely a personal health problem — it has become an extraordinarily expensive national public-health problem.</li><li>The heavier the burden of obesity becomes, the more expensive the medical consequences become. Healthcare expenditures rise substantially with increasing obesity severity as patients require more physician visits, medications, hospital care, diagnostic testing and treatment of obesity-associated diseases.</li><li>And obesity rarely sends only one bill. Diabetes, hypertension, cardiovascular disease, sleep apnea, fatty liver disease, osteoarthritis and other complications generate years — and sometimes decades — of additional medical care, prescriptions, procedures and hospitalizations.</li><li>Now add the enormous cost of treating obesity itself. Anti-obesity medications, including the new generation of GLP-1–based therapies, intensive weight-management programs and bariatric procedures add another layer of expenditure — often treating a problem only after substantial excess weight and its associated medical consequences have already developed.</li><li>This is why prevention cannot remain the forgotten step in obesity medicine. America cannot simply medicate, operate and insure its way out of an ever-expanding obesity epidemic while failing to confront the dietary and environmental forces driving excessive caloric consumption. The price of failing to prevent obesity is eventually paid somewhere — in the doctor’s office, the pharmacy, the operating room, the workplace, insurance premiums, Medicare and Medicaid, or the taxpayer’s pocket.</li></ul><h3>BOTTOM LINE: STOP REFRAMING THE OBESITY EPIDEMIC — CONFRONT IT</h3><ul><li><strong>STOP TURNING A FUNDAMENTAL ENERGY PROBLEM INTO A MEDICAL MYSTERY.</strong> Obesity is subject to the laws of energy: repeatedly consume more food, calories and energy than the body uses through metabolism and activity, and the excess energy is stored — much of it as fat. Continue that surplus long enough, more fat accumulates and obesity develops. Severe restriction of available calories produces weight loss regardless of whether someone exercises — the biology can alter appetite, expenditure and the difficulty of losing weight, but it cannot repeal the laws of energy.</li><li><strong>OBESITY EXPLODED AS OUR WAY OF EATING AND LIVING CHANGED.</strong> The modern obesity epidemic took off around the late 1970s and has since ballooned among children and adults. Declining physical activity contributes, but the transformation of the food environment — ultra-processed, calorie-dense foods, constant snacking, sugary drinks and oversized portions — has made chronic excess caloric intake remarkably easy. We move less, eat more often, and consume more calories with less effort — and the expanding waistline is the predictable result.</li><li><strong>CHILDHOOD OBESITY CAN BUILD A PROBLEM THAT BECOMES HARDER TO REVERSE.</strong> Excess energy during childhood can do more than enlarge existing fat cells (hypertrophy); during growth, adipose tissue can also expand through increases in fat-cell number (hyperplasia). Later weight loss can shrink those cells, but does not simply erase the expanded adipose-cell population — making prevention of childhood obesity far easier than fighting entrenched obesity later in life.</li><li><strong>OBESITY IS BALLOONING — AND SO IS THE MEDICAL BILL.</strong> As obesity rises among children and adults, so do its downstream consequences — type 2 diabetes, cardiovascular disease, fatty liver disease, sleep apnea, joint disease and other costly chronic conditions. The result is a multiplying burden of disease, disability, medications, procedures and healthcare spending that makes obesity not merely a weight problem, but a major public-health and economic crisis. The media should report the complexity without burying the obvious.</li><li><strong>STOP KICKING THE OBESITY CAN DOWN THE ROAD — PREVENTION MUST CONFRONT THE ROOT CAUSE.</strong> Obesity may be common, but common does not mean normal, healthy or harmless: some newer measurements classify nearly <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2843228">75% of U.S. adults</a> as having obesity, while other data suggest that only about <a href="https://journals.sagepub.com/doi/10.1089/met.2018.0105?cf-mal-redirected=true&amp;">12% of American adults</a> meet criteria for optimal metabolic health. Its downstream diseases can be devastating, and some estimates place its total U.S. economic burden near <a href="https://www.sciencedaily.com/releases/2018/10/181030163458.htm">$1.7 trillion</a> annually. And when some 88% of American adults fail to meet criteria for optimal metabolic health, we are looking at one very sick society — and a monumental public-health warning. This catastrophe demands prevention laser-focused on the fundamentals of energy balance: prevent chronic excess caloric intake and excessive weight gain before the damage is done. Anything less simply keeps kicking an enormous healthcare and economic disaster down the road.</li></ul><h3>READ MORE</h3><p><a href="https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/">WHEN A DOCTOR JUMPS IN: WHEN ACTIONS SPEAK LOUDER THAN WORDS</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-deception-how-psa-screening-men-vorstman-md-xajie/">THE GREAT PROSTATE CANCER DECEPTION: How PSA screening and treatments betrayed countless men</a></p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/great-obesity-denial-epidemic-hiding-plain-sight-bert-vorstman-md-iehge/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fb5fdfc8f703" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[THE GREAT PROSTATE CANCER DECEPTION: How PSA Screening and Treatments Betrayed Countless Men]]></title>
            <link>https://bvorstman.medium.com/the-great-prostate-cancer-deception-how-psa-screening-and-treatments-betrayed-countless-men-c9f76b1b75b0?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/c9f76b1b75b0</guid>
            <category><![CDATA[sap]]></category>
            <category><![CDATA[prostate-health]]></category>
            <category><![CDATA[prostate-cancer]]></category>
            <category><![CDATA[prostate]]></category>
            <category><![CDATA[psa-screening]]></category>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Tue, 15 Sep 2026 14:25:20 GMT</pubDate>
            <atom:updated>2026-09-15T14:25:20.227Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*fBaReLmkXyRY5Lq-" /></figure><p>Bert Vorstman MD, Ron Piana</p><p>Physicians have long been aware that their own studies have concluded that PSA screening and prostate cancer treatments fail to save significant numbers of lives. They are equally aware that these tests and treatments can cause some of the most life-altering complications in healthcare—because they have spent decades developing techniques to prevent, repair, or manage those very harms. And they know that most prostate cancers are ultimately outlived, while medicine continues to struggle with the problem that matters most: reliably identifying and effectively treating the minority of aggressive cancers that actually threaten men’s lives. Yet instead of confronting these fundamental failures of the prostate cancer narrative, physicians continue recycling misinformation and producing studies showing marginal benefits to defend entrenched beliefs, practices, and the deceptive “standard of care” label—driving anxiety, fear, massive over-detection and overtreatment, and potentially devastating lifelong harm among vulnerable and unwitting patients.</p><p>Patients have every right to expect truthful medical recommendations grounded in rigorous, reproducible scientific evidence demonstrating safety, meaningful benefit, and life-saving ability—not recommendations built upon beliefs, opinions, assumptions, institutional dogma, or historical practice that make false promises and deliver false hope. When that fundamental obligation is abandoned, this approach to prostate cancer care underscores shameful intellectual dishonesty and professional negligence, violates the physician’s fiduciary responsibility to protect patients from harm and injustice, and is ethically indefensible.</p><h3>1. PSA Screening: A Multibillion-Dollar Experiment Without Substantial Reproducible Life-Saving Evidence</h3><ul><li>PSA (Prostate Specific Antigen) screening has never consistently demonstrated that it saves significant numbers of lives. Despite more than three decades of widespread use, major randomized trials and long-term follow-up studies—including the European Randomized <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2503223">Study</a> of Screening for Prostate Cancer (ERSPC), the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">Screening</a> Trial, the Göteborg Randomized Prostate Cancer <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9275849/">Screening</a> Trial, systematic <a href="https://www.cochrane.org/evidence/CD004720_blood-test-psa-effective-screening-method-prostate-cancer">reviews</a> by the Cochrane Collaboration, and <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/">analyses</a> published in JAMA—have failed to produce consistent, reproducible evidence that population-wide PSA screening substantially improves overall survival or saves significant numbers of lives. This is hardly surprising as the PSA test is highly unreliable and fails to meet the criteria for being a useful screening test.</li><li>Prostate cancer studies are commonly undermined by two fundamental weaknesses: unreliable screening and scientifically heterogeneous studies. The DRE and PSA cannot reliably distinguish the minority of aggressive, potentially lethal cancers from the far more common indolent cancers men frequently outlive, while studies routinely combine different Gleason grades, scores, tumor volumes, biological behaviors, and risks—as though they represent the same disease. This failure to compare like with like will skew results toward an appearance of screening benefit without establishing that screening actually saves substantial numbers of men from the high-grade cancers that threaten their lives.</li><li>Early detection has never been shown to reliably prevent metastatic disease. The assumption that finding prostate cancer earlier prevents later metastatic spread remains unproven. Some biologically aggressive prostate cancers produce very <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.29691">little</a> or no PSA and therefore escape detection altogether, while others may have already disseminated <a href="https://www.sciencedirect.com/science/article/pii/S0304383521004985">microscopic amounts</a> of cancer to the bone marrow long before the primary tumor becomes clinically detectable. Detecting the prostate lesion earlier cannot necessarily reverse biology that has already occurred.</li><li>No currently available prostate cancer biomarker has reproducibly demonstrated substantial life-saving ability. Beyond PSA, PSA derivatives and PSA density, numerous biomarkers, imaging strategies, genomic panels, and diagnostic algorithms have entered clinical practice. Yet none has consistently demonstrated reproducible evidence that population screening meaningfully reduces mortality from aggressive prostate cancer.</li><li>The commercialization of PSA transformed uncertainty into accepted medical practice. During the late 1980s and early 1990s, PSA screening rapidly evolved from a monitoring tool into a population-wide screening program. This transformation occurred before convincing evidence demonstrated that routine screening improved meaningful clinical outcomes, creating an enormous industry built around testing, biopsies, treatment, surveillance, and repeated follow-up despite continuing scientific controversy.</li></ul><h3>2. The ERSPC 23-Year Follow-up: Does a Small Disease-Specific Mortality Difference Justify Population-Wide PSA Screening?</h3><ul><li>The European Randomized Study of Screening for Prostate Cancer (ERSPC) is frequently cited as evidence that PSA screening saves lives. After a median follow-up of 23 years, the investigators reported a 13% relative reduction, but only a 0.22% absolute reduction, in deaths attributed to prostate cancer, while prostate cancer diagnoses increased by approximately 30% among men invited to screening.</li><li>The study did not demonstrate a substantial improvement in overall survival or measure the full downstream consequences of cancer detection. It did not comprehensively quantify overdiagnosis, repeat PSA testing, biopsies, biopsy complications, treatment-related urinary, sexual and bowel dysfunction, psychological distress, treatment regret, quality-of-life impairment, financial costs, or deaths related to subsequent interventions. Without these outcomes, the true net harm-benefit balance cannot be fully determined.</li><li>The ERSPC findings should be interpreted within the biological complexity of prostate cancer. Screening trials inevitably include large numbers of biologically indolent cancers—including the Gleason 6 pseudo-cancer and many low-risk cancers that may require 40 years or more to reach a clinically significant size—alongside the relatively small proportion of biologically aggressive cancers. This can dilute or distort the apparent treatment benefit for the subgroup of truly aggressive cancers. Furthermore, some high-grade prostate cancers can disseminate cancer cells into the bone marrow and remain dormant for years or even decades before becoming clinically detectable.</li><li>Fundamental biological and diagnostic limitations remain unresolved. PSA is not a cancer-specific biomarker, produces large numbers of false-positive results, misses some biologically aggressive cancers that produce little or no PSA, and is used to detect a disease in which the majority of cancers are indolent and mostly outlived, while only a minority—approximately 10–15%—are biologically <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4508854/">aggressive</a> and potentially life-threatening.</li><li>The central scientific question therefore remains unanswered. A modest reduction in prostate cancer-specific mortality, without a demonstrated substantial improvement in overall survival and without comprehensive measurement of the downstream harms of detection and treatment, does not by itself establish that population-wide PSA screening provides a clear net life-saving benefit.</li></ul><h3>3. Prostate Cancer Treatment: Extensive Intervention Without Demonstrated Substantial Survival Advantage</h3><ul><li>The assumption that treatment is curative and saves substantial numbers of lives remains scientifically unproven. Radical prostatectomy, robotic surgery, radiation therapy, proton therapy, brachytherapy, focal therapies and active surveillance have all become accepted treatments despite an absence of reproducible long-term evidence demonstrating substantial life-saving benefit for men with localized disease. Numerous studies extending to approximately <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">12</a>,<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15</a>, and <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20</a> years have failed to consistently demonstrate major survival advantages for treatment populations. In fact, at about 20 years treated and untreated patients had similar survival rates. A detail that makes a mockery of treatment guidelines, screening recommendations and active surveillance.</li><li>Treatment is frequently directed toward cancers that may never become clinically dangerous. Most prostate cancers exhibit remarkably slow biological behavior and are outlived. Many low-risk tumors require decades to reach clinically significant size, meaning numerous patients undergo irreversible treatment for disease that would likely never have threatened their lives. Additionally, most men diagnosed with prostate cancer—particularly those with localized, low-risk disease—will ultimately die from competing illnesses and age-related co-morbidities rather than from their prostate cancer. This fundamental reality is too often lost in a prostate cancer narrative that treats the diagnosis itself as an impending threat to life.</li><li>No reproducible evidence demonstrates that local treatment consistently prevents metastatic progression of biologically aggressive disease. Aggressive cancers may already possess metastatic potential before diagnosis. Removing or irradiating the prostate cannot necessarily eliminate disseminated cancer cells that have already migrated beyond the prostate gland.</li><li>Treatment recommendations often rely on beliefs, opinions and assumptions rather than demonstrated benefit. The absence of a better treatment option does not constitute evidence that current treatments are effective. Medical recommendations should rest upon reproducible scientific evidence showing that benefits clearly outweigh harms—not on historical practice patterns or theoretical expectations.</li><li>Castration May Delay Prostate Cancer—It Does Not Cure It. Castration may be medical as with Androgen Deprivation Therapy (ADT) using GnRH “shots” or other drugs or surgical by removing the testicles—lowering testosterone to temporarily suppress prostate cancer may extend life a few years but it is also not curative and associated with complications. Adding ADT to another prostate cancer procedure should not be confused with proof of cure or substantial life-saving benefit—more treatment does not necessarily mean more lives saved. About <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7242115/">45–50%</a> of prostate cancer patients receive ADT, despite substantial metabolic, cardiovascular, skeletal, cognitive, sexual, and quality-of-life consequences.</li></ul><h3>4. The Extraordinary Burden of Treatment Complications</h3><ul><li>Few medical interventions produce such a broad spectrum of life-altering complications. Urinary incontinence, erectile dysfunction, bowel dysfunction, urethral strictures, chronic pelvic symptoms, infertility, loss of ejaculation, shortened penis after surgery, chronic pain, and psychological distress remain distressingly common <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">consequences</a> of prostate cancer treatment.</li><li>Initial treatment frequently fails to end the treatment journey. Many patients require salvage radiation, hormonal therapy, salvage surgery, artificial urinary sphincters, penile prostheses, urethral reconstruction, additional medications, rehabilitation programs, or repeated procedures to manage complications created by previous interventions.</li><li>Cancer control itself is frequently incomplete. Positive surgical margins or residual cancer occur in <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of radical prostatectomy specimens (whether open or robotic), and biochemical recurrence or rising PSA develops in <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients within ten years, demonstrating that treatment does not necessarily eliminate cancer.</li><li>Complications generate ongoing financial and emotional costs. Long-term medical appointments, repeat imaging, laboratory monitoring, medications, prosthetic devices, rehabilitation, revision procedures, lost productivity, anxiety and treatment regret impose enormous burdens extending years beyond the initial diagnosis.</li><li>Metastatic disease is increasingly compatible with prolonged survival. Although metastatic prostate cancer remains serious, advances in systemic therapies frequently allow many patients to live for years with acceptable quality of life. Therefore, portraying localized treatment as the only alternative to catastrophic suffering oversimplifies a far more complex clinical reality. Around 10-20% of men with prostate cancer present with <a href="https://www.sciencedirect.com/science/article/abs/pii/S146238891470002X">metastatic</a> disease at diagnosis while 20-30% of those with localized disease will go on to develop metastases.</li></ul><h3>5. Managing Patient Expectations—or Managing the Damage?</h3><ul><li>Few treatment arenas require as much preparation for treatment-related harm as prostate cancer. Physicians know that surgery, radiation, hormonal therapy, and other interventions can produce profound urinary, sexual, bowel, hormonal, and psychological consequences. Yet rather than beginning with the fundamental question—where is the reproducible evidence that the proposed intervention is safe, beneficial, and meaningfully life-saving?—the discussions focus on treatment &quot;benefits&quot;, informed consent, shared decision-making, risk tolerance, risk stratification, treatment preferences, the standard of care racket and personalized care.</li><li>“Managing patient expectations” becomes damage control when serious complications are anticipated before treatment even begins. Patients and their spouses are counseled about impotence, incontinence, loss of ejaculation, sexual changes, rehabilitation, medications, implants, and other consequences. Preoperative counseling and postoperative rehabilitation may be valuable, but their very existence underscores an uncomfortable reality: medicine has developed an extensive infrastructure for preparing patients for harm and managing the damage after it occurs.</li><li>Shared decision-making becomes deeply problematic when the underlying benefits remain uncertain. Asking frightened patients to choose among surgery, radiation, focal therapy, hormonal therapy, or surveillance based upon their “preferences” and “risk tolerance” can create an illusion of informed choice if the magnitude of life-saving benefit is uncertain or overstated. Informed consent cannot be truly informed when potential benefits are emphasized while the limitations of the evidence are not communicated with equal force.</li><li>The terrifying word “cancer” profoundly distorts the decision before the conversation even begins. Newly diagnosed men commonly equate cancer with impending death, and that fear can be amplified by awareness campaigns, internet misinformation, “survivor” stories, and repeated claims that “early detection saves lives.” What patients may fail to appreciate is that many prostate cancers are slow-growing and ultimately outlived, while testing and treatment themselves can impose permanent complications affecting not only the patient but sexual intimacy, relationships, quality of life, and treatment regret.</li><li>Managing expectations must never become a substitute for confronting the evidence. Preparing patients and their spouses for impotence, incontinence, rehabilitation, additional treatments, or other adverse outcomes does not establish that the original intervention was necessary or life-saving. When testing and treatment overpromise and underdeliver, managing the resulting harm becomes institutionalized damage control. Patients deserve more than preparation for bad outcomes—they deserve an unvarnished accounting of what is known, what remains unproven, how serious the harms can be, and whether the proposed intervention has actually been shown to meaningfully extend their lives.</li></ul><h3>6. Prostate Cancer Awareness Campaigns: Amplifying Fear, Overtreatment, and Health Robbery</h3><ul><li>Prostate cancer awareness campaigns make September a very dangerous month for men. Prostate cancer awareness groups (along with their Foundations, Advocacy, Support and Men’s Health groups) have become the propaganda machine for an entrenched prostate cancer industry—promoting its narrative through fear, urgency, half-truths, catchy slogans, exaggerations, and misrepresentations. Few messages are more persuasive to a frightened man than “early detection saves lives,” steering vulnerable and unwitting patients directly into the screening, biopsy, detection, and treatment machinery despite a lack of reproducible evidence over the magnitude of life-saving benefit and the well-established risks of overdiagnosis and overtreatment. Decades of relentless repetition have transformed a false prostate cancer narrative into a self-perpetuating ideology—repeated so often that belief has become a substitute for proof.</li><li>Prostate cancer awareness campaigns are remarkably effective at exploiting celebrity diagnoses to reinforce the prostate cancer narrative and imply that earlier detection might have saved the day. Movie-star diagnoses and even former President Joe Biden’s metastatic prostate cancer have been used to reignite the familiar “early detection saves lives” message—despite the fact that an individual celebrity case cannot establish that earlier PSA screening would have prevented metastatic disease or saved a life. “Survivor stories” can be equally misleading: many men may simply have survived treatment for a slow-growing cancer that would never have killed them, rather than having their lives saved by treatment. Men deserve rigorous, reproducible evidence of substantial life-saving benefit—not celebrity anecdotes, manipulated survivor stories, fear, false promises, and false hope.</li><li>Prostate cancer awareness campaigns commonly exaggerate urinary and sexual changes as early warning signs of prostate cancer—dribbling, weak flow, getting up at night, microscopic blood in the urine, and changes in sexual function. Yet these symptoms are far more commonly associated with benign prostatic enlargement, aging, or other non-cancerous conditions than prostate cancer. Furthermore, most prostate cancers arise in the peripheral zone, away from the urinary channel, making early urinary obstruction an unlikely early cancer warning sign.</li><li>High-risk populations are aggressively targeted for earlier and intensified PSA screening despite a lack of reproducible evidence that this strategy substantially improves overall survival. Age, family history, inherited mutations, and ancestry can increase prostate cancer risk, yet targeting these men more aggressively does not by itself prove that screening saves substantial numbers of lives. Despite decades of screening and awareness campaigns, roughly 35,000 American men still die from prostate cancer annually—predominantly from aggressive disease. Earlier declines in mortality may reflect multiple factors, including improvements in treatment and management of competing illnesses; more recent mortality trends also require careful interpretation. The ballooning obesity epidemic presents another serious challenge: obesity is associated with lower PSA concentrations and with more aggressive, advanced disease and poorer outcomes. This failure of the annual death rate statistics to show any significant drop is likely because prostate cancer treatments fail to save a substantial number of lives.</li><li>The prostate cancer awareness industry grew through advocacy, lobbying, institutional endorsement, and relentless public messaging—not reproducible evidence that screening and treatment save substantial numbers of lives. Governments, corporations, advocacy groups, foundations, hospitals, and medical institutions were fooled into amplifying this narrative, often alongside financial support from industries benefiting from increased screening and treatment. The result is a self-perpetuating prostate cancer narrative in which advocacy, financial incentives, and repetition have helped fuel overscreening, overdiagnosis, overtreatment, and ultimately the health robbery of countless men.</li></ul><h3>7. One Name, Many Diseases: Why the Prostate Cancer Label Misleads Patients</h3><ul><li>The single term &quot;prostate cancer&quot; conceals enormous biological diversity. Tumors vary dramatically in aggressiveness, molecular biology, growth rate, metastatic potential, and clinical significance. Treating every diagnosis as biologically identical ignores fundamental scientific reality.</li><li>Most prostate cancers are biologically indolent. Autopsy studies demonstrate that areas of prostate cancer are extraordinarily common in older men, many of whom lived normal lifespans without ever knowing these lesions existed. In fact, some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60% of men</a> over 65 have areas of prostate cancer. Additionally, many prostate cancers have very sluggish growth rates with cell division counts about 479 +/- 56 days per cycle, so that from mutation to a growth of 1 cm takes 40 <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">years</a> or more.</li><li>Multifocal disease further complicates diagnosis. 80-90% of prostate cancers are <a href="https://www.nature.com/articles/s41467-020-14657-7">multifocal</a>, meaning two or more separate tumor nodules which frequently differ in Gleason grade, genetic profile, size, and biological behavior, making simplistic classifications misleading.</li><li>Only a minority of prostate cancers behave aggressively. Approximately 10–15% exhibit <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4508854/">high-grade</a> biology capable of causing significant morbidity or mortality, whereas the majority follow a far more indolent course.</li><li>Aggressive cancers often evade conventional assumptions. Some high-grade cancers produce little or no PSA, while other high-grade cancers may disseminate cells to the bone marrow years before detection on MRI, illustrating why biological behavior—not merely timing of detection—determines outcome.</li></ul><h3>8. Gleason 6: When is Cancer Not Cancer?</h3><ul><li>The biological behavior of pure Gleason 6 differs fundamentally from cancer. Grade 3 cells within the Gleason 3+3=6 <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lack the biological</a> mechanisms necessary to behave as cancerous.</li><li>Its classification was originally based largely on microscopic appearance rather than demonstrated malignant behavior. Partial basal cell layer loss, subtle architectural changes, and perineural invasion were interpreted as evidence of malignancy despite similar findings and minor biochemical changes also occurring in benign prostate tissue.</li><li>Evidence demonstrating progression into higher-grade disease remains unproven. There is no reproducible scientific evidence that pure Gleason 6 lesions themselves biologically transform into more aggressive cancers.</li><li>Pure Gleason 6 fails to behave as deadly. Verified deaths attributable solely to pure Gleason 6 remain absent, fueling continued debate regarding appropriate terminology.</li><li>Maintaining the &quot;cancer&quot; label for Gleason 6 disease carries profound psychological and medical consequences, despite the absence of many of the biological mechanisms associated with cancer. The diagnosis itself often triggers fear, anxiety, repeated testing, invasive procedures, overtreatment, treatment-related complications, financial burden, and diminished quality of life. When a diagnostic label drives harm out of proportion to the biological behavior of the lesion, its continued use demands careful scientific and clinical re-evaluation.</li></ul><h3>9. The Reproducibility Crisis: When Medical Belief Outpaces Scientific Evidence</h3><ul><li>Medicine has repeatedly transformed assumptions into accepted practice. Numerous interventions have progressed from beliefs to accepted practice, standard practice and standard of care before undergoing rigorous scientific validation.</li><li>Most if not all, prostate cancer studies combine fundamentally different diseases into one analysis. Pooling the Gleason 6 pseudo-cancer, low-risk cancers, intermediate-risk disease, high-grade cancers, varying tumor volumes, unreliable imaging and differing treatments makes interpretation of outcomes extraordinarily dubious.</li><li>Multiple confounding variables weaken conclusions. Testosterone suppression, crossover treatments, heterogeneous patient populations, and differing follow-up protocols complicate attempts to isolate true treatment effects.</li><li>The reproducibility crisis affects medicine broadly. Independent investigators frequently fail to reproduce published findings, highlighting weaknesses in methodology, publication bias, statistical practices, and academic incentives.</li><li>Scientific credibility requires reproducibility—not repeated opinion. Clinical recommendations should ultimately rest upon independently reproducible evidence demonstrating meaningful patient benefit rather than tradition, authority, or consensus alone.</li></ul><h3>10. The Original Claims for Radical Prostate Cancer Surgery Were Unsupported by the Evidence</h3><ul><li>Modern radical prostate cancer surgery began with H. H. Young&#39;s radical perineal prostatectomy at Johns Hopkins in 1904–1905. Combining an existing perineal surgical approach with William Halsted&#39;s principle of removing tissue surrounding a cancer, Young introduced the first radical operation for prostate cancer and <a href="https://www.hopkinsmedicine.org/-/media/brady-urology-institute/documents/historical-research-papers/1905b.pdf">published</a> his results in the 1905 <em>Johns Hopkins Hospital Bulletin</em> under the ambitious title, <em>The Early Diagnosis and Radical Cure of Carcinoma of the Prostate.</em></li><li>The title itself promised far more than the evidence supported. There was no reliable method for the early diagnosis of prostate cancer and no scientific evidence that radical prostatectomy produced a cure. Nevertheless, Young presented the operation as both an early diagnostic and curative procedure despite the absence of objective supporting data.</li><li>Young&#39;s own clinical results contradicted his conclusions. Although he described the operation as demonstrating its &quot;simplicity, effectiveness and remarkably satisfactory functional results,&quot; two of his first four patients died following surgery, while the remaining two endured prolonged hospitalizations and lifelong urinary incontinence. Sexual function was not reported, although erectile dysfunction was likely given the extent of the surgery.</li><li>These early reports established a pattern of herd mentality and optimistic claims preceding rigorous scientific validation. Conclusions regarding effectiveness, safety, and cure were drawn from an extremely small case series without controls, long-term follow-up, standardized outcome measures, or reproducible evidence demonstrating that the operation was safe, effective and life-saving.</li><li>The history of radical prostatectomy illustrates an enduring lesson in medicine. Surgical innovation should not be confused with scientific proof. Claims of safety, effectiveness, or cure require rigorous, reproducible clinical evidence rather than enthusiastic interpretation of limited early experience. The subsequent evolution of prostate cancer surgery would involve more than a century of technical refinements attempting to reduce complications while the fundamental questions regarding long-term patient benefit remain unproven.</li></ul><h3>11. The Hidden Cost of Radical Prostatectomy: A Century of Attempts to Reduce Its Harm</h3><ul><li>The significant complications of radical prostatectomy drove decades of continual modification. Surgeons abandoned early perineal approaches in favor of retropubic surgery and introduced <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12300103/">numerous</a> technical refinements—including improved bleeding control, nerve-sparing procedures, and bladder-neck preservation—in an effort to reduce hemorrhaging, urinary incontinence, erectile dysfunction, and other life-altering complications.</li><li>When surgical refinements failed to eliminate these complications, an entire prosthetic industry emerged. Beginning in the 1970s, penile implants and artificial urinary sphincters were developed to treat post-prostatectomy erectile dysfunction and urinary incontinence (limp and leaking). While often beneficial, these devices introduced additional complications, including infection, mechanical failure, revision surgery, chronic pain, and irreversible loss of natural erectile function.</li><li>Shared decision-making evolved as patients faced multiple treatments with similar long-term outcomes but different side-effect profiles. Although designed to improve informed consent and reduce treatment regret, shared decision-making becomes more challenging when the magnitude of treatment benefit remains uncertain and patients must weigh irreversible complications against incomplete evidence of long-term benefit.</li><li>Persistent complications led to the development of preoperative and postoperative rehabilitation programs. Pelvic floor rehabilitation, penile rehabilitation, and Enhanced Recovery After Surgery (ERAS) pathways were progressively introduced to improve continence, sexual function, recovery, and patient expectations following treatment.</li><li>Treatment regret after prostate cancer therapy is <a href="https://www.sciencedirect.com/science/article/abs/pii/S2588931123000378">reported</a> at about 20%, but the true human cost may be substantially greater when spouses and partners are included. Men commonly underreport or minimize their postoperative “limp and leaking” problems—often out of pride, embarrassment, or reluctance to acknowledge the full extent of the damage. Wives and partners may report the persistent urinary leakage, erectile dysfunction, loss of sexual function, and destruction of intimacy far more openly. The high treatment-regret rate is hardly surprising: prostate cancer treatments can produce life-altering complications, fail and require re-treatment or salvage therapy, while the complications themselves trigger still more counseling, procedures, rehabilitation, medications, or implants. These harms do not end with the patient: they can profoundly disrupt identity, intimacy, relationships, and quality of life—leaving both the man and his partner to live with the aftermath long after the treatment is over. For some men, a frightening cancer diagnosis, traumatic surgery, complications, loss of bodily function, and repeated interventions can also produce post-traumatic stress symptoms or PTSD.</li></ul><h3>12. The Evolution of Robotic-Assisted Surgery</h3><ul><li>After nearly 80 years of refining open radical prostatectomy, robotic technology entered surgery during the 1990s. Originally developed through DARPA, NASA, and U.S. military research, robotic systems were designed for remote &quot;telepresence&quot; surgery to treat wounded soldiers and, potentially, astronauts in environments where expert surgeons were not physically present.</li><li>Early robotic systems focused on improving surgical precision rather than replacing surgeons. Milestones included the PUMA 560 for neurosurgery, ROBODOC for orthopedic procedures, and AESOP, a voice-controlled robotic camera holder that functioned as a surgeon&#39;s &quot;third hand.&quot;</li><li>The introduction of the da Vinci Surgical System marked the beginning of modern robotic surgery. By integrating earlier military and commercial technologies, Intuitive Surgical developed a comprehensive robotic platform that received FDA clearance in 2000 for laparoscopic gallbladder surgery and subsequently became the dominant robotic surgical system worldwide.</li><li>Robotic surgery represented an evolution in surgical technology rather than a new operation. The surgeon remained in complete control while the robotic system translated hand movements into more precise instrument movements, offering enhanced visualization, improved dexterity, tremor filtration, and minimally invasive access.</li><li>The rapid adoption of robotic surgery fundamentally transformed surgical practice. Within two decades, robotic-assisted techniques expanded across multiple specialties—particularly urology—where radical prostatectomy became one of the most commonly performed robotic procedures, reshaping surgical training and the global practice of minimally invasive surgery.</li></ul><h3>13. The Overseas Robotic Surgery Trial: Testing Instruments Rather Than Proving Clinical Benefit</h3><ul><li>The first human clinical studies of the robotic system were remarkably limited in scope. The initial prospective <a href="https://wayback.archive-it.org/7993/20170404123010/https:/www.fda.gov/ohrms/dockets/ac/99/transcpt/3523t1.pdf">clinical investigation</a> was performed in Mexico City using laparoscopic gallbladder removal (cholecystectomy) and Nissen fundoplication—not prostate cancer surgery. Patients were randomized to conventional laparoscopy or robotic-assisted procedures, but the primary objective was not to determine whether robotic surgery improved patient outcomes.</li><li>The trial evaluated the robotic instruments—not the entire robotic surgical concept. The FDA-directed study focused on whether the robotic endoscopic instruments could safely perform basic surgical tasks such as grasping, cutting, suturing, electrocautery, dissection, and ligation compared with standard laparoscopic instruments. It was not designed to establish that robotic surgery produced superior clinical results, fewer complications, or better long-term patient outcomes.</li><li>No meaningful clinical advantage was demonstrated. The study failed to establish clinically important improvements in patient recovery, complication rates, long-term outcomes, or overall surgical effectiveness. At best, it suggested that the robotic instruments could perform similar technical functions during selected laparoscopic operations.</li><li>The procedures studied bore little resemblance to prostate cancer surgery. Gallbladder surgery and gastric fundoplication are fundamentally different operations from radical prostatectomy in anatomy, surgical objectives, technical complexity, and expected complications. Extrapolating findings from one field to another required substantial assumptions rather than direct scientific evidence.</li><li>The early robotic trials represented technological feasibility rather than proof of clinical superiority. Demonstrating that robotic instruments could perform surgical movements safely is fundamentally different from proving that patients benefit from robotic surgery. These are distinct scientific questions requiring entirely different levels of evidence.</li></ul><h3>14. FDA Approval: Regulatory Acceptance Without Demonstrated Patient Benefit</h3><ul><li>The FDA accepted evidence generated outside the United States. The pivotal clinical study supporting regulatory review was conducted in Mexico rather than within the more extensive U.S. clinical research infrastructure, raising questions regarding regulatory oversight, ethical review, and study rigor.</li><li>The approval in 2000 was not based upon demonstrated clinical superiority. According to FDA panel discussions, the <a href="https://wayback.archive-it.org/7993/20170404123010/https:/www.fda.gov/ohrms/dockets/ac/99/transcpt/3523t1.pdf">available evidence</a> failed to show meaningful improvements in patient outcomes compared with conventional laparoscopic surgery. No convincing reductions in complications, faster recovery, improved function, or superior effectiveness were demonstrated.</li><li>Regulatory optimism replaced demonstrated clinical benefit. The robotic platform received regulatory approval largely because reviewers believed it showed &quot;potential for future enhancements to surgery&quot; rather than because it had already demonstrated substantial improvements in patient care.</li><li>Even members of the FDA advisory panel expressed reservations. During deliberations, concerns were raised regarding efficacy and equivalence, with some reviewers concluding that while safety might be acceptable, convincing evidence demonstrating effectiveness or equivalence had not yet been established.</li><li>Patients frequently equate &quot;FDA approved&quot; with scientifically proven. In reality, regulatory approval and proof of meaningful clinical benefit are not synonymous. Approval allows marketing under defined regulatory standards, but it does not necessarily establish that a technology improves survival, reduces complications, or produces superior long-term outcomes.</li></ul><h3>15. Robotic Prostatectomy: Adoption Before Definitive Scientific Validation</h3><ul><li>Robotic prostatectomy was FDA approved in 2001 and entered practice without randomized evidence demonstrating superior cancer outcomes. Once robotic technology proved commercially unsuccessful in gallbladder surgery, attention shifted toward prostate cancer surgery, where enthusiasm for radical prostatectomy already existed despite longstanding controversy regarding its overall survival benefit.</li><li>The regulatory pathway differed substantially from formal clinical approval. Rather than requiring new randomized trials demonstrating improved prostate cancer outcomes, expansion into prostate surgery relied largely upon the FDA&#39;s 510(k) clearance <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K011002">process</a>, which evaluates <a href="https://www.linkedin.com/pulse/strategies-demonstrating-substantial-equivalence-fda-510k-caro-rwh9c/">substantial equivalence</a> to previously marketed devices rather than requiring proof of superior clinical effectiveness.</li><li>Substantial equivalence does not establish clinical superiority. Demonstrating that surgical instruments resemble previously marketed devices is fundamentally different from demonstrating that an entirely new surgical platform improves cancer control, reduces complications, or prolongs survival.</li><li>Technical improvements should not be confused with biological improvements. Smaller incisions, reduced blood loss, lower transfusion rates, and shorter hospital stays represent procedural refinements, but they do not independently demonstrate better long-term cancer outcomes or improved survival.</li><li>The central scientific question remained unresolved. Whether robotic-assisted radical prostatectomy meaningfully improves long-term patient outcomes compared with existing treatments requires reproducible evidence beyond regulatory clearance or technological innovation.</li></ul><h3>16. Open and Robotic Surgery Share the Same Fundamental Biological Complications</h3><ul><li>Changing the surgical platform does not eliminate the biological consequences of removing the prostate. Whether surgery is performed through an open incision or with robotic assistance, the same anatomical structures—including urinary sphincters, neurovascular bundles, pelvic fascia, rectum and surrounding tissues—remain <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8863696/">vulnerable</a> to injury.</li><li>Urinary complications remain among the most common long-term consequences. Stress urinary incontinence, urge incontinence, bladder-neck contracture, urethral narrowing, anastomotic strictures, and urinomas continue to affect significant numbers of patients following both open and robotic procedures.</li><li>Sexual complications remain substantial despite nerve-sparing techniques. Erectile dysfunction, loss of ejaculation, altered orgasm, penile shortening, corporal fibrosis, penile bending and diminished sexual function frequently occur because even meticulous nerve preservation cannot guarantee preservation of delicate neurovascular structures.</li><li>Robotic surgery reduces certain perioperative risks without eliminating major complications. Blood loss, transfusion requirements, and hospital length of stay are generally improved, yet infections, thromboembolic events, limp and leaking events, bowel injury, ureteral injury, lymphoceles and other perioperative complications continue to occur. As well, robotics introduces new potential complications such as trocar injuries, trocar site hernias, positioning injuries, eye injuries, nerve damage, rhabdomyolysis, subcutaneous emphysema, gas embolism, pneumothorax and other problems.</li><li>Cancer control remains imperfect regardless of surgical technique. Positive surgical margins <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">(residual cancer)</a> in 11-48% of patients, biochemical recurrence <a href="https://www.nature.com/articles/s41391-023-00712-z">(rising PSA)</a> in 20-50% of patients by 10 years, and the potential presence of disseminated tumor cells from high-grade cancer in the bone marrow remain challenges that neither open nor robotic surgery completely eliminates.</li></ul><h3>17. Less-Invasive Treatments: Different Technologies, the Same Fundamental Scientific Question</h3><ul><li>The wide variety of treatments for localized prostate cancer underscores the absence of a single universally accepted therapy. In addition to radical surgery, physicians may recommend active surveillance, watchful waiting, external beam radiation therapy (EBRT), brachytherapy, proton beam therapy, androgen deprivation therapy (ADT), or combinations of these approaches. The combination of EBRT with the radiosensitizing ability of ADT has not been conclusively proven to extend life beyond 20 years.</li><li>More recently, minimally invasive focal therapies—including High-Intensity Focused Ultrasound (HIFU), cryotherapy (freezing), Irreversible Electroporation (IRE/NanoKnife®), Focal Laser Ablation (FLA), Transurethral Ultrasound Ablation (TULSA), and Vascular Targeted Photodynamic Therapy (VTP)—have been introduced in an effort to reduce treatment-related morbidity while preserving cancer control.</li><li>The expansion of treatment options reflects the ongoing search for alternatives to the significant complications of radical prostatectomy. Less-invasive therapies attempt to preserve urinary continence, sexual function, and quality of life by treating only part of the prostate or avoiding surgery altogether. However, the growing number of competing technologies also highlights the continuing lack of consensus regarding the optimal management of localized prostate cancer.</li><li>Despite impressive technological advances, the central scientific question remains unchanged. While many of these therapies can provide local tumor ablation and favorable short to intermediate-term outcomes, reproducible scientific evidence demonstrating substantial long-term life-saving benefit remains unproven. Local tumor control, declining PSA levels, or delayed progression should not automatically be interpreted as proof that treatment prolongs life or prevents metastatic disease.</li><li>Less-invasive treatments have their own limitations and complications. Patients remain at risk of urinary retention, urinary tract infections, urethral strictures, hematuria, dysuria, urinary incontinence, erectile dysfunction, ejaculatory dysfunction, rectourethral fistulas, and prostatic abscesses. While radiation is also associated with a small risk of developing a second primary cancer, focal therapies intentionally leave untreated prostate tissue behind and persistent, previously undetected, or newly developing cancers may remain or arise outside the treatment zone, often requiring additional treatment. Furthermore, biochemical recurrence—a rising PSA following treatment—has been reported in a substantial proportion of patients within 10 years, with published rates varying widely according to treatment type, disease characteristics, and duration of follow-up.</li></ul><h3>18. Residual Disease and Biochemical Recurrence Challenge the Concept of Cure</h3><ul><li>Positive surgical margins remain common. Cancer extending to the edge of the surgical specimen (in 11-48% of patients) indicates that residual tumor remains despite complete removal of the prostate, often leading to recommendations for additional radiation or hormonal therapy.</li><li>Biochemical recurrence demonstrates that many patients are not permanently cured. Rising PSA following treatment affects 20-50% of patients within ten years and increases with longer follow-up, reflecting persistent or recurrent disease despite definitive local therapy.</li><li>Prostate cancer treatment commonly fails, triggering a relentless cycle of treatment piled upon treatment. When surgery fails, salvage radiation may follow; when radiation fails, salvage surgery or focal therapy may be considered; and when PSA rises after treatment, ADT may become the next intervention—yet there’s no long-term reproducible evidence of substantial life-saving benefit for these salvage treatments. And there’s no single PSA threshold that dictates when ADT should begin, and hormonal therapy may be administered intermittently, with PSA monitored and allowed to rise before another treatment cycle rather than being permanently driven to zero. The disturbing reality is that every additional intervention brings another opportunity for harm without certainty that the accumulating burden will meaningfully extend his life.</li><li>Aggressive prostate cancer may already have escaped the prostate long before diagnosis or treatment. Disseminated cancer cells (DCCs) may migrate into the bone marrow while the primary tumor remains extremely small, placing disease beyond the reach of local treatment. These disseminated cells may then remain clinically dormant for years or even decades before becoming active, creating the appearance of long-term cure even though systemic disease may have been established long before the prostate was treated.</li><li>Long disease-free intervals should not automatically be interpreted as proof of curative treatment. The natural history of prostate cancer—including prolonged biological dormancy—makes distinguishing treatment effects from underlying tumor biology particularly difficult.</li></ul><h3>19. The Expanding Landscape of &quot;Standard of Care&quot; Treatments</h3><ul><li>Multiple radically different treatments share remarkably similar long-term survival outcomes but not cures for many patients. Surgery, radiation, brachytherapy, proton therapy, focal therapies, hormonal treatment, salvage procedures, and active surveillance frequently demonstrate comparable long-term overall survival for many localized cancers despite markedly different complication profiles.</li><li>Technological innovation does not automatically establish improved effectiveness. Cryotherapy, HIFU, irreversible electroporation, focal laser ablation, TULSA, and photodynamic therapy represent engineering advances that still require rigorous long-term evaluation before superiority can be assumed.</li><li>Hormonal therapy remains palliative rather than curative. Although androgen deprivation therapy may prolong survival in selected patients with metastatic disease, it carries substantial metabolic and quality-of-life consequences and does not eliminate metastatic cancer. Androgen deprivation therapy (ADT) is one of the most physiologically disruptive treatments in medicine, affecting virtually every organ system. Beyond eliminating libido and causing erectile dysfunction, it is associated with genital shrinkage, hot flashes, night sweats, breast enlargement, weight gain, muscle wasting, osteoporosis and fractures, diabetes, adverse lipid changes, fatigue, cognitive impairment, depression, anemia, and an increased risk of cardiovascular disease, heart attack, and stroke—often leaving men with additional lifelong complications that can profoundly diminish both health and quality of life.</li><li>Many comparative treatment studies remain methodologically heterogeneous. Mixing patients with different Gleason grades, scores, tumor volumes, biological risk profiles, prior treatments, and hormonal therapies makes definitive interpretation of treatment effectiveness highly unreliable.</li><li>Medical reversals remind medicine that accepted practice is not permanent truth. Numerous interventions once regarded as standard of care have later been abandoned after better-quality evidence demonstrated little benefit or unexpected harm, emphasizing the importance of continual scientific reassessment.</li></ul><h3>20. When “Standard of Care” Escapes Scientific Scrutiny</h3><ul><li>“Standard of care” is not a scientific seal of approval. It is principally a medical and legal benchmark describing what a reasonably competent practitioner would do under similar circumstances. It does not establish that a routinely used test or treatment is safe, beneficial, necessary, or life-saving.</li><li>Common practice is not the same as proven practice. A procedure can become widely accepted through historical precedent, professional consensus, training, reimbursement, and repetition without ever having been subjected to the level of scientific scrutiny that would be demanded of a new intervention today.</li><li>Once a treatment becomes “standard,” an extraordinary paradox develops. The very designation that legitimizes its widespread use can insulate it from the prospective controls, independent oversight, and rigorous experimentation that would be required if the same intervention were introduced as experimental research.</li><li>Radical prostatectomy illustrates the problem. It entered clinical practice long before modern randomized trials, standardized outcome reporting, contemporary ethics oversight, and today&#39;s evidence-based expectations. Decades of subsequent use cannot retroactively substitute for rigorous proof that the intervention produces a meaningful survival advantage in the patients receiving it.</li><li>Medicine cannot allow “standard of care” to become a refuge from scientific scrutiny. Tradition, consensus, guidelines, reimbursement, and widespread utilization are not substitutes for reproducible evidence. If an intervention is truly beneficial, it should withstand continual scientific reassessment and demonstrate that its benefits—particularly meaningful improvements in survival and quality of life—outweigh its harms.</li></ul><h3>21. What Makes a Screening Test Truly Worthwhile?</h3><ul><li>A useful screening test must accurately distinguish disease from health. High sensitivity and high specificity are <a href="https://www.ncbi.nlm.nih.gov/books/NBK436014/">essential</a> to minimize both missed disease and unnecessary false-positive results that expose healthy individuals to invasive follow-up procedures.</li><li>Early detection must lead to better patient outcomes—not merely earlier diagnosis. Detecting disease sooner has value only if earlier intervention measurably reduces morbidity or mortality compared with later diagnosis.</li><li>Benefits must clearly outweigh harms. Screening should reduce illness and death without producing excessive anxiety, unnecessary biopsies, over-diagnosis, overtreatment, or treatment-related complications.</li><li>Disease prevalence strongly influences screening performance. When disease is relatively uncommon, even technically accurate tests may generate large numbers of false-positive results, initiating costly and potentially harmful cascades of additional testing.</li><li>The ultimate benchmark is improved health—not increased diagnosis. Successful screening programs should demonstrate reproducible improvements in meaningful clinical outcomes, including reduced disease-specific mortality, improved quality of life, and acceptable cost-effectiveness.</li></ul><h3>22. The Digital Rectal Examination: A Crude and Subjective Assessment</h3><ul><li>The digital rectal examination (DRE) is not a worthwhile screening test as it evaluates only a limited portion of the prostate and is highly unreliable. Because the examining finger reaches only the posterior surface of the gland, much of the prostate—including deep anterior regions—cannot be adequately assessed. And, although the check takes only a moment, it can be quite uncomfortable or even painful for those who have an anal fissure, hemorrhoids, or have some anal stenosis after hemorrhoid surgery.</li><li>Small aggressive cancers frequently escape detection. Lesions generally must become relatively large before they produce palpable abnormalities, limiting the examination&#39;s sensitivity for early clinically significant disease.</li><li>Most palpable abnormalities are not cancer. Benign prostatic enlargement nodules, fibrosis, inflammation, and calcification commonly produce irregular findings, reducing specificity and increasing unnecessary investigations.</li><li>Observer variability remains substantial. Interpretation depends heavily upon examiner experience, subjective judgment, and tactile perception, leading to significant differences between clinicians evaluating the same patient.</li><li>A normal examination should not be mistaken for reassurance. A negative DRE cannot exclude clinically important prostate cancer, particularly small or anatomically inaccessible tumors.</li></ul><h3>23. PSA: A Marker of Prostatic Activity Rather Than a Specific Cancer Test</h3><ul><li>The PSA is not a worthwhile screening test as it is highly unreliable. As well the specific label is a hoax. Although called prostate-specific antigen, PSA is neither uniquely specific for prostate cancer nor exclusively confined to the prostate. It is a normal physiological enzyme involved in liquefying semen and can also be detected in several other body fluids such as amniotic fluid, breast milk, female ejaculate, saliva and some B-cell lymphomas.</li><li>PSA levels reflect prostate activity—not cancer biology. Elevated PSA levels may result from benign prostatic enlargement, prostatitis, urinary retention, recent ejaculation, instrumentation, or numerous other non-malignant conditions. Many indolent cancers are detected because the BPH elevated the PSA and not the cancer.</li><li>No universally normal PSA threshold exists. Traditional cutoffs such as 4.0 ng/mL represent practical clinical conventions rather than biologically precise boundaries separating health from cancer.</li><li>False-positive and false-negative results remain major limitations. The PSA has about a 75% <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3183963/">false positive</a> rate. Many men with elevated PSA have no clinically significant cancer, while some biologically aggressive cancers produce little or no PSA and therefore escape detection despite advancing disease.</li><li>PSA screening illustrates the fundamental challenge of cancer screening. Detecting more abnormalities does not necessarily translate into saving more lives. When screening preferentially identifies indolent tumors while simultaneously missing some biologically aggressive cancers, increased diagnosis alone cannot be assumed to represent improved patient outcomes.</li></ul><h3>24. PSA Manipulation: A Number That Can Rise or Fall Without Reflecting Cancer</h3><ul><li>A high PSA is far more often a signal of prostate activity than proof of prostate cancer. Benign prostatic enlargement, prostatitis, urinary infections, inflammation, urinary retention, recent instrumentation, trauma, cycling, ejaculation, and testosterone therapy can all raise PSA. Yet once the number crosses an arbitrary threshold, many men are immediately pushed into a cancer investigation despite the absence of cancer-specific evidence.</li><li>A low PSA is equally capable of creating false reassurance. Finasteride, dutasteride, statins, thiazide diuretics, anti-inflammatory medications, metformin, and certain supplements may lower measured PSA without eliminating an existing cancer. When these medications are stopped, PSA may rise again—not necessarily because a new cancer appeared, but because an artificially suppressed laboratory value returned toward its untreated level.</li><li>Obesity further distorts the PSA result. Men with obesity may have lower PSA concentrations because the antigen is diluted within a larger circulating blood volume. This means an apparently reassuring PSA may conceal clinically important disease, particularly because obesity is also associated with more advanced and aggressive prostate cancer.</li><li>The same test can therefore create both unnecessary alarm and dangerous reassurance. Benign conditions can generate false-positive elevations, while medications, obesity, and low-PSA-producing aggressive cancers can generate false-negative results. As well, temporary PSA fluctuations in elevation are very common. A test that behaves this inconsistently cannot reliably separate harmless disease from lethal disease. It is also important to remember that PSA was originally developed to monitor men already diagnosed with prostate cancer—not to screen millions of healthy, asymptomatic men.</li><li>Billions of precious healthcare dollars are squandered by a number that has not reproducibly demonstrated substantial life-saving benefit. The downstream cascade includes repeat testing, imaging, biopsies, pathology, surveillance, treatment, complication management, and years of anxiety—all triggered by a biomarker profoundly influenced by factors unrelated to cancer.</li></ul><h3>25. Prostate MRI: A Sophisticated Image Mistaken for Biological Truth</h3><ul><li>Prostate MRI is frequently marketed as though it can reveal the complete truth inside the gland. In reality, it has substantial detection limits, meaningful false-negative rates, interpretation errors, and wide variability between readers and institutions. Even more concerning, diffuse microscopic scattering of high-grade prostate cancer cells within the bone marrow can remain invisible on MRI—simply because these dispersed cells may never form a distinct lesion or alter signal intensity enough to distinguish them from normal marrow. A technologically sophisticated image remains constrained by lesion size, image quality, equipment, technique, and human judgment.</li><li>Small and biologically important cancers may remain invisible. Lesions often must reach <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7815233/">approximately</a> 5–10 millimeters before they are reliably detected, while anterior tumors and small high-grade cancers are especially vulnerable to being overlooked. Some clinically significant prostate cancers are simply MRI-invisible regardless of reader experience.</li><li>False-positive findings create another pathway to unnecessary biopsy. Benign prostatic hyperplasia, inflammation, granulomatous prostatitis, scarring, and prior trauma may resemble malignancy on MRI, producing suspicious PI-RADS assessments that trigger invasive follow-up procedures in men who do not have clinically dangerous cancer.</li><li>The PI-RADS system does not remove subjectivity—it formalizes it. Radiologists must interpret complex patterns and assign categories based upon judgment. Community readings may differ significantly from interpretations at high-volume expert centers, demonstrating that the result depends heavily upon who reads the scan.</li><li>MRI may improve targeting, but it cannot overcome the biological complexity of prostate cancer. Multifocal disease, heterogeneous tumor grades, MRI-invisible lesions, and small high-grade cancers ensure that a negative or reassuring MRI cannot exclude dangerous disease and a suspicious MRI cannot establish that life-threatening cancer exists.</li></ul><h3>26. The Prostate Needle Biopsy: Pretending a Tiny Sample Represents an Entire Organ</h3><ul><li>The standard prostate biopsy is embarrassingly unscientific as it samples only a microscopic fraction of the gland. Twelve narrow cores taken from a large, heterogeneous organ may represent <a href="https://www.medscape.com/viewarticle/945928#vp_2">approximately</a> 0.1% of the prostate by volume. Yet physicians frequently treat this minuscule sample as though it accurately defines the grade, volume, distribution, and biological behavior of every cancer within the gland.</li><li>Multifocal disease makes this sampling problem enormous. Prostate cancer commonly arises in several distinct locations, with each nodule potentially carrying a different Gleason grade, tumor volume, and genetic profile. A biopsy may detect a large indolent lesion while completely missing a smaller, more aggressive cancer elsewhere.</li><li>MRI-targeted biopsy does not solve the fundamental sampling failure. Targeting works only when a lesion is first seen and correctly interpreted on MRI. A tumor that is too small, MRI-invisible, located in a difficult region, or overlooked by the radiologist cannot be targeted at all. Most prostate biopsies use a fusion technique combining pre-procedure MRI images with live in-office transrectal ultrasound. But fusion biopsy remains subject to the same fundamental risks, detection limits, targeting limits, sampling errors (whether transrectal or transperineal), false positives, and false negatives—and can still miss the high-grade cancer that matters most.</li><li>Even a successfully targeted biopsy samples only fragments of the target. The needle does not remove or examine the entire lesion. It may pass through a lower-grade area while missing the highest-grade component only millimeters away, resulting in false reassurance, grade underestimation, or inappropriate management.</li><li>The biopsy itself carries real harm. Pain, anxiety, rectal bleeding, infection, sepsis, urinary retention, erectile difficulties, false negatives, over-diagnosis, and overtreatment are imposed upon men through a procedure whose central limitation—massive sampling error—cannot be eliminated merely by taking a few additional cores.</li></ul><h3>27. Targeted Biopsy: More Precise Aim, but Still a Fundamentally Incomplete Test</h3><ul><li>The phrase “targeted biopsy” creates an illusion of certainty. Whether MRI-guided, fusion-guided, transrectal, or transperineal, the needle still samples only tiny tissue fragments. Improved aim does not transform a partial sample into a complete biological assessment.</li><li>Targeting is entirely dependent upon prior detection. A biopsy cannot target what the MRI fails to reveal. Small cancers, anterior tumors, MRI-invisible cancers, and lesions missed because of reader error remain outside the procedure’s reach.</li><li>The highest-grade component may still escape the needle. Prostate tumors are internally diverse. One portion may contain low-grade architecture while another small area contains aggressive disease, meaning even a needle accurately placed within a lesion may underestimate its true grade.</li><li>Taking more cores only marginally expands the amount of tissue examined. Doubling from 12 to 24 cores may double the percentage sampled from about 0.1% to 0.2%, but it still leaves almost the entire prostate unexamined. More needles do not eliminate multifocality, hidden lesions, or uneven tumor distribution.</li><li>Targeted biopsy improves technical precision without resolving biological uncertainty. It may better sample visible abnormalities, but it cannot establish the full status of an organ containing multiple tumors of different sizes and grades. The claim that a targeted biopsy reveals the definitive truth of the prostate is scientifically indefensible.</li></ul><h3>28. Prostate Pathology: A Subjective Interpretation Built Upon an Inadequate Sample</h3><ul><li>Pathology is often presented to patients as the final and unquestionable truth. Yet the pathologist is examining only the tiny fragments selected by an already unreliable biopsy. Even perfect interpretation cannot reveal cancers that were never sampled.</li><li>Gleason grading contains substantial inter-observer variability. The Gleason grading system for prostate cancer is complex. Different pathologists may assign different patterns and Grade Groups to the same tissue, especially when distinguishing borderline Gleason Pattern 3 from Pattern 4 architecture. These <a href="https://pubmed.ncbi.nlm.nih.gov/16372494/">disagreements,</a> including those about the indolent Gleason 6 disease, can directly determine whether a man is monitored, irradiated, hormonally treated, or surgically altered.</li><li>Benign tissue can mimic cancer and cancer can be underestimated. Atrophy, adenosis, crowded benign glands, seminal vesicle tissue, Cowper gland tissue, inflammation, and technical artifacts can create diagnostic ambiguity, leading to overcalls, undercalls, or uncertain categories such as ASAP and high-grade PIN.</li><li>Specimen handling can further undermine accuracy. Tissue fragmentation, compression, cautery artifact, poor orientation, and placing multiple cores into a single container may destroy anatomical relationships and prevent accurate measurement of tumor extent.</li><li>A second pathology opinion should be regarded as a safeguard, not an optional luxury. When an interpretation based upon a minuscule tissue sample may trigger irreversible treatment, accepting one subjective reading without expert review exposes patients to avoidable misclassification and potentially lifelong harm.</li></ul><h3>29. Why High-Grade Prostate Cancers Are Still Missed Despite Screening and Active Surveillance</h3><ul><li>The greatest weakness of current prostate cancer screening and surveillance is that the most dangerous cancers can still escape detection. Digital rectal examination (DRE) and PSA testing are highly unreliable, and some aggressive high-grade prostate cancers produce little or no PSA. Consequently, a proportion of men with high-grade disease may have &quot;normal&quot; PSA levels, meaning the cancers most important to detect early can remain undetected.</li><li>The multifocal nature of prostate cancer compounds this problem. More than 80–90% of prostate cancers arise in multiple independent areas within the prostate, with individual tumor nodules varying widely in size, Gleason grade, and biological aggressiveness. Detecting one low-risk lesion does not exclude the presence of a separate, clinically significant high-grade cancer elsewhere in the gland.</li><li>MRI has important biological and technical limitations. Although modern multiparametric MRI has improved detection of larger lesions, small tumors, anterior cancers, MRI-invisible cancers, detection limits, and observer variability mean clinically significant cancers may still be overlooked despite advanced imaging.</li><li>Needle biopsy samples only a minute fraction of the prostate. A standard 12-core biopsy examines approximately 0.1% of the gland by volume, leaving the overwhelming majority unsampled. Even expanding to 24 cores or using MRI-targeted biopsy cannot eliminate the fundamental problem of sampling error, because only visible lesions and tiny portions of those lesions are actually biopsied.</li><li>Prostate cancer treatments are not even consistently effective at accomplishing their most basic objective—eliminating or controlling the cancer. Radical prostatectomy has reported positive surgical margins in roughly 11–48% of patients, indicating cancer at the edge of the removed specimen, while 20–50% of treated patients may develop a rising PSA or biochemical recurrence within 10 years, with additional failures emerging beyond 15 years. These men cannot simply be declared “cured”; substantial numbers require further intervention, including salvage radiation, additional procedures, and androgen-deprivation therapy (ADT)—each carrying its own potential complications.</li></ul><h3>30. More Reasons Why High-Grade Prostate Cancers Are Still Missed Despite Screening and Active Surveillance</h3><ul><li>Apparent &quot;progression&quot; on repeat biopsy often reflects disease that was missed initially. Because needle biopsy samples only a minute fraction of the prostate, the later discovery of higher-grade or more extensive cancer commonly represents pre-existing disease that escaped the original biopsy rather than true biological transformation or &quot;upgrading.&quot;</li><li>The biology of most low-risk prostate cancers does not support rapid progression. Most low-risk prostate cancers (the Gleason 6 is a pseudo-cancer) grow extremely slowly, often requiring 40 years or more to reach 1 cm in size. Consequently, what is commonly labeled as disease progression during active surveillance may, in many cases, reflect the delayed detection of previously unsampled higher-grade cancer rather than rapid biological change.</li><li>Field effects further complicate prostate cancer biology. In addition to multifocal disease, genetically altered prostate tissue (field effect or field cancerization) elsewhere in the prostate may give rise to new tumors over time. Although most newly developing cancers remain low-grade and indolent, a minority may be biologically aggressive and arise independently of the known low-risk lesions under surveillance.</li><li>Some high-grade cancers may have already disseminated before they become detectable. Aggressive tumors may shed disseminated cancer cells into the bone marrow while the primary lesion remains too small to be identified by PSA, MRI, or biopsy. These dormant cells can remain clinically silent for years or decades before later producing metastatic disease, creating only a temporary appearance of cure after treatment of apparently localized cancer.</li><li>These combined limitations of screening, detection, and treatment help explain why some men still die from high-grade prostate cancer despite screening, active surveillance, and treatment. Highly unreliable prostate examinations and PSA testing, MRI detection limits and observer errors, needle-biopsy sampling error, multifocal disease, field effects, early dissemination, and the biological realities of aggressive cancers can all allow potentially lethal disease to escape detection and control. Underscoring why the minority of aggressive cancers remain the central problem that current screening and treatment strategies have yet to solve reliably. Additionally, obesity is associated with more advanced prostate cancer and poorer cancer outcomes.</li></ul><h3>31. Field Effects: Why Prostate Cancer Biology Is More Complex Than a Single Tumor</h3><ul><li>Prostate cancer is not simply a disease of one isolated tumor. In addition to being <a href="https://www.nature.com/articles/s41467-020-14657-7">multifocal</a>—with multiple independent cancerous and precancerous areas often present throughout the gland—the prostate may also exhibit so-called field effects (or field cancerization), in which broader regions of tissue have undergone molecular and genetic changes that may predispose them to developing additional cancers over time. This means the visible tumor may represent only one manifestation of a more widespread biological process.</li><li>Field effects create ongoing uncertainty during surveillance. While a patient is being monitored for an easily detected, slow-growing, low-risk lesion, new tumors may arise elsewhere within the biologically altered prostate tissue <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3690597/">(field effects)</a>. The future timing, location, and aggressiveness of these new tumors cannot be predicted with certainty, highlighting one of the biological challenges of managing prostate cancer based solely on the characteristics of an already identified lesion and the highly unreliable detection methods used.</li><li>A key concern is the possibility that an aggressive tumor could develop independently of the known low-risk cancer. If such a high-grade lesion were to arise from this altered field, it could remain clinically undetectable in its earliest stages while still possessing greater metastatic potential than the larger, more obvious low-grade tumor under observation.</li><li>Fortunately, most newly arising prostate cancers are not highly aggressive. Epidemiological studies consistently show that only a minority—approximately 10–15%—of newly diagnosed prostate cancers exhibit high-grade biological features at diagnosis. The majority are lower-grade, slower-growing lesions that often follow a prolonged natural history, underscoring the marked biological diversity of prostate cancer.</li><li>Field effects underscore the need for better biological markers rather than simply finding more tumors. The central challenge is not merely detecting additional abnormalities within the prostate, but distinguishing the relatively uncommon cancers with true metastatic potential from the far larger number of indolent lesions that may never threaten a patient&#39;s life. We need better tests and treatments for high-grade prostate cancer that actually work.</li></ul><h3>32. Dormant Disseminated Cancer Cells: The Hidden Disease That Creates a False Appearance of Cure</h3><ul><li>High-grade prostate cancer may disseminate before the primary tumor appears clinically important. Microscopic cancer cells (Disseminated Cancer Cells or DCCs) can leave the prostate and enter bone marrow or distant tissues while the prostate lesion remains barely detectable.</li><li>These DCCs are usually invisible to routine imaging. Conventional scans may show apparently localized disease even though microscopic systemic spread has already occurred, allowing patients and physicians to believe the cancer is confined to the prostate.</li><li>Dormancy can last for years or decades. Disseminated <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8234151/#:~:text=Prostate%20cancer%20has%20a%20variable,target%20DCCs%20in%20prostate%20cancer">cancer cells</a> may remain inactive for prolonged periods before some acquire the ability to grow, spread, and produce clinically detectable metastases.</li><li>Long recurrence-free intervals may therefore create only a semblance of cure. A patient may remain well for ten, fifteen years or more after surgery or radiation, not necessarily because every cancer cell was eliminated, but because previously disseminated cells remain biologically dormant.</li><li>Late metastatic recurrence challenges the claim that local treatment cured systemic biology. When disease reappears many years later, it may reflect activation of cells that had escaped before diagnosis rather than a new failure arising at the prostate treatment site.</li></ul><h3>33. Malpractice Law Built Upon the Assumption That Earlier Detection Would Have Saved the Patient</h3><ul><li>Failure-to-diagnose lawsuits rest on a scientifically unproven premise. Claims that an earlier PSA test, earlier prostate cancer detection, or earlier treatment would have saved a particular patient’s life are difficult to establish when there is no reproducible evidence that PSA screening or prostate cancer treatment saves substantial numbers of lives across broad populations—and when aggressive cancers may produce little PSA, escape detection, or disseminate before they are even detectable. Presenting earlier screening or treatment as proof that a death would have been prevented turns scientific uncertainty into courtroom certainty.</li><li>A delayed diagnosis does not automatically establish causation. The fact that a cancer was found late does not prove that earlier identification would have changed its biology, prevented metastasis, or extended the patient’s life. Multifocal disease, unreliable screening and detection tools as well as detection limits are major factors impacting delayed diagnosis.</li><li>High-grade disease may already be systemic at the time of the allegedly missed opportunity. Dormant disseminated cancer cells may have entered the bone marrow years or decades earlier, making the assumption of curability through earlier local treatment highly speculative.</li><li>The legal “standard of care” focuses heavily upon conformity rather than demonstrated outcome. A physician may be judged according to whether customary tests were ordered, even when those tests and treatments have not been scientifically proven to be reliable, safe, beneficial and or, save significant numbers of lives.</li><li>Both plaintiffs and defendants can be trapped inside the same flawed prostate cancer narrative. One side claims that testing and treatment would certainly have saved the patient, while the other argues that customary protocols were followed. Neither position addresses the more fundamental scientific question of whether the intervention could have altered the outcome. Especially when prostate cancer treatments fail to show reproducible evidence of substantial survival advantage.</li></ul><h3>34. Medical Reversals: The Graveyard of Former Standards of Care</h3><ul><li>Medical history is filled with interventions once defended as standards of care. Radical mastectomy, transorbital lobotomy, internal mammary artery ligation, gastric freezing, and other procedures were widely performed before better evidence revealed that their benefits had been exaggerated or were nonexistent.</li><li>Professional acceptance did not protect patients from harm. Many abandoned interventions were supported by respected institutions, experienced physicians, plausible theories, and consensus recommendations—the same arguments used to defend the current prostate cancer narrative.</li><li>Invasive procedures can persist for years before their assumptions are tested. Once training systems, reimbursement structures, specialist identities, hospital programs, and commercial interests develop around an intervention, reversing course becomes institutionally painful.</li><li>Device regulation has repeatedly reacted only after harm became visible. Power morcellators, for example, were heavily restricted after evidence showed that tissue fragmentation could disseminate previously unrecognized uterine cancers.</li><li>Calling an intervention “standard of care” cannot ethically substitute for reproducible scientific proof. When physicians know that evidence of substantial life-saving benefit remains inconsistent, patients should be told that directly. Anything less transforms informed consent into managed persuasion and places institutional preservation ahead of patient autonomy.</li></ul><h3>35. A System That Confuses Consensus With Truth Betrays the Patient</h3><ul><li>The prostate cancer industry repeatedly presents beliefs, opinions and assumptions as settled science. Screening, biopsy, pathology, surgery, radiation, and active surveillance are promoted through a narrative that minimizes uncertainty while amplifying fear of doing nothing.</li><li>Studies are commonly constructed in ways that preserve predetermined conclusions. Mixing biologically dissimilar cancers, relying upon surrogate outcomes, using short follow-up periods, and including men unlikely to die from prostate cancer can manufacture the appearance of treatment success.</li><li>Fear-based marketing converts uncertainty into compliance. Terrifying cancer terminology, promises of cure, slogans about early detection, and warnings about metastatic suffering pressure men into accepting tests and treatments before they fully understand the limitations and potential harms.</li><li>Financial conflicts and medical groupthink make correction harder. Hospitals, manufacturers, pharmaceutical companies, specialist groups, advocacy organizations, and professional careers may all benefit from sustaining the existing testing-and-treatment infrastructure.</li><li>Artificial intelligence can magnify the same institutional errors. AI systems trained on literature saturated with repeated assumptions, biased studies, guideline consensus, and commercial messaging may reproduce those conclusions with greater speed and confidence rather than independently establish whether they are true.</li></ul><h3>36. When Money, Lobbyists, and Vote-Seeking Lawmakers Undermine Healthcare Regulatory Oversight</h3><ul><li>The healthcare regulatory apparatus is supposed to protect patients—but financial and institutional incentives can undermine that mission. CMS determines whether Medicare services are “reasonable and necessary,” while AHRQ evaluates comparative effectiveness, yet the system remains fragmented across federal agencies, state regulators, insurers, professional organizations, and private healthcare interests. The result is enormous administrative complexity in which responsibility for proving that an intervention actually improves patient outcomes is dangerously diffuse.</li><li>American healthcare financially rewards doing more, not necessarily proving more. Drug companies, device manufacturers, hospitals, insurers, and professional organizations operate within a system of opaque pricing, negotiated reimbursement, powerful commercial incentives, and aggressive lobbying. The seven largest health plans produced more than $54 billion in combined net profit. They are publicly traded on Wall Street, where investors focus on profits and share price, at the expense of patients and physicians. Health insurers and their trade associations spend well over $100 million annually lobbying vote-seeking government lawmakers, helping preserve an enormously profitable insurance-based healthcare machine while top executives receive massive compensation. Sadly, all this money and spending have failed to translate into superior overall health for the American population. When everyone profits from doing more, the healthcare financial engine becomes self-sustaining—while patient protection through effective healthcare regulatory oversight becomes increasingly diluted.</li><li>When some 50% of medical treatments are of <a href="https://theincidentaleconomist.com/wordpress/half-of-medical-treatments-of-unknown-effectiveness/">unknown</a> effectiveness and a majority of healthcare studies are not founded on <a href="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0020124">sound scientific</a> principles, it makes a farce of peer-reviewed journals—a process itself <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1420798/">deeply flawed</a>, riddled with concerns, and unsupported by reproducible evidence that it actually works. Prostate cancer provides a striking example: screening and treatments without significant, reproducible long-term benefit remain deeply embedded in clinical practice despite continuing questions about overdiagnosis, overtreatment, complications, and whether benefits clearly outweigh harms.</li><li>The government-industry “revolving door” creates an unavoidable conflict-of-interest concern. Research has reported that approximately 15% of political appointees entering HHS came from private industry and nearly 32% subsequently left government for private-sector employment. Movement between regulator and regulated industry does not itself prove corruption, but it creates legitimate concerns about regulatory capture and whether agencies charged with protecting patients can remain sufficiently independent of the enormously profitable industries they oversee.</li><li>Perhaps most troubling, coding and reimbursement can precede definitive proof of patient benefit. The AMA (owns the copyright and trademark for the CPT code set) establishes CPT codes for procedures; CMS and private insurers then determine reimbursement, with the RUC influencing Medicare valuation recommendations. But receiving a billing code and payment from a health insurance plan does not establish that an intervention has been proven safe, beneficial, or life-saving. When the medical arena can create a procedure, code it, reimburse it, institutionalize it, and call it “standard of care” before rigorous reproducible science establishes that its benefits clearly outweigh its harms, financial incentives have outrun patient protection—and regulatory oversight has failed at its most fundamental responsibility.</li></ul><h3>37. Early Critics Who Exposed the Cracks In the Prostate Cancer Story</h3><ul><li>Outspoken critics. Long before mainstream medicine began admitting even limited harms from prostate cancer screening and treatment, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and the treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the Gleason 6 cancer label - he dismantled it: showing that <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">the grade 3</a> within the Gleason 6 lacked the biological mechanisms to behave as cancerous, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3>38. Bottom Line: How Misguided Physicians Steer Vulnerable Patients Toward Needless Harm is Incomprehensible</h3><ul><li>Screening and active surveillance fail the most basic test—reliably saving lives. After more than 30 years of widespread PSA screening, major trials and long-term studies extending to approximately 20 years have failed to demonstrate that screening saves substantial numbers of lives. Prostate cancer screening rests on two highly unreliable tests. The DRE examines only part of the prostate and has poor detection performance for significant cancers. PSA is not cancer-specific, its traditional 0–4 ng/mL “normal” range is arbitrary, and false-positive results are about 75%. Cancer can exist below 4 while benign conditions can drive PSA well above it. The most dangerous cancers can produce little or no PSA, escape MRI and biopsy, and potentially disseminate early.</li><li>Detection creates an illusion of precision that technology cannot deliver. Prostate MRI and needle biopsy create an illusion of diagnostic precision. MRI produces false positives, false negatives and observer disagreement, while a 12-core biopsy samples only about 0.1% of a prostate that commonly has multifocal areas of cancer. What is later called “progression” or “upgrading” is invariably an aggressive disease that unreliable detection missed from the beginning.</li><li>Treatment has not solved the central problem—significant life-saving ability. Despite an extraordinary menu of surgery, robotic surgery, radiation, brachytherapy, proton therapy, ADT, HIFU, cryotherapy, NanoKnife®, FLA, TULSA, VTP, active surveillance, and combinations of these approaches, studies at roughly 12, 15, and 20 years have failed to establish substantial survival advantages for these treatment strategies. In fact, at about 20 years treated and untreated patients had similar survival rates. And despite decades of fear-based messaging, relentless screening, detection and treatment, the annual U.S. prostate cancer death toll remains stubbornly at about 35,000 men a year—driven predominantly by high-grade disease. However, the annual death toll from high-grade prostate cancer—after an earlier decline that may partly reflect better management of co-morbidities—remains substantial and has recently shown a possible increase, potentially compounded by our ballooning obesity epidemic and its association with more advanced and aggressive prostate cancer.</li><li>When treatment causes harm or fails, the response is more treatment. Prostate cancer therapy can produce profound urinary, sexual, bowel, hormonal, and psychological complications. Radical prostatectomy has reported positive surgical margins in roughly 11–48% of patients, while 20–50% of treated patients develop biochemical recurrence within 10 years. Approximately 50% of prostate cancer patients ultimately receive ADT, adding another substantial burden of adverse effects. These treatment failures are hardly surprising when robotic prostatectomy, like virtually all prostate cancer treatments, entered widespread clinical use without prostate-cancer-specific trials demonstrating substantial life-saving benefit. When treatment failure generates still more treatment, the prostate cancer industry keeps winning. The patient does not.</li><li>When the prostate cancer narrative becomes medically indefensible, it demands a reset—especially when the “standard of care” resembles licensed medical malpractice while fueling a global public-health disaster. When physicians disconnect from the Hippocratic obligation to keep patients from harm and injustice; when entrenched beliefs, opinions, assumptions, misrepresentations, and misinformation expose countless men to overtreatment and devastating harm, squander billions in healthcare dollars, and leave accountability elusive; when the legal construct of “standard of care” is mistaken for evidence that an intervention is safe, effective, or life-saving; and when the healthcare regulatory apparatus abjectly fails to protect vulnerable and unwitting patients, the system itself becomes part of the problem. Against this backdrop, relentlessly proclaiming “early detection saves lives” without rigorous, independently reproducible evidence of substantial life-saving benefit risks becoming orchestrated deception—and makes a mockery of evidence-based medicine and treatment guidelines. Indifferent to the data, too many physicians continue to drive fear, doubt, confusion and harm—protecting an entrenched prostate cancer narrative instead of protecting the patients betrayed by it. The entire prostate cancer narrative should therefore be confronted with medicine’s simplest and most important question: Where is the rigorous, independently reproducible evidence that these interventions actually save substantial numbers of lives—and that their benefits clearly outweigh the devastating harms they can cause?</li></ul><h3>Required Reading</h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/">https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D">https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p><a href="https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D">https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D">https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/">https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/</a></p><p><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/">https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/</a></p><p><a href="https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D">https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/?trackingId=72w2uaCNQaCjmnF0TeOnjA%3D%3D">https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/?trackingId=72w2uaCNQaCjmnF0TeOnjA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/active-surveillance-prostate-cancer-benefit-hoax-bert-vorstman-md-rbxee/">ACTIVE SURVEILLANCE FOR PROSTATE CANCER: BENEFIT OR HOAX?</a></p><p><a href="https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/">https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/</a></p><h3>Discover the YouTube HEALTHdrum channel where medical fact is separated from medical fiction.</h3><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/great-prostate-cancer-deception-how-psa-screening-men-vorstman-md-xajie/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c9f76b1b75b0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[WHEN A DOCTOR JUMPS IN: WHEN ACTIONS SPEAK LOUDER THAN WORDS]]></title>
            <link>https://bvorstman.medium.com/when-a-doctor-jumps-in-when-actions-speak-louder-than-words-cf523ef6a640?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/cf523ef6a640</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Thu, 30 Jul 2026 09:01:54 GMT</pubDate>
            <atom:updated>2026-07-30T09:01:54.387Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Y3ABec_PhP3gf4Vk" /></figure><p>Bert Vorstman MD</p><h3>Actions define a person far more powerfully than words ever can. Words are effortless. Promises are easy. Opinions cost nothing. Anyone can claim courage, compassion, integrity, or leadership from the comfort of safety. True character, however, is never measured by what a person says — it is measured by what they repeatedly choose to do when confronted with danger, hardship, sacrifice, and uncertainty. Actions demand commitment, time, skill, perseverance, and often enormous personal risk. They expose genuine values because they cannot be faked indefinitely. When lives hang in the balance, there is no room for empty rhetoric or self-promotion. There are only decisions, sacrifices, and deeds.</h3><h3>MEDICINE IS TRULY TESTED WHEN EVERYTHING MEDICINE DEPENDS UPON IS GONE</h3><ul><li>Physicians are normally trained to practice within highly organized systems built around modern tests, proven treatments, sterile instruments, reliable medications, electricity, laboratories, imaging, blood products, anesthesia, oxygen, and skilled support personnel. These resources make contemporary medicine safer and more predictable, but they can also conceal how dependent medical care has become upon infrastructure. In combat, disaster, isolation, or extreme poverty, that infrastructure may disappear completely. The physician is then left with knowledge, judgment, experience, courage, and whatever materials can be found.</li><li>In hostile and resource-starved environments, the so-called standard of care may no longer be physically possible. A surgeon cannot order a CT scan where no electricity exists, administer blood when there is no blood bank, or perform a conventional operation when there are no sterile instruments, anesthetics, lights, trained assistants, or secure buildings. Under such conditions, insisting upon ideal treatment may amount to doing nothing. The more responsible course may be to improvise, adapt, and deliver the best achievable care with the few resources available.</li><li>Improvisation is not careless medicine when the alternative is abandonment or death. Proper improvisation requires deep knowledge of anatomy, physiology, infection, shock, wound healing, surgical principles, and the limitations of every substitute being used. A poorly trained person may improvise recklessly; a knowledgeable physician improvises with purpose. The ability to convert ordinary objects into useful medical tools is not evidence of lowered standards — it is evidence of intellectual command over fundamental medical principles.</li><li>Military surgeons face a level of difficulty that extends far beyond clinical complexity. They may be treating devastating injuries while exhausted, starving, freezing, under bombardment, hunted by enemy troops, or forced to move before an operation is complete. They must decide which patients can be saved, which procedures can be attempted, which supplies must be conserved, and when remaining in place will lead to the destruction of the hospital and everyone inside it. Medicine, logistics, survival, and military judgment become inseparable.</li><li>Clinical judgment and reliability under pressure are among the clearest measures of leadership. Anyone can appear competent in safety and abundance. The real test comes when conditions collapse, resources vanish, fear rises, and every decision has consequences. The physician who remains calm, creative, decisive, technically capable, and compassionate under those conditions demonstrates a level of leadership that no title, résumé, lecture, or public claim can prove.</li></ul><h3>DR. LINDSAY ROGERS WAS BUILT FOR THE IMPOSSIBLE</h3><ul><li>Dr. Lindsay Rogers was one of those exceptional physicians whose character was revealed most clearly under extreme adversity. He was stocky, rugged, physically fit, knowledgeable, confident, determined, persistent, generous, unselfish, brave, and prepared to place himself in danger for others. He also smoked, could be impatient, irreverent, resistant to criticism, and intolerant of delay or incompetence. He was not a polished fictional hero. He was a forceful, complicated, highly capable man whose flaws existed alongside extraordinary courage and service.</li><li>His defining strength was his ability to act rapidly when ordinary systems had failed. Rogers did not freeze when supplies were missing or when standard methods were impossible. He assessed what was available, identified what the patient needed most urgently, and found a practical way forward. That ability to improvise quickly was repeatedly life-saving in circumstances where hesitation, indecision, or attachment to textbook methods would have condemned patients to death.</li><li>He established and supported hidden hospitals throughout the wild, mountainous, unforgiving regions of occupied Yugoslavia. His work extended through areas that included Croatia, Slovenia, Dalmatia, and Bosnia. These were not hospitals in any conventional sense. They were improvised networks of caves, forest camps, cabins, barns, farmhouses, stables, and concealed shelters used to treat wounded Partisans, civilians, and, at times, downed Allied airmen.</li><li>Rogers served in Yugoslav territory treating Yugoslav Partisans from late November 1943 until April 1944, and again from July 14, 1944 until early May 1945. He arrived on the island of Vis in late November 1943 as part of the British Special Operations Executive mission known as “Vaseline.” From there, he moved to Split and into Partisan-controlled territory and remained involved until he was eventually airlifted back to Italy as the war neared its conclusion.</li><li>His service was not a single dramatic act but a prolonged campaign of risk, exhaustion, movement, and repeated sacrifice. For nearly a year and a half, he lived amid bombing, pursuit, hunger, disease, cold, surgical emergencies, shortages, and the constant possibility of capture or execution. His courage was therefore not momentary. It was sustained, practical, and repeatedly proven.</li></ul><h3>FROM DUNEDIN MINING STUDENT TO NEW ZEALAND SURGEON</h3><ul><li>Lindsay Rogers’ route into medicine was not entirely direct. He initially studied for approximately two years at the School of Mines in Dunedin before changing direction and entering the University of Otago Medical School also in Dunedin, New Zealand. That early technical education may have contributed to his later mechanical resourcefulness, practical mindset, and willingness to use unfamiliar tools when conventional surgical equipment was unavailable.</li><li>After medical school in New Zealand, he pursued surgical training in England. Although trained as a general surgeon, he did not build his career around prestige, academic status, or a major metropolitan hospital. Instead, before and after the war, he chose the demanding breadth of rural family practice in Te Awamutu in New Zealand’s North Island.</li><li>Te Awamutu was also the town where I grew up and attended school, giving Rogers’ story a personal connection beyond military history. At that time, Te Awamutu had two main medical practices. One included Dr. Sare and Dr. Forbes. The other was a larger collaborative clinic that included Dr. Keith Hiskens, Dr. Lindsay Rogers, Dr. John Watson and Dr. Allison Marshall.</li><li>After returning from the war, Rogers resumed work in the highly collaborative rural practice in Te Awamutu. The doctors divided responsibilities across a broad and rugged territory extending toward the Kawhia coast. They functioned not only as office physicians but also as emergency responders, proceduralists, obstetric doctors, and community medical leaders. Rural practice demanded versatility, self-reliance, travel, and the ability to manage problems without immediate specialist support — qualities Rogers had already demonstrated under the most extreme conditions imaginable.</li><li>Local hospitals and referral systems reflected the practical medicine of that era. San Michele Hospital in Te Awamutu once handled minor procedures, including tonsillectomies; my brother and sisters underwent their procedures there on the same day in the late 50s. The facility now operates primarily as a rest home. More complex operations were referred to regional base hospitals, especially Waikato Hospital in Hamilton. Rogers moved from guerrilla surgery back into ordinary community medicine, but the discipline, decisiveness, and practicality required in both settings were closely related.</li></ul><h3>HE LEFT SAFETY BEHIND AND RETURNED TO WAR</h3><ul><li>At the outbreak of the Second World War, Rogers left Te Awamutu and returned to England to provide frontline medical service. He could have remained in New Zealand, continued a respected civilian career, and allowed others to carry the burden. Instead, he deliberately placed himself closer to danger because he believed his skills were needed.</li><li>His preparation extended far beyond medicine. Rogers underwent military training in escape, survival, evasion tactics, sabotage, weapons, explosives, and guerrilla warfare. He learned to use pistols, rifles, machine guns, grenades, and other explosives. He was taught how to destroy trucks, telegraph lines, bridges, and railways, and how to function where capture could mean torture or execution.</li><li>He also received instruction in defensive combat, silent killing, parachuting, and Serbo-Croatian. These skills reveal the extraordinary role he was being asked to perform. He was not being sent to a protected field hospital behind friendly lines. He was being prepared to survive and operate inside hostile territory, where the physician might have to fight, hide, escape, sabotage enemy operations, and protect patients by force.</li><li>After time in Egypt, he was carried by Yugoslav fishing boat to the island of Vis off the Croatian coast near Split. From Vis, he linked with the Partisans and moved inland behind Split. His journey into Yugoslavia was therefore not the arrival of a conventional army doctor into an established base. It was the insertion of a medically trained operative into a clandestine guerrilla war.</li><li>Rogers travelled repeatedly between Yugoslavia and Italy to obtain supplies and evacuate the severely wounded. Makeshift airfields were used whenever geography, weather, enemy activity, and aircraft availability allowed. On one return from Italy, he parachuted into Slovenia. Each journey involved danger, uncertain navigation, exposure, and the possibility that enemy forces would discover the landing area or hidden hospitals.</li></ul><h3>THE MOUNTAINS WERE BEAUTIFUL — AND MERCILESS</h3><ul><li>I have travelled in Croatia and seen the inland mountains and hills rising in the distance. They reminded me of the alpine regions of New Zealand’s South Island, where I hunted and hiked for several days on a number of occasions. The terrain can be steep, remote, physically punishing, and rapidly transformed by weather.</li><li>During my own trips, I became tired, dirty, worn down, and exposed to the elements. Yet I still had the security of returning to a tent and sleeping bag. I had food, equipment, planned routes, and the knowledge that no enemy patrol was hunting me. Even fatigue in the wilderness is fundamentally different when it is voluntary and supported by the expectation of safety.</li><li>On one occasion, I was trapped in a mountain hut by a blizzard and had to wait several days for helicopter evacuation. That experience provided some appreciation for isolation, severe weather, uncertainty, and the way mountains can make human beings feel small and vulnerable.</li><li>But nothing in my experience approached what Rogers and the Partisans endured. They moved through similar countries while hungry, poorly clothed, wet, diseased, sleep-deprived, and responsible for wounded patients. They could not simply remain in a hut until conditions improved. Remaining in place might allow German troops, aircraft, dogs, or collaborators to find and kill them.</li><li>The landscape was therefore not merely a backdrop to Rogers’ work — it was an active participant in the struggle. Mountains concealed hospitals but also isolated them. Snow hid movement but also erased paths. Forests protected the wounded but made transport agonizing. Rivers provided water but carried contamination. Every natural advantage was accompanied by a new danger.</li></ul><h3>FEAR, SECRECY, AND DANGER WERE PART OF EVERY MEDICAL DECISION</h3><ul><li>Rogers treated patients under conditions where secrecy was essential to survival. Makeshift hospitals were hidden in forests, caves, mountain huts, cabins, barns, stables, and remote farm buildings. A hospital discovered by the Nazis could be bombed, burned, or overrun, with patients, doctors, and nurses murdered.</li><li>Medical care had to remain almost invisible. Firelight could be seen. Smoke could reveal a hidden camp. Footprints could expose the route to a hospital. The sound of movement, animals, tools, or distressed patients could attract attention. Even the disposal of bloodied dressings, amputated limbs, food waste, or human waste could leave evidence for trackers.</li><li>Road signs had been removed or altered by the Partisans to confuse enemy troops. This protected villages and concealed routes, but it also made travel difficult for Rogers and his medical teams. They sometimes became lost, particularly when snow covered paths or darkness concealed landmarks.</li><li>Medical supplies were occasionally dropped by parachute, but such drops depended upon weather, aircraft availability, secure coordinates, and the absence of nearby enemy forces. A failed drop could scatter supplies across inaccessible terrain or place them within reach of German troops. A visible parachute could also betray the existence of a nearby Partisan unit or hospital.</li><li>Every hospital was temporary because every hospital could be discovered. Rogers’ medical networks had to remain mobile. Patients who would normally require uninterrupted bed rest or traction sometimes had to be lifted onto crude stretchers and carried for hours through mountains because the alternative was capture and death.</li></ul><h3>THE YUGOSLAV PARTISANS FOUGHT WITH LEGENDARY COURAGE</h3><ul><li>The Yugoslav Partisans created one of the fiercest and most effective resistance movements in Nazi-occupied Europe. They fought not from secure bases with abundant supplies but from forests, mountains, caves, villages, and improvised positions. They confronted German forces and their allies despite severe shortages of food, ammunition, footwear, clothing, medical care, and heavy weapons.</li><li>Both men and women participated directly in the resistance. Women were not confined to nursing or domestic roles. They served as rifle fighters, machine gunners, snipers, scouts, saboteurs, couriers, medics, nurses, cooks, political organizers, and squad leaders. Many occupied the same frontline positions and faced the same risks as men.</li><li>A large proportion of the women fighters were extremely young. About 80 percent were reported to be under twenty-five, with many joining while still teenagers. They entered a world of gunfire, bombing, hunger, forced marches, capture, torture, and death at an age when modern young people are usually protected from even minor hardship.</li><li>Thousands of women were killed, and many were formally decorated for bravery. Their service destroys any romantic image of war as an exclusively male ordeal. Women endured battlefield wounds, menstruation without modern products, exposure, sexual violence, pregnancy risks, loss of family members, and the same relentless physical exhaustion experienced by male fighters.</li><li>Their courage was not abstract patriotism expressed from a distance. It was demonstrated by carrying ammunition uphill in snow, treating wounded comrades under fire, returning to battle after injury, moving at night through enemy territory, and continuing to resist despite knowing that capture could bring torture, rape, or execution.</li></ul><h3>DAILY LIFE WAS AN ASSAULT ON THE HUMAN BODY</h3><ul><li>The Partisans and their medical teams endured freezing winters with inadequate clothing and poor footwear. Many were continually cold, wet, exhausted, and unable to dry their clothes. Boots were scarce. Feet blistered, froze, became infected, and sometimes progressed to gangrene. The body’s energy was consumed merely trying to remain warm.</li><li>Hunger and thirst were constant. Food depended upon what local villagers could spare, what could be taken from the land, or what was occasionally dropped by Allied aircraft. Long marches, wounds, infection, fever, and cold increased caloric needs precisely when almost no nutritious food was available.</li><li>Sleep was fragmented by movement, fear, bombardment, pain, and guard duties. People slept in caves, forests, barns, huts, or on pine bunks without sheets or proper blankets. They remained alert for aircraft, patrols, dogs, gunfire, and sudden orders to evacuate.</li><li>Personal cleanliness became a luxury. Bodies remained unwashed, clothing stayed dirty, lice spread rapidly, shaving was irregular, and sponge baths were performed only when water, privacy, and time allowed. Even washing could be dangerous because streams, lakes, smoke, or repeated activity around a water source might reveal a position.</li><li>The threat never truly stopped. Partisans were strafed by aircraft, bombed, encircled, followed by dogs, and hunted through snow. They had to remain aware of wolves and other dangers while conserving ammunition needed for enemy forces. Extreme discomfort was not an occasional hardship — it was their normal condition of existence.</li></ul><h3>HUNGER AND DEFICIENCY DISEASES WEAKENED EVERY PATIENT</h3><ul><li>Food was often monotonous, nutritionally inadequate, and insufficient in quantity. At times, the only available meal was unsalted boiled meat. Other foods included beans, bacon fat, wild deer, fresh milk directly from a cow, and sour cheese made by the Partisans.</li><li>Occasional Allied drops supplied rice, flour, dehydrated vegetables, and dehydrated meat. These deliveries were valuable but uncertain. Food had to be divided among fighters, civilians, medical staff, and wounded patients whose nutritional requirements were especially high.</li><li>Vitamin deficiencies produced serious medical consequences. Scurvy impaired wound healing, weakened tissues, caused bleeding, and increased vulnerability to infection. Peripheral neuritis, rickets, weakness, constipation, and other deficiency-related conditions compounded the effects of wounds and exposure.</li><li>Treatment itself had to be improvised from the landscape. Grass, spruce or fir tips, and spinach-like herbs were boiled in an attempt to provide nutrients and combat scurvy. Such remedies were crude but reflected practical recognition that the patients required substances missing from their diet.</li><li>Water came from streams, melted snow, lakes, or other local sources, frequently without reliable purification. The same water used for drinking, washing, cooking, and waste disposal could spread infection. The need to drink often overruled the inability to disinfect the water, leaving patients vulnerable to diarrheal disease, typhoid, and dehydration.</li></ul><h3>PERSONAL HYGIENE WAS REDUCED TO RAW HUMAN NECESSITY</h3><ul><li>Ordinary bodily functions became difficult, exposed, and potentially dangerous. Men generally urinated standing wherever some concealment could be found. Women squatted behind trees, bushes, buildings, or rocks. Privacy was minimal, particularly when groups were moving rapidly or living in crowded shelters.</li><li>Defecation required whatever arrangement the terrain allowed. People squatted over shallow holes, held onto branches, sat across logs, or used openings cut into verandas or floors so waste fell to the ground below. Proper latrines were not always available, especially during rapid movement or in temporary camps.</li><li>Toilet paper was usually absent. Newspaper, magazine pages, cloth, snow, water, soft grass, moss, and leaves were used when available. In desperate circumstances, people might defecate directly into rivers or lakes, further contaminating water sources used by others downstream.</li><li>Handwashing was inconsistent because soap, clean water, and time were scarce. Hands might be rinsed in snow, streams, or lakes, wiped on grass or leaves, or simply left unwashed. These conditions promoted the spread of typhoid, dysentery, wound contamination, lice, skin infections, and other communicable diseases.</li><li>Female Partisans faced the additional burden of menstruation without modern sanitary products. They relied upon washable cloth rags, moss, soft grasses, leaves, animal materials, or whatever was available. These makeshift methods had to be managed while marching, fighting, hiding, freezing, and living without privacy or reliable washing facilities.</li></ul><h3>TRANSPORT MEANT USING ANYTHING THAT MOVED — OR WALKING</h3><ul><li>Transport was governed by necessity rather than organization: beg, borrow, capture, steal, improvise, or walk. A stolen truck might carry wounded patients for part of a journey, but fuel, mechanical reliability, roads, and enemy checkpoints limited vehicle use.</li><li>Motorcycles, bicycles, bullock carts, wagons, horses, and other animals were used whenever available. Each method had disadvantages. Vehicles created noise, required fuel, and left tracks. Animals needed food and could be heard. Wagons were slow and difficult to move across mountain terrain.</li><li>Most travel was still performed on foot. Rogers, medical personnel, Partisan fighters, and wounded patients covered mile after mile along steep tracks, through forests, across snow, and over mountain passes. Those already injured, malnourished, or febrile were expected to endure journeys that would exhaust a healthy person.</li><li>Skis were sometimes used in winter. They improved movement over snow but demanded skill, balance, and physical energy. Transporting a wounded patient by ski or improvised sled across an uneven country remained hazardous and could worsen bleeding, fractures, pain, and hypothermia.</li><li>Secrecy determined every route. Main roads invited ambushes or checkpoints. Tracks had to be covered, altered, or abandoned. Dummy trails were created to confuse pursuers, and night movement was common. Transport was therefore slow, indirect, exhausting, and inseparable from evasion.</li></ul><h3>THE HOSPITALS HAD TO DISAPPEAR BEFORE THE ENEMY ARRIVED</h3><ul><li>Hidden hospitals were created from whatever structures or terrain could conceal them. Rogers cleared farmhouses, barns, stables, caves, forest clearings, cabins, and deep woodland sites. Pine branches and timber were fashioned into bunks. Sheets and blankets were rare, and even basic equipment such as bedpans was unusual.</li><li>Patients were scattered across networks of small hospitals rather than concentrated in one easily discovered location. This reduced the risk of losing everyone in a single attack, but it forced Rogers and his staff to tramp for hours among distant facilities through difficult terrain.</li><li>When discovery appeared likely, the entire hospital had to move. Wounded patients were lifted onto makeshift stretchers and carried through forests, snow, and mountains. Fracture traction might have to be dismantled. Dressings could be applied quickly simply to permit escape. Patients too ill to move faced almost certain death if left behind.</li><li>Tracks had to be concealed or falsified. Snow made movement especially dangerous because every footprint could lead enemy patrols directly to the hospital. Partisans created dummy trails, doubled back, brushed away evidence, and used deceptive routes to confuse German troops and tracker dogs — at times dragging an amputated limb across the snow to confuse these animals.</li><li>Rogers sometimes operated by candlelight, firelight, flashlight, lamp, or tallow wick in barns, caves, cow sheds, and forest shelters. Even that weak illumination was dangerous. A glow through a crack or smoke above trees could reveal the hospital. Surgery therefore occurred not only without proper light but under the pressure of knowing that the light itself could bring death.</li></ul><h3>SURGICAL TOOLS CAME FROM WORKSHOPS, FARMS, FORESTS, AND PARACHUTES</h3><ul><li>The absence of standard surgical infrastructure forced Rogers to convert ordinary objects into medical instruments. Carpenter’s hammers, hacksaws, chisels, knives, nails, wire, timber, tubing, and household containers became substitutes for equipment normally supplied by hospitals. Supplies were often hidden underground somewhere away from these hospitals.</li><li>Salt water was used for cleansing when conventional antiseptics were unavailable. Wounds might also be prepared with petrol when no better disinfecting agent could be obtained. These approaches were far from ideal, but untreated contamination from bullets, soil, fabric, shrapnel, and dead tissue was often more immediately lethal.</li><li>Razor blades were used to harvest skin grafts. Parachute silk cord provided ligatures. Tree branches became splints. Logs, beams, stones, and nails were incorporated into traction systems. Medical improvisation extended from surgery to immobilization, drainage, hydration, lighting, transport, and patient bedding.</li><li>Tallow lights were frequently used. Rendered animal fat, usually beef or mutton, was placed around a wick to produce a dim flame. Lamps, candles, flashlights, and open fires were used when available, but all light and smoke had to be controlled to prevent discovery.</li><li>These substitutions were not crude theatrics but practical applications of surgical principles. A surgeon who understands what an instrument must accomplish can sometimes replace its form while preserving its function. Rogers’ genius lay in recognizing what was essential and discarding what was merely conventional.</li></ul><h3>MEDICAL SUPPLIES WERE PRECIOUS, UNCERTAIN, AND NEVER ENOUGH</h3><ul><li>There was a persistent shortage of nearly everything required for medical care. Anesthetics, disinfectants, bandages, surgical instruments, vitamins, plasma, blood, intravenous tubing, medications and soap. Gloves, gowns, masks, oxygen, and sterile dressings were scarce or entirely absent.</li><li>Bandages were washed and reused because replacement supplies could not be assumed. Reuse increased infection risk, yet leaving wounds uncovered or allowing bleeding to continue was worse. Medical teams were forced to balance one danger against another continually.</li><li>Some useful drugs reached the Partisans in limited quantities. Sulfa preparations and penicillin might be dusted into wounds. Morphine, Pentothal, Nembutal, alcohol, chloroform, and Benzedrine tablets were occasionally available. However, possession of a drug did not mean an adequate supply, proper dosing equipment, or the ability to monitor its effects safely.</li><li>Blood products were extraordinarily valuable. Plasma bottles, intravenous lines, and actual blood were rare. Some gravely ill patients survived because plasma or transfusion became available at the critical moment, but many others died of hemorrhage and shock that would have been treatable in a major hospital.</li><li>Medical stores had to be hidden separately from the hospitals. Concentrating supplies in one place risked losing everything in a raid or bombing. Rogers and the Partisans therefore concealed caches throughout the area, creating additional problems of transport, security, memory, access, and retrieval during emergencies.</li></ul><h3>INFECTION AND DISEASE FOUGHT ALONGSIDE THE ENEMY</h3><ul><li>Many patients arrived days or weeks after being wounded. They were often emaciated, dehydrated, filthy, lice-infested, hypothermic, and carrying infected injuries filled with dead tissue, pus, clothing fragments, dirt, and shrapnel. Delay transformed treatable wounds into threats of sepsis, gas gangrene, osteomyelitis, and death.</li><li>Lice were nearly universal and spread epidemic typhus. Typhus, caused by rickettsial organisms and commonly transmitted by body lice, produced high fever, severe headache, rash, delirium, weakness, and death. Clothing had to be washed, treated, or exposed to limited fuel and disinfectant when available, but true delousing was difficult.</li><li>Typhoid fever spreads through contaminated water, food, poor latrines, and inadequate hand hygiene. Without dependable antibiotics, treatment centered on hydration, fever control, nutrition, rest, and whatever supportive measures could be provided. Even these basic measures were difficult in mobile hospitals with scarce water and supplies.</li><li>Tuberculosis flourished among malnourished and exhausted fighters. Rogers encountered pulmonary tuberculosis and Pott disease, or tuberculosis of the spine, which could cause severe pain, weakness, abscesses, neurological damage, and marked spinal deformity.</li><li>Rickets, scurvy, frostbite, peripheral neuritis, constipation, skin infections, and respiratory disease weakened resistance and impaired healing. Rogers was not treating isolated bullet wounds in otherwise healthy soldiers. He was treating profoundly compromised human beings attacked simultaneously by trauma, infection, hunger, exposure, and chronic disease.</li></ul><h3>THE WOUNDS WERE OLD, FILTHY, COMPLEX, AND OFTEN BEYOND SAVING</h3><ul><li>Rogers treated injuries involving nearly every part of the body. These included wounds of the head, brain, face, neck, chest, abdomen, spine, pelvis, and limbs, along with bullet injuries, grenade fragments, mortar shrapnel, blast fractures, frostbite, burns, hemorrhage, and infection.</li><li>Many injuries were already severely contaminated or necrotic when first examined. Damaged tissue had to be cut away. Bomb or mortar fragments, bullets, bone, clothing, dirt, and pus had to be removed. Wounds were drained, cleaned, packed, grafted, or dressed using inadequate materials.</li><li>Raw wounds sometimes required skin grafting and pressure dressings after debridement. Skin grafts were taken with razor blades because specialized grafting instruments were unavailable. The procedure required courage from both surgeon and patient, particularly where anesthesia was limited.</li><li>Some wounds were fundamentally unsalvageable under field conditions. Major abdominal, thoracic, spinal, cerebral, or vascular injuries that might have required advanced surgery, intensive care, oxygen, imaging, blood products, and prolonged hospitalization could not be adequately treated. Many Partisans died not because Rogers lacked knowledge, but because the system required to apply that knowledge did not exist.</li><li>The reality of guerrilla surgery was therefore not a continuous sequence of miraculous rescues. It included unavoidable deaths, agonizing triage, failed procedures, delayed treatment, and patients who reached Rogers too late. His achievement lies not in having defeated every injury, but in saving many who otherwise had no chance at all.</li></ul><h3>ABDOMINAL AND CHEST SURGERY WITHOUT A MODERN HOSPITAL</h3><ul><li>Abdominal wounds demanded immediate judgment because delay could mean peritonitis, hemorrhage, bowel obstruction, overwhelming infection, or death. Rogers performed abdominal operations in improvised surroundings without the diagnostic certainty, lighting, suction, anesthesia, monitoring, blood replacement, and postoperative support expected today.</li><li>Gastric decompression was used to remove fluid and gas from the stomach or upper intestine. Controlled continuous or intermittent negative pressure could be improvised, but standard suction apparatus was rarely available. Tubing, containers, gravity, and manual methods had to replace hospital equipment.</li><li>Chest injuries included penetrating trauma, hemothorax, damaged ribs, lung injury, and retained shrapnel. Rogers removed damaged tissue, fragments of bone, pieces of clothing, and missile debris when possible. Drainage systems had to be constructed from available tubing and containers.</li><li>Head and brain injuries presented some of the most severe limitations. Without imaging, neurosurgical equipment, blood products, controlled ventilation, or intensive monitoring, Rogers relied upon clinical examination, wound exploration, removal of accessible debris, control of bleeding, and observation.</li><li>Every major operation continued after the final stitch. Patients required warmth, fluids, nutrition, dressings, infection control, pain relief, and nursing. These postoperative needs were difficult enough under normal circumstances and nearly impossible while the hospital itself might have to move before morning.</li></ul><h3>FRACTURES WERE HELD TOGETHER WITH BRANCHES, NAILS, PLASTER, AND STONES</h3><ul><li>Fractures varied enormously in age, severity, contamination, and stability. Some were fresh. Others had been untreated for days or weeks. Many were open fractures caused by blasts, bullets, or shrapnel and were already infected.</li><li>Splints were made from branches and other available materials. Immobilization was essential to reduce pain, bleeding, tissue damage, and further displacement. Even a crude splint could transform an impossible evacuation into a survivable one.</li><li>Metal frames (if available) were combined with plaster of Paris wrapped around the limb and frame. These constructions attempted to stabilize fractures that would normally require specialized orthopedic equipment. However, plaster and prolonged immobilization could create pressure sores, skin breakdown, nerve injury, and circulatory problems.</li><li>Traction was improvised from beams, four-inch nails, logs, frames, ropes, and bags of stones. Such systems could align fractures and reduce deformity, but they were difficult to control and almost impossible to transport. When enemy attack threatened, traction had to be dismantled and the limb rapidly wrapped or splinted for escape.</li><li>Osteomyelitis and chronic infection were common consequences. Sulfa drugs provided some help, but contaminated bone, retained fragments, dead tissue, malnutrition, and delayed treatment made infection difficult to eradicate. A saved limb could remain painful, deformed, shortened, or chronically draining for life.</li></ul><h3>ANESTHESIA WAS LIMITED, DANGEROUS, AND SOMETIMES ABSENT</h3><ul><li>Anesthesia could not be assumed for any operation. Morphine, Pentothal, chloroform, Nembutal, alcohol, and local anesthetics were used when available, but quantities were small and monitoring was primitive.</li><li>Intravenous pentothal could provide rapid anesthesia but also suppress breathing and circulation. Without oxygen, suction, airway equipment, monitoring, or a trained anesthetist, every dose carried significant danger.</li><li>Chloroform was often used because it was portable and familiar, yet it also carried serious risks. Irregular dosing, poor ventilation, cardiac toxicity, and lack of monitoring made its administration hazardous.</li><li>Local and regional anesthesia offered alternatives when general anesthesia was impossible. Injections around nerves or vessels could permit limited procedures and were also explored in attempts to improve blood flow in frostbitten limbs.</li><li>At times, patients had to endure painful procedures with little or no anesthesia. Debridement, dressing changes, fracture manipulation, drainage, grafting, and amputation could be agonizing. The courage of the patients and the emotional burden upon the medical staff must not be erased by purely technical descriptions of the procedures.</li></ul><h3>FROSTBITE WAS TREATED WITH HEAT, POSITION, NERVE BLOCKS, AND HOPE</h3><ul><li>Frostbite was common because Partisans marched and slept in freezing conditions with wet clothing and inadequate boots. Damaged tissue could remain numb initially and then become intensely painful, swollen, blistered, infected, and gangrenous.</li><li>Hot rocks and stones were used for warming. A heated stone could also help dilate a collapsed peripheral vein, making intravenous access more achievable. The temperature had to be controlled because insensate tissue could be burned without the patient realizing it.</li><li>Local anesthetic was injected around the major artery supplying the leg in an attempt to improve circulation. Regional injections near the nerves emerging from the spinal column were also tried and appeared in some cases to increase blood flow to frostbitten feet.</li><li>Positioning was modified in an effort to use gravity to improve perfusion. Raising the head of the bed was believed to promote blood flow toward the lower extremities. Such measures reflected a pragmatic attempt to influence circulation when modern vascular treatments were unavailable.</li><li>Many severely affected toes, feet, and limbs still progressed to gangrene and amputation. Frostbite was not merely cold skin. It was tissue death intensified by malnutrition, smoking, infection, prolonged exposure, immobility, and delayed access to care.</li></ul><h3>AMPUTATION COULD SAVE A LIFE — OR DESTROY THE POSSIBILITY OF A FUTURE</h3><ul><li>Amputation was frequently required for gangrene, gas gangrene, crushed limbs, uncontrollable infection, and irreparable trauma. In such cases, preserving a dead limb could kill the patient through sepsis and toxin production.</li><li>The traditional guillotine amputation involved cutting directly through skin, muscle, and bone and leaving the stump open. This allowed drainage, dressing changes, and observation while infection remained uncontrolled. It could be a necessary emergency procedure in a contaminated battlefield wound.</li><li>Once infection and shock were controlled, a second operation could revise the stump at a higher level. Proper tissue flaps could then be fashioned to cover the bone and produce a durable, functional residual limb.</li><li>Rogers recognized that the technique chosen affected the patient’s entire future. A badly formed stump could make the later fitting of an artificial limb difficult or impossible. Creating adequate flaps, even under desperate conditions, offered the patient a chance to walk again.</li><li>This concern reveals the depth of his medicine. Rogers was not simply cutting away disease to keep a person alive for another day. Whenever circumstances allowed, he considered long-term function, dignity, mobility, and the life the patient might lead after the war.</li></ul><h3>EVEN TUBING FROM A STETHOSCOPE COULD BECOME A LIFE-SAVING DEVICE</h3><ul><li>Fluid replacement was extremely difficult when veins collapsed from dehydration, hemorrhage, cold, or shock. Intravenous equipment was scarce, and obtaining access in a desperately ill patient could be nearly impossible.</li><li>Hot stones could be used to warm the patient and dilate a vein. This simple measure might make the difference between obtaining intravenous access and losing the patient to shock.</li><li>Rectal fluids offered another route of hydration when intravenous treatment was unavailable. Warm saline could be introduced slowly through improvised tubing, allowing some absorption through the bowel.</li><li>Stethoscope tubing could be repurposed for rectal infusion, drainage, enemas, or washout. The act of converting a diagnostic instrument into a treatment device illustrates Rogers’ willingness to see equipment according to function rather than intended label.</li><li>Such improvisations were not substitutes for proper resuscitation when proper resuscitation was available. They were desperate, reasoned attempts to keep a patient alive where no better option existed. In those conditions, an unconventional measure that worked imperfectly was infinitely more valuable than an ideal method that could not be delivered.</li></ul><h3>ROGERS TREATED HUMAN BEINGS, NOT JUST BATTLEFIELD WOUNDS</h3><ul><li>His patients included both men and women, Partisan fighters, civilians, and others caught within the conflict. Their needs did not fit neatly into surgical categories. A patient could have a bullet wound, tuberculosis, lice, scurvy, frostbite, grief, terror, and starvation at the same time.</li><li>He encountered at least one female Partisan suffering from advanced breast cancer. Metastatic cancer did not pause because a war was underway. It appeared in a setting with no oncology service, imaging, pathology, radiotherapy, chemotherapy, or effective palliative care.</li><li>Rogers had to treat chronic disease amid acute catastrophe. Tuberculosis, spinal deformity, deficiency diseases, infections, constipation, skin disease, and cancer existed alongside fractures, hemorrhage, and blast trauma.</li><li>The emotional suffering was immense. Patients had lost parents, children, spouses, homes, villages, and comrades. Some had survived torture or rape. Others knew their families had been executed in reprisals. Medical care could not erase those losses, but humane treatment provided recognition that their lives still mattered.</li><li>Rogers’ willingness to care for civilians as well as fighters demonstrated that his mission was fundamentally humanitarian. He possessed military skills and operated within a resistance movement, but his central purpose remained the relief of suffering and the preservation of life.</li></ul><h3>NAZI BRUTALITY TURNED MEDICINE INTO A DEFENSE OF HUMANITY ITSELF</h3><ul><li>Human history contains repeated examples of unspeakable cruelty, but Nazi occupation brought organized torture, execution, reprisal killings, rape, village destruction, and deliberate terror to the regions where Rogers worked. The purpose was not merely military victory but the intimidation and destruction of entire communities.</li><li>Rogers encountered murdered civilians, dead combatants, bombed families, burned villages, and victims of torture. Men, women, and children were killed in reprisals for resistance activity. Wounded people could be executed simply because they had received assistance from the Partisans.</li><li>Some victims had endured mutilation, eyes gouged out, genital torture, sexual violence, and other deliberate injuries. Rogers reportedly treated a perforated bladder resulting from wire tied around the genitals and weighed down by a brick. Such wounds were not accidental products of combat; they were intentional assaults designed to instill fear, terrorize, and destroy.</li><li>Hidden hospitals were themselves targets. Enemy forces destroyed makeshift facilities, murdered patients and medical staff, slit throats, locked people inside burning huts or houses, and used dogs to pursue the wounded. A hospital offered no recognized sanctuary.</li><li>Under those conditions, medicine became an act of resistance against dehumanization. Every wound cleaned, every frightened patient comforted, every limb saved, and every life protected declared that Nazi brutality would not be allowed to decide whose life had value.</li></ul><h3>SOMETIMES A DOCTOR HAD TO FIGHT TO KEEP HIS PATIENTS ALIVE</h3><ul><li>Rogers was not protected by the conventions surrounding civilian medical practice. He operated behind enemy lines as part of a guerrilla resistance. German troops searching for his hospitals were not arriving to inspect them; they were arriving to kill the patients, doctors, and nurses.</li><li>He therefore sometimes carried weapons and fought. His training in pistols, rifles, machine guns, explosives, and silent combat was not theoretical. At times he had to kill enemy soldiers who were hunting the wounded under his protection.</li><li>This creates a severe moral tension for any physician. Medicine is dedicated to preserving life, yet a doctor confronted by armed men intent upon murdering helpless patients may be forced to choose between passive purity and active defense.</li><li>Protecting patients from immediate slaughter can be understood as an extension of the duty to prevent harm and injustice. Rogers did not seek combat as a substitute for medicine. Combat was imposed upon him by circumstances in which refusing to resist could mean abandoning his patients to execution.</li><li>His experience demonstrates that ethical principles do not always arrive in clean, comfortable forms. In war, a physician may confront choices in which every available action carries moral cost. Rogers’ decisions must be understood within the brutal reality of a conflict where the enemy deliberately hunted hospitals and murdered the wounded.</li></ul><h3>THE SOUNDS AND SMELLS OF HIS WAR CANNOT BE CAPTURED BY A CLINICAL LIST</h3><ul><li>A list of diagnoses and procedures cannot recreate the sensory horror Rogers experienced. It does not convey the screaming of patients, the crying of the frightened, the thunder of bombs, the cracking of rifle fire, the mechanical tearing of machine guns, or the sudden silence after an explosion.</li><li>Nor can it reproduce the smells. The smell of explosives, body odor accumulated in unwashed clothing, smoke from tallow lights, infected dressings, feces, urine, blood, gas gangrene, rotting flesh, dead animals, and human corpses would have filled enclosed caves, barns, and shelters.</li><li>Pain was constant and often untreated. Patients cried during dressing changes, debridement, fracture manipulation, drainage, and surgery. Medical workers had to continue despite the cries because stopping could mean death.</li><li>Fear existed within every sound. An aircraft overhead could mean supplies or bombing. A dog barking could mean a villager’s animal or a German tracking unit. Footsteps outside a hut could signal a courier, a wounded Partisan, a collaborator, or an execution squad.</li><li>Rogers’ achievement must therefore be understood emotionally as well as medically. He did not perform isolated procedures in sterile silence. He worked inside an atmosphere of terror, grief, exhaustion, filth, pain, and death — and still retained the ability to think, decide, operate, and care.</li></ul><h3>GUERRILLA SURGEON IS MORE THAN A WAR MEMOIR</h3><ul><li>Rogers’ book, <em>Guerrilla Surgeon</em>, records his experiences in the mountains of Yugoslavia between 1943 and 1945. It provides a rare first-person account of medicine conducted within a resistance movement under conditions of extreme scarcity and danger.</li><li>The book describes far more than operations. It captures movement through hostile territory, interactions with Partisan fighters, supply problems, evacuations, hidden hospitals, disease, weather, fear, enemy pursuit, and the moral complexity of serving as both physician and military operative.</li><li>Rogers functioned as an unofficial liaison between local Partisan forces and the Allies. His role involved communication, coordination, transport, supplies, intelligence, and the evacuation of the wounded, in addition to direct medical care.</li><li>His account is valuable because it shows what happens when medical theory meets absolute and brutal reality. It reveals the distance between a textbook recommendation and what can actually be accomplished in a cave with a dying patient, a candle, a hacksaw, a little morphia, and enemy troops approaching.</li><li>The book also preserves the humanity of people who might otherwise survive only as statistics. The wounded Partisans, young women fighters, villagers, nurses, civilians, and medical workers emerge as individuals struggling to live within one of history’s most violent conflicts.</li></ul><h3>ROGERS EMBODIED THE BEST QUALITIES OF A PHYSICIAN</h3><ul><li>Rogers gave his medical knowledge freely, expertly, and without expectation of personal reward. He did not treat the Partisans to build wealth, status, influence, or reputation. He treated them because they were wounded, vulnerable, and in need.</li><li>He demonstrated compassion through conduct rather than sentiment. Compassion in his world meant walking through snow to reach another hospital, operating while exhausted, surrendering scarce supplies to a patient, staying behind during danger, or returning to hostile territory after reaching relative safety.</li><li>He led by example. He accepted the same cold, hunger, lice, danger, and uncertainty endured by the people around him. He did not issue instructions from a safe headquarters while others carried the burden.</li><li>He fought tenaciously against suffering and death. Not every patient could be saved, but Rogers refused to allow scarcity, fear, or discomfort to become excuses for inaction. When conventional medicine was impossible, he created another form of medicine from knowledge, ingenuity, and determination.</li><li>He represented the deepest spirit of the Hippocratic tradition. That tradition is not merely a recited oath or professional ceremony. It is the practical commitment to use one’s knowledge for the vulnerable, to oppose injustice, to reduce suffering, and to remain at one’s post when abandoning it would be easier and safer.</li></ul><h3>HIS COURAGE WAS NOT THE ABSENCE OF FEAR</h3><ul><li>True bravery does not require a person to feel no fear. A person who does not understand danger may behave recklessly, but that is not courage. Courage begins when the danger is understood and the fear is real.</li><li>Rogers knew what capture could mean. He had seen murdered civilians, destroyed hospitals, tortured prisoners, burned villages, and dead medical workers. He knew that German patrols might shoot him, torture him, or execute him as an enemy operative.</li><li>He also understood the dangers of the terrain, weather, disease, and exhaustion. He knew that a blizzard, infected wound, aircraft attack, failed supply drop, or wrong turn in the mountains could kill him just as surely as a bullet.</li><li>Yet he repeatedly chose to return, continue, operate, move patients, obtain supplies, and stand beside the Partisans. His courage was not a single impulse. It was a repeated decision to act despite fear.</li><li>That is why his example remains so powerful. Courage is not dramatic language, self-description, or public performance. It is the decision to stand up for what is right, persist through adversity, and accept sacrifice when walking away would be safer.</li></ul><h3>ACTIONS SPEAK LOUDER THAN WORDS BECAUSE ACTIONS CARRY A PRICE</h3><ul><li>Words are easy to produce. Anyone can make promises, claim virtue, offer opinions, praise courage, announce expertise, or condemn injustice. Speaking usually costs little and can be done from comfort and safety.</li><li>Actions demand something real. They require time, energy, skill, discipline, resources, accountability, and the willingness to accept consequences. Under extreme circumstances, action may demand pain, exhaustion, fear, sacrifice, and personal danger.</li><li>Modern culture often confuses visibility and numerous sheep-like followers with value. Follower counts measure attention, not character. Algorithms reward controversy, repetition, emotional reaction, and confidence. They do not reliably measure integrity, knowledge, kindness, competence, bravery, or service.</li><li>Opinions unsupported by knowledge and evidence do not become truth merely because they are repeated. A crowd can amplify ignorance as easily as wisdom. Online commentary allows people to express absolute certainty without bearing responsibility for the real-world consequences of their claims.</li><li>Rogers did not merely state his values — he paid for them in effort, danger, exhaustion, and sacrifice. His deeds are proof. They establish more convincingly than any speech that courage, compassion, leadership, and honor are not qualities a person announces. They are qualities a person demonstrates.</li></ul><h3>A TOWERING EXAMPLE OF HONOR IN ACTION</h3><ul><li>Dr. Lindsay Rogers stands as a towering example not because he was flawless, but because he used his strengths in the service of others when service was most difficult. His impatience, irreverence, stubbornness, and resistance to criticism were parts of a complex personality, yet they did not prevent him from giving generously or acting courageously.</li><li>He transformed surgical knowledge into survival where conventional medicine had almost ceased to exist. He built hospitals without buildings, operated without operating rooms, created instruments from ordinary objects, moved patients without ambulances, and treated infection without dependable antibiotics.</li><li>He stood beside men and women who were cold, starving, wounded, hunted, and frequently forgotten by the outside world. He treated them not as expendable fighters but as human beings entitled to care, dignity, relief from suffering, and a chance to live.</li><li>His life demonstrates the highest standard of leadership: competence joined to sacrifice. Knowledge without courage remains unused. Courage without knowledge can become reckless. Rogers combined both, and then added compassion, persistence, judgment, and action.</li><li>Tragically, Dr. Lindsay Rogers died in an accident in New Caledonia in 1962. Yet his legacy survives because the lives of honorable people are not measured solely by their length. They are measured by what those people chose to do, whom they protected, what suffering they relieved, and what example they left behind. Rogers’ actions continue to speak — and they speak louder than words ever could.</li></ul><p>OTHER READS</p><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-screening-prostate-cancer-massive-public-health-bert-vorstman-md-1nide/">PSA SCREENING FOR PROSTATE CANCER: A MASSIVE PUBLIC HEALTH DISASTER</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/when-doctor-jumps-actions-speak-louder-than-words-bert-vorstman-md-ol25e/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cf523ef6a640" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[PSA SCREENING FOR PROSTATE CANCER: A MASSIVE PUBLIC HEALTH DISASTER]]></title>
            <link>https://bvorstman.medium.com/psa-screening-for-prostate-cancer-a-massive-public-health-disaster-11bbf6306228?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/11bbf6306228</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Sun, 19 Jul 2026 12:43:15 GMT</pubDate>
            <atom:updated>2026-07-19T12:43:15.503Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*OTmayiBYm8Gmu-GP" /></figure><p>Bert Vorstman MD, Ron Piana</p><p>Patients trust that when physicians recommend a screening test, it has been rigorously proven to be reliable, safe, beneficial, and capable of meaningfully saving lives. Few men would willingly consent to testing if they knew the science was weak, the false positive rate massive, the downstream harm potentially life-altering, and the life-saving benefit deeply uncertain. Yet for decades, fear-based slogans like “catch it early before it spreads” and “early detection saves lives” have driven millions of healthy men into a medical conveyor belt of PSA testing, biopsies, surveillance, surgery, radiation, impotence, incontinence, anxiety, and regret. The uncomfortable truth is this: the PSA test fails the very criteria required of a useful screening test — poor specificity, overdiagnosis, overtreatment, no reliable ability to identify lethal disease, and no irrefutable and reproducible evidence that it saves significant numbers of lives. This article asks a disturbing but necessary question: How did one of medicine’s weakest and inaccurate screening tools become one of its most aggressively marketed — and most damaging — public health programs?</p><h3>FROM ONE FLAWED MARKER TO ANOTHER: HOW PSA REPLACED PAP WITHOUT SOLVING THE PROBLEM</h3><ul><li>Before PSA became the centerpiece of prostate cancer medicine, Prostatic Acid Phosphatase (PAP) served as the first clinically useful blood biomarker for prostate cancer tracking — discovered in 1938 when researchers observed elevated serum acid phosphatase levels in men with advanced metastatic prostate cancer.</li><li>For decades, PAP became the dominant biochemical tool used to monitor prostate cancer progression and assess responses to treatments such as hormone therapy or orchiectomy, helping physicians follow disease that had already clearly declared itself.</li><li>But PAP had a major weakness: it was largely useful only in advanced, metastatic disease, particularly cancers that had spread to the bones, and proved unreliable as a screening or early detection tool for localized prostate cancer.</li><li>By the 1980s, PAP was largely abandoned and replaced by PSA, not because PSA solved the problem, but because it proved more sensitive — detecting more abnormalities — while remaining profoundly non-specific, unable to reliably distinguish cancer from benign enlargement, inflammation, infection, or harmless disease.</li><li>Prostate cancer medicine effectively moved from one flawed biomarker to another, replacing a marker that was poor for early detection with a test that finds more abnormalities but introduced a new era of false positives, overdiagnosis, anxiety, biopsies, and treatment for cancers many men would likely never suffer from or die with.</li></ul><h3>THE PSA: A SEXUAL ENZYME REPURPOSED AS A CANCER TEST</h3><ul><li>The Prostate-Specific Antigen (PSA) is not a cancer marker by design — it is an enzyme whose biological role is reproduction, not cancer detection. PSA’s primary function is to liquefy semen after ejaculation, breaking down the gel-like seminal coagulum so sperm can move freely and swim toward an egg for fertilization.</li><li>PSA is technically a serine protease enzyme, naturally produced in large amounts by the prostate and secreted into semen. Its job begins and ends in reproduction. It was never biologically designed to identify cancer, predict aggressive disease, or reliably distinguish dangerous tumors from harmless abnormalities.</li><li>Tiny amounts of PSA normally leak into the bloodstream, where blood tests attempt to measure it. Yet medicine transformed this ordinary biological leakage into one of the most heavily marketed cancer screening tools in history — despite enormous scientific uncertainty about what the number actually means.</li><li>The uncomfortable truth is this: PSA elevation simply reflects leakage, not cancer. Anything that disrupts the prostate — including inflammation, enlargement, infection, aging, sexual activity, or medical manipulation — can raise PSA levels without cancer ever being present.</li><li>A reproductive enzyme whose purpose is helping sperm swim was gradually rebranded into a cancer alarm bell for millions of men — despite major questions regarding specificity, accuracy, and meaningful life-saving benefit.</li></ul><h3>“PROSTATE-SPECIFIC” IS A MEDICAL MISNOMER: IT’S NOT SPECIFIC</h3><ul><li>The term “Prostate-Specific Antigen” sounds scientific and reassuring — but the name itself is profoundly misleading. PSA is not prostate-specific, because it has been detected in numerous organs, tissues, and bodily fluids in both men and women.</li><li>PSA has been found in some B-cell lymphomas, female ejaculate, breast tissue, breast milk, saliva, urine, amniotic fluid, ovaries, endometrium, sweat glands, thyroid tissue, pancreas, and salivary glands, making the term “specific” scientifically problematic and intellectually dishonest.</li><li>Female Skene’s glands, often referred to as the “female prostate,” also produce PSA. This discovery completely undermines the simplistic narrative that PSA belongs exclusively to men or to prostates.</li><li>In a scientific irony that should have triggered major reassessment, researchers accidentally discovered PSA in breast cancer tissue in 1993, proving that PSA was not exclusively prostate-derived, despite decades of assumptions and marketing.</li><li>PSA is therefore not prostate-specific and certainly not cancer-specific, yet healthcare systems continue to rely heavily on a test whose very name exaggerates its biological precision.</li></ul><h3>A TEST BUILT ON FALSE POSITIVES, FALSE FEARS, AND FALSE PROMISES</h3><ul><li>The PSA test suffers from a staggering false positive rate <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3183963/">approaching</a> 78%, meaning most men with elevated results do not have clinically meaningful prostate cancer, yet many are thrust into anxiety, repeat testing, imaging, and invasive biopsies.</li><li>Elevated PSA results often trigger a cascade of fear. A man who feels perfectly healthy is suddenly told he may have cancer, sending him psychologically into survival mode, despite overwhelming uncertainty regarding what the PSA actually signifies.</li><li>PSA testing fails to distinguish aggressive cancer from harmless, slow-growing disease, creating one of the biggest dilemmas in modern medicine: identifying abnormalities without understanding whether they are dangerous.</li><li>The consequence is predictable — overdiagnosis and overtreatment. Millions of men have undergone biopsies, surgeries, radiation, and hormone therapy for abnormalities they likely would have outlived without symptoms or harm.</li><li>A screening test with massive false positives and poor predictive value raises a difficult question: How did medicine normalize a test that creates fear faster than it provides answers?</li></ul><h3>THE PSA IS A POOR PREDICTOR OF THE FEW DANGEROUS CANCERS</h3><ul><li>In the bloodstream, PSA exists in two forms: free PSA, which circulates unbound, and bound PSA, which attaches to proteins. The total PSA commonly measured in blood tests simply represents the sum of these fractions.</li><li>Yet despite decades of use, there is no irrefutable and reproducible scientific evidence proving PSA screening saves significant numbers of lives, especially when weighed against the enormous harms of overdiagnosis and unnecessary treatment.</li><li>High PSA numbers do not necessarily mean dangerous cancer, and low PSA numbers do not guarantee safety. Some aggressive cancers produce little or no PSA, while benign conditions can generate dramatic elevations.</li><li>This means PSA often performs poorly at the one job society expects of a screening test: accurately identifying dangerous disease while minimizing unnecessary harm.</li><li>Instead, PSA frequently creates uncertainty, repeated testing, and invasive downstream interventions — while still missing some biologically aggressive cancers.</li></ul><h3>WHY WAS PSA CALLED “SPECIFIC” IN THE FIRST PLACE?</h3><ul><li>PSA was labeled “specific” largely because the prostate produces dramatically higher concentrations than other tissues — up to one million times greater in seminal fluid than blood serum.</li><li>When researchers first isolated PSA in the late 1970s, testing technology lacked the sensitivity needed to detect tiny amounts elsewhere in the body. Scientists mistakenly believed PSA was unique to prostate tissue.</li><li>The label survived despite mounting evidence proving otherwise. Instead of renaming or reframing the test, medicine continued marketing the illusion of specificity.</li><li>The problem is not merely semantics. Names shape perception. Calling something “prostate-specific” naturally convinces patients — and many physicians — that elevations must originate from prostate disease.</li><li>In reality, the word “specific” vastly overstated certainty, helping create decades of misplaced confidence in an inherently nonspecific biomarker.</li></ul><h3>THE DISCOVERY OF PSA: NEVER INTENDED FOR MASS SCREENING</h3><ul><li>In 1970, immunologist Richard J. Ablin intentionally observed PSA while studying prostate tissue — but he never intended it for widespread screening of healthy men.</li><li>Ablin envisioned PSA as a tool to monitor men already known to have advanced prostate cancer, not as a population-wide screening program.</li><li>In 1979, researchers led by T. Ming Chu purified PSA and developed methods to measure it in blood, laying the groundwork for commercialization.</li><li>What followed was mission creep. A marker intended for monitoring disease quietly transformed into a mass-screening test for millions of healthy men despite weak supporting evidence.</li><li>Ironically, one of PSA’s original discoverers later became one of its harshest critics, warning publicly that screening had become a dangerous and costly medical mistake.</li></ul><h3>FDA APPROVAL: A HISTORIC MEDICAL MISSTEP</h3><ul><li>In 1986, the FDA approved PSA testing only to monitor recurrence and treatment response in men already diagnosed with prostate cancer — a limited and arguably sensible role.</li><li>By 1994, however, PSA gained approval as an early detection screening aid, despite ongoing concerns over poor specificity and unclear survival benefit.</li><li>The screening approval relied on weak and questionable evidence, while downstream harms — including biopsies, surgeries, radiation, impotence, and incontinence — were poorly appreciated or ignored.</li><li>Powerful economic incentives, industry enthusiasm, and institutional momentum helped drive adoption faster than science justified.</li><li>The result was one of the most consequential shifts in men’s healthcare: millions screened, millions frightened, and countless interventions performed without clear proof of meaningful population benefit.</li></ul><h3>THE MOVING GOALPOSTS OF “NORMAL” PSA</h3><ul><li>For years, medicine treated 4.0 ng/mL as the universal cutoff for biopsy, creating the illusion of scientific precision where none truly existed.</li><li>Over time, medicine quietly abandoned the one-size-fits-all approach as evidence accumulated showing many men with low PSAs had cancer while many with high PSAs did not.</li><li>Today, age-adjusted ranges, PSA velocity, MRI imaging, and additional biomarkers are often used to refine risk assessment — an acknowledgment that PSA alone is deeply flawed.</li><li>Different laboratories also use different calibration systems, meaning PSA values may differ significantly between facilities. As well, PSA levels can naturally fluctuate by 20% to 30% — or even more — over the course of a day or from day to day</li><li>When a screening test repeatedly requires reinterpretation, changing thresholds, and secondary tests to explain itself, confidence in the original test naturally erodes.</li></ul><h3>THE PSA TEST FAILS THE BASIC REQUIREMENTS OF A USEFUL SCREENING TEST</h3><ul><li>A useful screening test must meet several essential scientific standards: it should have high sensitivity and specificity, safely and accurately identify disease early, be acceptable to patients, readily available, cost-effective, and — most importantly — lead to treatments that extend life with benefits clearly outweighing harms.</li><li>The PSA test fails to satisfy all of these criteria. It is not cancer-specific, poorly predictive of dangerous disease, vulnerable to massive false positives, and incapable of reliably distinguishing harmless abnormalities from biologically aggressive cancers.</li><li>A screening test should ideally reduce suffering and complications, yet PSA screening often funnels healthy men toward needle biopsies, surgeries, radiation, hormone therapies, impotence, urinary leakage, bowel dysfunction, anxiety, and lifelong medical surveillance.</li><li>Worse still, some of the most aggressive prostate cancers may produce little or no PSA at all, meaning men can be falsely reassured while dangerous disease quietly advances undetected.</li><li>After decades of widespread use and billions spent, there remains no irrefutable and reproducible evidence showing PSA screening delivers meaningful life extension sufficient to justify the enormous downstream burden of overdiagnosis and overtreatment.</li></ul><h3>THE PSA DOESN’T DETECT CANCER — IT DETECTS PROSTATE ACTIVITY</h3><ul><li>One of the biggest misconceptions in men’s health is that PSA is a “cancer test.” It is not. PSA does not directly measure cancer activity, tumor burden, or biologic aggressiveness — it merely reflects prostate activity and leakage into the bloodstream.</li><li>Elevated PSA levels are most commonly caused by Benign Prostatic Hyperplasia (BPH), a natural enlargement of the prostate that accompanies aging. In practical terms: bigger prostates make bigger PSA numbers.</li><li>Inflammatory conditions such as prostatitis, urinary tract infections, urinary retention, catheterization, cystoscopy, ejaculation, vigorous exercise, bicycle riding and testosterone supplements can elevate PSA levels without any cancer being present.</li><li>At the same time, obesity and medications such as finasteride, dutasteride, statins, NSAIDs, metformin, and thiazide diuretics may artificially lower PSA values — creating a false impression of safety.</li><li>Put simply, PSA does not tell doctors whether cancer exists, whether cancer matters, or whether treatment helps — it merely signals that something involving the prostate may be biologically active — clearly, it’s not cancer specific.</li></ul><h3>THE “NORMAL RANGE” OF PSA: A NUMBER BUILT ON GUESSWORK</h3><ul><li>For years, men were told that a PSA level between 0 and 4 ng/mL represented “normal,” while anything higher triggered anxiety and recommendations for biopsy. Yet this supposedly scientific threshold was never grounded in irrefutable biological truth.</li><li>The so-called normal range emerged largely from clinical convention, statistical averages, and guideline panels, not hard scientific boundaries separating healthy men from men with dangerous disease.</li><li>The problem became obvious quickly: many men with PSA values below 4 had cancer, while many men above 4 did not. This inconsistency forced medicine to repeatedly shift the goalposts.</li><li>Modern medicine now embraces age-adjusted PSA ranges, PSA velocity, PSA density, MRI scans, and additional biomarkers, quietly acknowledging that a single universal cutoff never made much scientific sense.</li><li>When doctors continuously revise the definition of “normal,” patients are left wondering whether the original certainty surrounding PSA thresholds was scientific precision — or educated guesswork disguised as confidence.</li></ul><h3>TOO MANY BIOMARKERS, TOO FEW ANSWERS</h3><ul><li>Faced with PSA’s shortcomings, the medical industry introduced a growing menu of newer tests — often marketed with sophisticated scientific language promising greater accuracy, better prediction, and fewer unnecessary biopsies.</li><li>Tests such as PHI, 4Kscore, PCA3, TMPRSS2:ERG, SelectMDx, ExoDx, MyProstateScore, IsoPSA, and DNA methylation assays are frequently presented as revolutionary advances in “personalized medicine.”</li><li>Yet despite fancy names, expensive marketing, and promises of precision, these tests largely suffer from the same core limitation as PSA: they cannot reliably determine which cancers are truly lethal and which men actually benefit from treatment.</li><li>For many patients, the expanding biomarker marketplace creates more confusion, more cost, and more testing, while still failing to provide certainty regarding life expectancy or treatment necessity.</li><li>These tests resemble efforts to repair a weak foundation rather than replacing it — more complexity layered onto a biomarker that remains fundamentally nonspecific.</li></ul><h3>URINE BIOMARKERS: A NONINVASIVE PROMISE STILL SEARCHING FOR PROOF</h3><ul><li>Urine biomarkers are often marketed as a type of “liquid biopsy,” promising painless, non-invasive methods to help men decide whether they truly need a prostate biopsy.</li><li>Tests such as PCA3, TMPRSS2:ERG fusion, SelectMDx, ExoDx Prostate Intelliscore, MyProstateScore, and DNA methylation assays analyze genes, RNA, and molecular signals associated with prostate cancer.</li><li>These tests sound impressive on paper and are often marketed as helping identify “clinically significant” cancers, but uncertainty remains regarding their ability to meaningfully change outcomes or reduce unnecessary treatment.</li><li>While urine tests may refine statistical probabilities, they still struggle to answer the most important question in prostate cancer: Will this cancer actually harm or kill the patient?</li><li>More technology, more algorithms, and more laboratory complexity may improve prediction — but prediction alone is not proof of meaningful survival benefit.</li></ul><h3>SALIVA TESTS: THE NEXT FRONTIER OR ANOTHER WAVE OF HYPE?</h3><ul><li>Saliva testing has emerged as an appealing frontier because it is painless, inexpensive, convenient, and suitable for home collection, making it attractive to researchers and companies alike.</li><li>Scientists are studying microRNAs, salivary proteins, tumor metabolites, and polygenic risk scores that may someday help estimate prostate cancer risk.</li><li>At-home “spit tests” analyzing inherited gene variants are increasingly marketed as future alternatives capable of outperforming PSA in identifying men at greater genetic risk.</li><li>Yet optimism should be tempered with caution. While biologically interesting, saliva biomarkers remain largely investigational, and their real-world effect on survival, treatment outcomes, or quality of life remains uncertain.</li><li>Medicine has repeatedly promised breakthroughs in prostate cancer detection — yet history suggests that new biomarkers often generate more enthusiasm than definitive answers.</li></ul><h3>AFTER DIAGNOSIS: EVEN MORE TESTS, EVEN MORE UNCERTAINTY</h3><ul><li>Once diagnosed, men are often introduced to another expensive layer of testing, including genomic assays such as Decipher, Prolaris, ConfirmMDx, Oncotype DX GPS, and inherited mutation panels including BRCA1, BRCA2, ATM, and CHEK2.</li><li>These tests claim to predict whether cancer behaves aggressively, estimate recurrence risk, or guide treatment decisions toward surgery, radiation, or surveillance.</li><li>Yet even sophisticated genomic profiling struggles with a fundamental truth: biology is unpredictable, and no test can reliably guarantee whether treatment will help or meaningfully extend life.</li><li>Patients are often left navigating increasingly expensive layers of probability estimates, statistics, and personalized risk calculations — while still confronting major uncertainty.</li><li>The biomarker explosion increasingly resembles a high-cost ecosystem built around uncertainty rather than clarity, where more testing frequently generates more fear without better answers.</li></ul><h3>PROSTATE CANCER AWARENESS OR FEAR-BASED MARKETING?</h3><ul><li>Prostate cancer awareness groups often promote emotionally powerful slogans such as “Catch it early before it spreads” or “Early detection saves lives,” creating urgency around screening despite persistent controversy regarding benefit.</li><li>Campaigns frequently emphasize urinary symptoms, sexual dysfunction, or subtle physical complaints as early warning signs — even though most urinary symptoms reflect aging or BPH, not cancer, and most prostate cancers arise in the outer gland away from the urinary channel.</li><li>Particular emphasis is placed on higher-risk populations — advancing age, men with strong family histories, inherited mutations, Black men, and men of Ashkenazi Jewish ancestry — encouraging screening discussions decades earlier.</li><li>These campaigns often exaggerate benefits while minimizing harms such as false positives, unnecessary biopsies, overdiagnosis, overtreatment, sexual dysfunction, urinary leakage, and psychological distress.</li><li>Fear, uncertainty, and urgency are powerful motivators in healthcare — and awareness campaigns often thrive by amplifying the belief that doing nothing is dangerous, even when there’s a lack of evidence for survival benefit.</li></ul><h3>THE BUSINESS OF PROSTATE CANCER AWARENESS: FALSE HOPE, FALSE PROMISES, PROFITEERING</h3><ul><li>Many awareness organizations maintain financial relationships with pharmaceutical companies, medical device manufacturers, hospitals, and healthcare businesses that directly benefit from increased screening and treatment.</li><li>Through cause-related marketing and “passion branding,” corporations align themselves with men’s health initiatives, sponsoring screenings at baseball games, breweries, shopping centers, churches, and public events.</li><li>Celebrity endorsements and “survivor” stories are frequently used to create emotionally compelling narratives that suggest PSA testing “saved my life,” even though individual anecdotes do not establish scientific proof.</li><li>But public messaging often fails to adequately discuss uncertainty, instead framing PSA screening as unquestionably beneficial while glossing over controversy regarding harms and life-saving benefits.</li><li>When powerful financial interests intersect with emotional storytelling, critics question whether awareness campaigns are driven primarily by patient welfare — or by healthcare economics.</li></ul><h3>THE FALSE HOPE INDUSTRY: AT PATIENT EXPENSE</h3><ul><li>Prostate cancer awareness programs often recycle the same emotionally charged claims: “Catch it early,” “Don’t wait,” “Screening saves lives,” and “You’ll regret doing nothing.”</li><li>Yet these messages frequently oversimplify a highly complex disease where most prostate cancers are slow-growing, many are outlived, and some aggressive cancers escape detection despite testing.</li><li>Men are often placed into cycles of repeat PSA testing, MRI scans, biopsies, consultations, and treatment decisions built more on fear, uncertainty, and statistical probability than certainty.</li><li>The result can be devastating: men undergo life-altering interventions believing catastrophe was avoided — while never knowing whether treatment was truly necessary in the first place.</li><li>The real danger lies not only in the limitations of PSA itself, but in a healthcare culture that transforms uncertainty into urgency and sells fear as prevention while offering false hope disguised as reassurance.</li></ul><h3>WHY PROSTATE CANCER MARKETING IS EVERYWHERE</h3><ul><li>Prostate cancer marketing survives because it uses a powerful emotional contradiction: many prostate cancers are slow-growing and outlived, yet a minority of high-grade cancers are dangerous and potentially lethal.</li><li>Awareness campaigns often spotlight the “1 in 8 men” diagnosis statistic, but that number includes mostly cancers that will never cause symptoms, suffering, or death.</li><li>The dangerous 10–15% of aggressive high-grade cancers are often used to frighten the entire male population into broad screening, even though PSA testing cannot reliably separate lethal disease from harmless disease.</li><li>Rising advanced-stage diagnoses are frequently used to justify more screening, while deeper drivers such as obesity, metabolic disease, delayed care, and healthcare inequity receive far less attention.</li><li>The marketing message becomes brutally simple: use the fear generated by the deadly minority to push testing on everyone, even when most detected cancers may never matter.</li></ul><h3>THE MEDICAL- INDUSTRIAL ENGINE BEHIND PSA SCREENING</h3><ul><li>PSA testing is not merely a blood test — it is the front door to a massive healthcare revenue chain involving repeat testing, office visits, MRI scans, biopsies, pathology, surgery, radiation, drugs, surveillance, and complication management.</li><li>Once a PSA is labeled “abnormal,” the patient may be pulled into an expensive and anxiety-producing pathway where every next step is framed as responsible medicine.</li><li>The prostate cancer industry profits not only from cancer treatment, but from uncertainty itself: borderline numbers, suspicious findings, repeat tests, and “just to be safe” interventions.</li><li>Overdiagnosis becomes the engine of overtreatment, and overtreatment becomes the engine of complications, follow-up care, medications, devices, and long-term medical dependence.</li><li>The business of prostate cancer continues to push a false, fear-based prostate cancer narrative designed to stoke ongoing doubt, anxiety, and uncertainty in men, while relentlessly promoting exaggerated “life-saving” claims and endless reports of “promising new studies” that have often been massaged sufficiently to suggest hope and justify continued testing and intervention. A deeply underhanded strategy that keeps the false prostate cancer narrative alive so that a self-perpetuating financial machine of repeat PSA testing, MRIs, biopsies, surveillance, treatments, and lifelong follow-up continues to generate enormous revenue.</li></ul><h3>URINARY AND SEXUAL SYMPTOMS: THE GREAT RED HERRING</h3><ul><li>Men are frequently told that urinary frequency, weak stream, nighttime urination, urgency, or sexual problems may be warning signs of prostate cancer, but this messaging is deeply misleading.</li><li>These symptoms are far more commonly linked to aging, benign prostate enlargement, bladder issues, medications, vascular disease, diabetes, stress, and hormonal changes than to prostate cancer.</li><li>Most prostate cancers arise in the outer zone of the prostate, away from the urinary channel, which means early prostate cancer often causes no urinary symptoms at all.</li><li>By linking common aging symptoms to cancer fear, awareness campaigns create a powerful emotional trap: ordinary male aging becomes suspicious, frightening, and medically exploitable.</li><li>The result is predictable — men with benign symptoms are steered toward PSA testing, anxiety, biopsies, and possible treatment for cancers that may never have harmed them.</li></ul><h3>“STANDARD OF CARE” DOES NOT MEAN SCIENTIFICALLY PROVEN</h3><ul><li>The phrase “standard of care” sounds like a guarantee of safety, effectiveness, and scientific certainty, but in reality it is often a legal and professional convention.</li><li>A test or treatment can become standard of care through habit, consensus, institutional adoption, fear of litigation, guideline repetition, and medical culture — not necessarily through irrefutable proof of life-saving benefit.</li><li>PSA testing became routine before its long-term harms were fully understood, before overdiagnosis was widely appreciated, and before patients were honestly informed about the uncertainty.</li><li>Once PSA screening entered guidelines and everyday practice, it became self-reinforcing: doctors ordered it because others ordered it, and patients accepted it because it sounded routine.</li><li>The tragedy is that the “standard of care” became a shield for a flawed screening system, allowing a weak test to masquerade as responsible prevention.</li></ul><h3>THE GLEASON 6 PROBLEM: THE CANCER LABEL THAT ISN’T</h3><ul><li>The label “cancer” instantly changes everything: fear rises, judgment narrows, and men often feel pressured to act before they fully understand what has been found.</li><li>Gleason 6 prostate cancer is described as low-risk on the basis of microscopic appearances and behaves in an indolent fashion, yet the word “cancer” makes it emotionally impossible for many men to accept observation.</li><li>The Gleason 6 fails to act as cancerous as the grade 3 within the Gleason 6 lacks the biological mechanisms for cancer development, spread, and death.</li><li>Once a man is told he has “cancer,” active surveillance may sound like neglect, even when immediate treatment may expose him to incontinence, impotence, regret, and reduced quality of life.</li><li>The cancer label itself becomes a weapon — turning biological uncertainty into psychological panic and pushing men toward interventions they may never have needed.</li></ul><h3>EARLY DETECTION FAILS AT LIFE-SAVING</h3><ul><li>The public has been trained to believe that earlier detection always means better outcomes, but prostate cancer exposes the weakness of that assumption.</li><li>Detecting a slow-growing cancer earlier may only extend the time a man knows about it, without extending his life — a problem known as lead-time bias.</li><li>Finding more prostate cancers does not prove more lives are saved; it may simply mean more harmless cancers are being detected, labeled, monitored, and treated.</li><li>If treated and untreated men show similar long-term survival in many low-risk settings, then the promise of “catch it early and cure it” is a falsehood.</li><li>Early detection becomes dangerous when it detects disease that would never have mattered, then converts healthy men into patients.</li></ul><h3>THE MARKET SIZE TELLS THE REAL STORY</h3><ul><li>PSA testing is big business, with the U.S. market estimated in the billions and tens of millions of PSA tests performed annually.</li><li>But the blood test is only the beginning; the real financial engine includes repeat PSA testing, urology consultations, imaging, biopsies, pathology, surgery, radiation, hormone therapy, and complication management.</li><li>More than one million prostate biopsies may be performed annually in the United States, many triggered by PSA abnormalities that do not reflect dangerous cancer.</li><li>Every abnormal PSA can become a revenue event, and every diagnosis can become a lifetime medical pathway.</li><li>The prostate cancer business model thrives because fear is profitable, uncertainty is profitable, and the cancer label is one of the most powerful sales tools in medicine.</li></ul><h3>THE HUMAN COST: IMPOTENCE, INCONTINENCE, REGRET, RUINED TRUST AND DAMAGED RELATIONSHIPS</h3><ul><li>Prostate cancer treatment can produce some of the most life-altering complications in medicine, including erectile dysfunction, urinary incontinence, bowel injury, hormonal collapse, depression, and relationship strain.</li><li>These harms do not fall only on the patient; they often affect wives, partners, intimacy, family stability, self-image, and emotional health.</li><li>Men who undergo treatment for cancers that may never have harmed them can be left with a devastating question: Was my life saved, or was my life permanently damaged by fear?</li><li>Financial toxicity adds another layer of harm, with patients and families facing bills, lost productivity, travel costs, medications, pads, devices, and follow-up care.</li><li>A screening program that creates lifelong complications without clear proof of meaningful life extension deserves to be called what it is: a public health failure.</li></ul><h3>THE PSA ANXIETY MACHINE: PTSD-LIKE SYMPTOMS</h3><ul><li>The PSA test does not merely produce numbers — it produces fear, waiting, panic, repeat testing, and emotional instability.</li><li>Men on active surveillance may live from PSA test to PSA test, MRI to MRI, biopsy to biopsy, never fully free from the threat that “something may be changing.”</li><li>Even when surveillance is undertaken, the psychological burden can become overwhelming, pushing men into surgery or radiation simply to escape uncertainty.</li><li>The anxiety spreads beyond the patient, affecting spouses, partners, relationships, sexual confidence, family life, and day-to-day peace.</li><li>PSA screening turns many healthy men into chronic cancer worriers, trapped in a system where uncertainty itself becomes the disease.</li></ul><h3>THE REGULATORY FAILURE: IMPOSSIBLE TO IGNORE</h3><ul><li>The continued use of PSA screening despite false positives, overdiagnosis, overtreatment, and uncertain life-saving benefit represents a profound failure of healthcare regulatory oversight.</li><li>Agencies responsible for protecting the public should have demanded stronger evidence before allowing such a test to become embedded in routine men’s healthcare.</li><li>Instead, PSA screening became normalized, commercialized, guideline-supported, and legally protected while millions of men were exposed to avoidable harm.</li><li>The USPSTF was one of the few major bodies to openly warn that the harms of PSA screening could outweigh benefits, yet the broader medical system largely continued forward.</li><li>When regulators, physicians, hospitals, industry, and advocacy groups all permit a weak test to keep driving harm, accountability has collapsed.</li></ul><h3>LICENSED MEDICAL MALPRACTICE: WHEN FEAR, WEAK SCIENCE AND REGULATORY INERTIA DRIVE PSA SCREENING</h3><ul><li>Prostate cancers are commonly outlived, yet prostate cancer awareness messaging remains heavily fear-based, exaggerated, and saturated with recycled misinformation designed to stoke doubt, confusion, and anxiety in men — driving them toward testing under the often hollow promise of “life-saving” benefits.</li><li>The cornerstone of screening — the PSA blood test and DRE — are highly unreliable. The PSA is not specific for prostate cancer, its “normal” limits are arbitrary and constantly shifting, it has a massive false positive rate, and some aggressive high-grade cancers produce little or no PSA.</li><li>The downstream diagnostic process is equally uncertain. MRI scans, biopsies, and pathology are not infallible, while prostate biopsies carry risks and are plagued by major sampling limitations, often evaluating only about 0.1% of the prostate to guide life-altering decisions.</li><li>Despite decades of widespread use, PSA screening and prostate cancer treatments still lack irrefutable and reproducible evidence proving meaningful safety, clear benefit, or significant life-saving ability. Yet the business of prostate cancer continues to incessantly promote poorly designed studies — commonly mixing men with vastly different Gleason grades, scores, and tumor volumes — while selectively massaging and emphasizing findings to imply benefit, even as more aggressive and advanced-stage cancers seem to be increasing.</li><li>Prostate cancer — like many cancers — still lacks a screening strategy proven to save significant numbers of lives, yet the current medical groupthink surrounding the prostate cancer narrative continues to market uncertainty as certainty while exploiting vulnerable and unwitting men through fear-based messaging and exaggerated claims. If men were fully informed about the weak science, massive false positive rates, arbitrary PSA thresholds, invasive follow-up testing, treatment complications, and disputed benefits, many would likely refuse PSA screening altogether. Most men find it incomprehensible that physicians, medical societies, and clinical guidelines could be so intellectually dishonest — or fail to fully disclose uncertainty, limitations, and lack of reproducible life-saving benefit — raising deeply uncomfortable questions about whether the continued promotion of PSA testing increasingly resembles a form of licensed medical malpractice and a gigantic medical fraud sustained by the business of prostate cancer.</li></ul><h3>EARLY CRITICS WHO EXPOSED THE CRACKS IN THE PROSTATE CANCER STORY</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and the treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the Gleason 6 cancer label — he dismantled it: showing that the grade 3 within the Gleason 6 lacks the biological hallmarks of cancer, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3>THE BOTTOM LINE — A NARRATIVE BUILT ON FEAR, PROFIT AND EVASION</h3><ul><li>Prostate cancer is very common and some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60%</a> of men over 65 harbor areas of prostate cancer. Most prostate cancers have very sluggish growth rates so that from mutation to about 1 cm in size takes about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">40 years</a>. Most cancers are <a href="https://www.sciencedirect.com/science/article/pii/S2468294220300605">outlived</a> and without need for detection and treatment. And, despite minor microscopic appearances of low-risk cancer the Gleason 6 lacks the ability to behave as cancerous because it <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lacks the biological</a> mechanisms to be cancerous. Physicians have been aware of this knowledge since the material was published in 2015.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://www.cochrane.org/evidence/CD004720_screening-prostate-cancer">Cochrane</a> study, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment (any treatment) — meaning they are not cured.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current culture surrounding prostate cancer awareness, screening, active surveillance, and treatment is marketed as compassion and life-saving prevention, yet too often operates as a medical lie — weaponizing fear to drive diagnosis and funneling vulnerable men into repeated testing, surveillance, and treatments whose benefits remain disputed while harms are undeniable. Saturated with exaggerations, recycled misinformation to exploit doubt, uncertainty presented as certainty, and unreliable tests unable to consistently distinguish harmless disease from the minority of biologically aggressive cancers, the prostate cancer arena has exposed countless men to unnecessary anxiety, financial toxicity, and potentially life-altering complications. If most prostate cancers are commonly outlived while some dangerous cancers still evade detection despite surveillance, then difficult questions must be asked about a system that often overdetects the harmless while missing some of the truly dangerous. The disconnect between medicine’s obligation to “first do no harm” and the inadequate regulatory scrutiny of weak evidence underscores a profound failure of physicians and the American healthcare regulatory apparatus to fully protect gullible and uninformed healthcare consumers. What men urgently need are better tests capable of reliably identifying high-grade disease and treatments for aggressive prostate cancer that actually work — alongside a complete re-examination of prostate cancer medicine grounded in scientific rigor, reproducible evidence, transparency, and truth rather than fear, financial incentives, habit, or tradition.</li></ul><h3>Required Reading</h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/">https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D">https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p><a href="https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D">https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D">https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/">https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/</a></p><p><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/">https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/</a></p><p><a href="https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D">https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/?trackingId=72w2uaCNQaCjmnF0TeOnjA%3D%3D">https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/?trackingId=72w2uaCNQaCjmnF0TeOnjA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/active-surveillance-prostate-cancer-benefit-hoax-bert-vorstman-md-rbxee/">ACTIVE SURVEILLANCE FOR PROSTATE CANCER: BENEFIT OR HOAX?</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/psa-screening-prostate-cancer-massive-public-health-bert-vorstman-md-1nide/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=11bbf6306228" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[ACTIVE SURVEILLANCE FOR PROSTATE CANCER: BENEFIT OR HOAX?]]></title>
            <link>https://bvorstman.medium.com/active-surveillance-for-prostate-cancer-benefit-or-hoax-9116dc98a356?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/9116dc98a356</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Fri, 10 Jul 2026 08:56:32 GMT</pubDate>
            <atom:updated>2026-07-10T08:56:32.989Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*-B1ICNm9hQRwNa1v" /></figure><h3>Bert Vorstman MD, Ron PIana</h3><h4>You’ve been told you have “low-risk” prostate cancer — your head explodes, fear takes over, and suddenly the medical conveyor belt of active surveillance begins: prostate exams, PSA tests, MRIs, and repeated needle biopsies, often stretching on for years. Yet the uncomfortable reality is that the Gleason 6 lacks the biological mechanisms to behave as cancerous and most low-grade prostate cancers grow extremely slowly and are commonly outlived. Despite this, millions of men are drawn into cycles of anxiety, repeated testing, financial toxicity, and — when so-called “progression” or “upgrading” is suspected — treatments associated with some of the most life-altering complications in medicine. But where is the irrefutable and reproducible evidence that active surveillance meaningfully saves significant numbers of lives? This article asks the uncomfortable question medicine rarely confronts: is active surveillance truly a patient safety strategy — or has it become a way to sustain a deeply flawed prostate cancer narrative?</h4><h3>ACTIVE SURVEILLANCE WAS CREATED BECAUSE PROSTATE CANCER TREATMENT WAS OFTEN WORSE THAN THE DISEASE</h3><ul><li>Active surveillance emerged in the 1990s after physicians recognized a troubling reality: many prostate cancers were being outlived while treatments such as surgery and radiation often left men with devastating complications including erectile dysfunction, urinary incontinence, bowel dysfunction, depression, and relationship strain.</li><li>Widespread PSA testing created an explosion in prostate cancer diagnoses, uncovering countless slow-growing tumors that appeared unlikely to threaten life, exposing a major problem of overdiagnosis and overtreatment.</li><li>The premise of active surveillance sounded logical: instead of immediately exposing men to potentially life-altering treatment complications, doctors would monitor low-risk disease and intervene only if signs of worsening appeared.</li><li>Surveillance protocols were designed around periodic PSA blood tests, prostate exams, MRIs, and prostate needle biopsies to supposedly identify dangerous changes before the disease became threatening.</li><li>Yet the uncomfortable contradiction remains glaring: if most prostate cancers are commonly outlived and treatment harms are frequently worse than the disease itself, what are the benefits of subjecting men to years of fear, testing, uncertainty and dangers?</li></ul><h3>ACTIVE SURVEILLANCE EXISTS BECAUSE THE PROSTATE CANCER INDUSTRY CREATED AN OVERDIAGNOSIS EPIDEMIC</h3><ul><li>PSA screening in the 1980s and 1990s led to a dramatic rise in prostate cancer diagnoses, exposing large numbers of slow-growing, indolent tumors that were unlikely to ever cause symptoms or death.</li><li>Autopsy studies revealed a startling truth: many men die with prostate cancer rather than from it, with silent low-grade prostate tumors found in a substantial percentage of men who died from unrelated causes.</li><li>Medicine was forced to acknowledge an uncomfortable fact — aggressive treatment of many prostate cancers was medically irrational because the complications frequently outweighed any measurable benefit.</li><li>Active surveillance evolved from “watchful waiting” into a structured monitoring program, marketed as a safer middle ground between doing nothing and aggressive treatment.</li><li>But active surveillance did not solve the deeper problem — it merely created a new management pathway for cancers that may never have needed detection in the first place.</li></ul><h3>THE WORD “CANCER” CREATES FEAR — AND FEAR DRIVES COMPLIANCE</h3><ul><li>The word “cancer” triggers immediate fear, panic, urgency, and emotional decision-making, often shutting down careful analysis and informed skepticism.</li><li>Most prostate cancers are slow-growing and commonly outlived, yet awareness campaigns frame all prostate cancers as urgent threats demanding immediate concern.</li><li>Fear-based messaging surrounding prostate cancer awareness can pressure men into screening, biopsies, monitoring, and treatments despite the uncertainty surrounding actual life-saving benefit.</li><li>Men on active surveillance frequently endure repeated cycles of anxiety before PSA tests, MRIs, and biopsies, creating psychological stress that can resemble chronic health-related trauma or PTSD-like symptoms.</li><li>The emotional burden often extends far beyond the patient, disrupting spouses, partners, intimacy, family stability, and overall quality of life.</li></ul><h3>THE GLEASON 6 PROBLEM: NOT EVEN CANCER</h3><ul><li>Gleason 3+3=6 disease is commonly labeled “low-risk prostate cancer,” yet the scientific data confirms that it lacks the biological hallmarks required to behave as cancer.</li><li>Cancer biology depends not simply on microscopic appearance but on molecular mechanisms such as tissue invasion, angiogenesis, metastasis, immune evasion, and uncontrolled growth.</li><li>The Gleason grade 3 growth pattern lacks many of these aggressive biological behaviors, raising questions about whether it should continue carrying the psychologically loaded “cancer” label.</li><li>Minor microscopic irregularities used to classify Gleason 6 disease have also been observed in benign tissue, raising concerns that this diagnosis overstates its biological danger — and no verifiable deaths have been recorded.</li><li>Since Gleason 6 lacks malignant behavior, then active surveillance represents a monitoring strategy for a condition that should never have been labeled cancer in the first place.</li></ul><h3>THE ACTIVE SURVEILLANCE PROTOCOL: A LIFETIME OF TESTING, ANXIETY AND UNCERTAINTY</h3><ul><li>Active surveillance for prostate cancer involves a structured schedule of repeated monitoring intended to detect signs of “progression” or “upgrading” while postponing or avoiding immediate whole gland or focal treatment.</li><li>Men are typically required to undergo PSA blood testing every 3–6 months, with changing PSA levels used to help guide concern about possible cancer activity.</li><li>The protocol commonly includes an annual digital rectal exam (DRE), where a physician physically examines the prostate for abnormalities or changes in texture and size.</li><li>Prostate MRI scans are often repeated every 1–2 years to evaluate for changes in tumor appearance, location, or suspected aggressiveness, although timing varies between physicians and institutions.</li><li>Periodic needle biopsies — often beginning within 6–24 months after diagnosis and then repeated every 1–5 years depending on findings — are used to reassess tissue grade and determine whether treatment is later recommended.</li></ul><h3>ACTIVE SURVEILLANCE DEPENDS ON TESTS THAT HAVE IMPORTANT LIMITATIONS</h3><ul><li>Active surveillance relies heavily on PSA testing, digital rectal examination (DRE), MRI imaging, and prostate needle biopsies — yet each of these tests has significant weaknesses and interpretive limitations.</li><li>A useful medical screening system should ideally be sensitive, specific, safe, cost-effective, reproducible, and linked to complication-free treatment that meaningfully extends life.</li><li>Prostate cancer surveillance testing falls short because false positives, false negatives, subjective interpretation, and inconsistent reliability complicate decision-making.</li><li>Despite prostate cancer tests being labeled “standard of care,” standard medical practice does not automatically mean a test or treatment has irrefutable and reproducible proof of safety, benefit, or life-saving value.</li><li>“Standard of care” is fundamentally a legal concept describing common professional behavior — not necessarily proof of scientific superiority or patient benefit.</li></ul><h3>THE DIGITAL RECTAL EXAM: A CRUDE TEST PRESENTED AS PRECISION</h3><ul><li>The digital rectal exam (DRE) depends entirely on what a physician believes they are feeling through a gloved finger, making the test inherently subjective.</li><li>Many nodules detected during prostate exams are benign, while smaller aggressive cancers may remain undetectable due to their size or location.</li><li>Nodules often need to reach roughly 1 cm or larger before becoming consistently detectable, meaning dangerous lesions may remain hidden for years.</li><li>Major differences exist between physicians in what they feel and how they interpret findings, creating substantial inter-observer variability.</li><li>Despite these limitations, the DRE continues to be portrayed as an important surveillance tool despite its crude and inconsistent nature.</li></ul><h3>THE PSA TEST: POWERFUL MARKETING, HIGHLY UNRELIABLE</h3><ul><li>PSA (Prostate Specific Antigen) is widely promoted as an essential prostate cancer marker even though it’s not specific for cancer and elevated levels may result from benign enlargement, inflammation, infection, ejaculation, or entirely non-cancerous conditions — some drugs can lower the PSA level.</li><li>False positives (about 78%) and false negatives complicate interpretation, undermining confidence in PSA as a precise cancer-detection tool.</li><li>Arbitrary “normal” PSA thresholds have shifted over time, exposing how uncertain the science surrounding cutoffs can be.</li><li>Some aggressive cancers produce little or no PSA, potentially escaping detection while biologically dangerous disease advances unnoticed.</li><li>PSA testing achieved enormous influence not because it proved highly reliable, but because healthcare systems, financial incentives, and entrenched medical habits reinforced its continued use.</li></ul><h3>PROSTATE MRI: NOT THE CRYSTAL BALL IT’S MARKETED TO BE</h3><ul><li>Prostate MRI is often portrayed as a revolutionary precision technology, yet meaningful observer variability still affects interpretation.</li><li>Smaller or biologically aggressive tumors may remain MRI-invisible, meaning clinically significant cancers can still be missed.</li><li>MRI classifications such as PI-RADS rely heavily on physician interpretation and judgment, leaving room for disagreement and error.</li><li>Imaging quality differs widely between centers, radiologists, and equipment, affecting reliability and reproducibility.</li><li>Sophisticated imaging does not eliminate uncertainty — it simply adds another imperfect layer to an already uncertain and imperfect process.</li></ul><h3>THE BIOPSY PROBLEM: TINY SAMPLES, MASSIVE ASSUMPTIONS</h3><ul><li>The standard prostate needle biopsy samples only a minuscule fraction of the gland, with 12 cores approximating 0.1% of total prostate, creating a massive sampling problem because the overwhelming majority of prostate tissue is never actually evaluated.</li><li>Prostate cancer is commonly multifocal, meaning 2 or more tumors of different sizes and grades may exist within the gland and still escape detection.</li><li>Beyond diagnostic limitations, prostate biopsies commonly provoke anxiety and emotional distress, particularly because men often undergo repeated biopsies over many years while on active surveillance.</li><li>The procedure — particularly the traditional transrectal ultrasound (TRUS) biopsy itself carries risks including pain, bleeding, infection, sepsis, urinary retention, urinary urgency, weakened urinary stream and erectile dysfunction, underscoring that surveillance is far from a harmless “do nothing” approach.</li><li>Despite these enormous sampling limitations and risks, biopsy findings are often treated as if they represent the biological truth of the entire organ creating a false sense of security.</li></ul><h3>THE PATHOLOGY REPORT: PRESENTED AS TRUTH — BUT FAR FROM INFALLIBLE</h3><ul><li>After a prostate needle biopsy, men are often told that the pathology report reveals the definitive truth about their disease, yet prostate pathology is complex, interpretive, and vulnerable to subjectivity, rather than being a perfectly objective science.</li><li>Different pathologists may examine the same biopsy tissue and assign different Gleason grades or interpretations, creating meaningful inter-observer variability that can substantially alter how a patient is classified and managed.</li><li>Even the same pathologist reviewing identical slides weeks or months later may not always reach the exact same conclusion, underscoring the inherent interpretive uncertainty involved in grading prostate tissue.</li><li>Over-calling, under-calling, or misclassification of disease can profoundly influence recommendations for active surveillance, surgery, radiation, or other interventions — decisions that may carry life-altering consequences.</li><li>Because of the uncertainty of pathology interpretation, obtaining a second pathology opinion becomes an important safeguard against error in a highly imperfect interpretive system.</li></ul><h3>THE CRUEL IRONY: THE SYSTEM OFTEN OVERDETECTS THE HARMLESS AND MISSES THE DANGEROUS CANCERS</h3><ul><li>Low-risk, slow-growing prostate cancers are commonly found and monitored, while some small aggressive cancers remain difficult to detect early.</li><li>Certain high-grade cancers may already be biologically advanced or metastatic while barely visible within the prostate gland itself.</li><li>Disseminated cancer cells may enter bone marrow and remain dormant for years or decades before some cells activate and spread further — before imaging detects convincing disease in the prostate.</li><li>Some high-grade prostate cancers produce little or no PSA, bypassing one of the central surveillance tools altogether.</li><li>The system risks overdetecting harmless abnormalities while still failing to consistently identify some of the cancers most worth finding early.</li></ul><h3>FOLLOW THE MONEY: FINANCIAL CONFLICTS OF INTEREST DISTORT PROSTATE CANCER DECISION-MAKING</h3><ul><li>Active surveillance exists inside a fee-for-service healthcare system where procedures such as surgery and radiation commonly generate substantially higher reimbursement than counseling, monitoring, or restraint.</li><li>Urologists and treatment centers may face competing financial incentives when deciding between long-term monitoring and immediate intervention, particularly when procedural revenue is involved.</li><li>Ownership interests in radiation facilities, imaging centers, or specialty practices can create concerns about “self-referral,” where expensive interventions may be financially attractive.</li><li>While active surveillance generates recurring income through PSA testing, MRIs, office visits, and biopsies, definitive treatments often provide faster and larger financial returns.</li><li>This creates a troubling question: how objective can medical recommendations remain when billions of dollars flow through the prostate cancer industry?</li></ul><h3>ACTIVE SURVEILLANCE MAY REDUCE OVERTREATMENT — BUT OFTEN REPLACES IT WITH ANXIETY</h3><ul><li>Many men on active surveillance live under the psychological weight of being told they have “cancer,” even while reassured that immediate treatment is unnecessary.</li><li>Repeated DREs, PSA tests, biopsies, MRIs, and clinic visits can create cycles of fear, dread, uncertainty, and emotional exhaustion.</li><li>Surveillance biopsies are uncomfortable and aside from massive sampling errors carry real risks including pain, bleeding, urinary complications, and infection.</li><li>Financial burdens, insurance gaps, travel demands, and lost work time add practical stress to an already emotionally difficult process.</li><li>Instead of freeing patients from unnecessary treatment, surveillance can leave many psychologically trapped in years of uncertainty.</li></ul><h3>MANY MEN EVENTUALLY LEAVE SURVEILLANCE — NOT ALWAYS BECAUSE OF DISEASE</h3><ul><li>Approximately half of men on active surveillance transition to surgery or radiation within 5–10 years.</li><li>While some of these decisions follow concerning findings, a substantial number are influenced by fear, uncertainty, and the emotional burden of ongoing monitoring.</li><li>For many men, repeated testing creates an urge to “do something” rather than continue tolerating uncertainty.</li><li>The psychological burden of surveillance may itself become a driver of intervention, even when disease remains biologically quiet.</li><li>In this way, active surveillance often delays overtreatment rather than preventing it.</li></ul><h3>ACTIVE SURVEILLANCE EXPOSES A DEEP CONTRADICTION IN THE PROSTATE CANCER STORY</h3><ul><li>Active surveillance openly acknowledges that many detected prostate cancers do not require immediate treatment because they are slow growing and unlikely to cause harm.</li><li>Yet the same system continues labeling these abnormalities as dangerous cancers requiring years of surveillance and vigilance.</li><li>If low-risk disease is commonly indolent, why frame it as dangerous enough to monitor like a ticking biological time bomb?</li><li>If treatments fail to meaningfully alter outcomes for many men, why is treatment commonly recommended once “progression” appears?</li><li>Surveillance reduces overtreatment on one hand while reinforcing fear of cancer on the other — exposing an unresolved contradiction.</li></ul><h3>“UPGRADING” COMMONLY REFLECTS MISSED DISEASE — NOT TRANSFORMATION</h3><ul><li>Later biopsies showing “worse” disease are often interpreted as proof that cancer “upgraded” or biologically transformed over time.</li><li>Yet prostate cancer is commonly multifocal, meaning 2 or more tumors of different grades and sizes may coexist within the gland.</li><li>Because the needle biopsy samples only a tiny fraction of tissue, higher-grade disease may have existed from the beginning but simply escaped earlier detection, helping explain why some men on active surveillance later develop metastatic disease.</li><li>Some aggressive cancers produce little PSA, evade blood testing, and remain difficult to visualize on MRI or even target with the needle biopsy.</li><li>The narrative of “upgrading” or “progression” often reflects delayed detection of missed high-grade disease rather than biological acceleration since many low-risk prostate cancers grow extremely sluggishly — often taking years to reach meaningful size.</li></ul><h3>FIELD EFFECTS COMPLICATE THE STORY EVEN FURTHER</h3><ul><li>Prostate tissue is also impacted by “field effects,” meaning a predisposition to future cancer development of unpredictable grade.</li><li>This raises the possibility that entirely new cancers of different grade or behavior may emerge in the prostate years later during surveillance.</li><li>A later aggressive cancer doesn’t appear to arise from the original low-grade lesion being monitored and may have already metastasized to the bone marrow before being detectable on MRI, helping explain why some men on active surveillance develop metastatic disease years later.</li><li>Since only 10–15% of prostate cancers appear biologically aggressive, many newly developing lesions detected on surveillance will be slow growing.</li><li>Surveillance therefore becomes a moving target — monitoring not only known disease but the uncertainty of future biological behavior.</li></ul><h3>THE PROSTATE CANCER INDUSTRY HAS HELPED SHAPE A POWERFUL NARRATIVE</h3><ul><li>Companies producing PSA tests, imaging technologies, pharmaceuticals, and robotic surgery platforms benefit from widespread belief in screening and intervention.</li><li>Marketing propaganda often emphasizes innovation, precision, and hope while minimizing uncertainty, limitations, and complications.</li><li>Hospitals and device manufacturers frequently promote advanced technology as if technological sophistication automatically equals better outcomes.</li><li>Small improvements in surgical process or imaging quality are often highlighted even when long-term outcome advantages remain unclear.</li><li>Commercial storytelling (often through prostate cancer awareness programs) can overpower scientific humility, replacing uncertainty with confidence and complexity with marketing slogans.</li></ul><h3>BIG MARKETING CLAIMS REQUIRE BIG EVIDENCE — YET FEAR OFTEN FILLS THE GAP</h3><ul><li>Physicians and institutions commonly promote phrases such as “catch it early before it spreads” and “early detection saves lives.”</li><li>Yet bold medical claims should always be supported by irrefutable and reproducible evidence demonstrating safety, benefit, and life-saving benefit. Yet commonly they are not.</li><li>Prostate cancer awareness messaging frequently emphasizes urgency and prevention while paying less attention to uncertainty, overdiagnosis, and treatment harms.</li><li>Fear, doubt, and false hope can become powerful tools influencing decision-making among vulnerable patients.</li><li>Healthcare messaging should empower informed skepticism — not rely primarily on emotional persuasion.</li></ul><h3>THE PROSTATE CANCER NARRATIVE: SCIENCE OR STORYTELLING?</h3><ul><li>Prostate cancer awareness campaigns often present simplified messages about risk, cure, and prevention despite data refuting the messaging.</li><li>Claims about early detection, risk factors, and aggressive intervention commonly overstate certainty while understating limitations and tradeoffs.</li><li>The ballooning obesity rate deserves more attention as it appears to be an important factor behind the apparent increase in aggressive and advanced prostate cancers.</li><li>Financial sponsorship of awareness campaigns by corporations connected to prostate cancer care raises concerns about messaging bias and conflicts of interest.</li><li>A prostate cancer narrative built on exaggerations and fear risks invalidating prostate cancer guidelines, prostate cancer awareness, active surveillance, shared decision-making, informed consent, trust and patient autonomy.</li></ul><h3>THE “STANDARD OF CARE” LABEL DOES NOT AUTOMATICALLY MEAN SCIENTIFIC TRUTH</h3><ul><li>Physicians often defend testing and treatment decisions by referencing “standard of care,” yet this phrase primarily reflects accepted professional behavior.</li><li>Standard practice does not automatically prove that an intervention is safe, beneficial, or life-saving.</li><li>Medicine has repeatedly embraced common practices later shown to be ineffective or harmful when better evidence emerged.</li><li>Guidelines may reflect consensus, habit, institutional momentum, or expert opinion rather than definitive proof.</li><li>Patients deserve to know that standard of care and scientific proof are not always the same thing.</li></ul><h3>DOGMA, HABIT, AND GROUPTHINK CAN KEEP MEDICAL PRACTICES ALIVE</h3><ul><li>Medicine sometimes continues practices long after evidence becomes weak, conflicting, or uncertain.</li><li>Training, hierarchy, anecdote, professional identity, and institutional habit can become stronger than uncomfortable scientific questions.</li><li>Physicians may rely heavily on experience and consensus even when data raise difficult challenges to conventional thinking.</li><li>Repetition of guidelines and accepted teaching can gradually transform assumptions into unquestioned dogma.</li><li>Once medicine convinces itself it is helping, acknowledging unintended harm becomes profoundly difficult.</li></ul><h3>THE REGULATORY SYSTEM: GATEKEEPER OR BYSTANDER?</h3><ul><li>Agencies such as the FDA, CMS, and CDC exist to protect public health through oversight of healthcare products, services, and medical safety.</li><li>Yet major gaps remain when tests and treatments lacking clear benefit continue receiving institutional support.</li><li>Prostate cancer screening and treatment controversies raise difficult questions about how regulatory bodies define evidence and acceptable risk.</li><li>Large amounts of healthcare spending continue flowing toward interventions later questioned as low value, unnecessary, or ineffective.</li><li>Regulatory weakness erodes public trust when patients feel exposed to risks without meaningful benefit.</li></ul><h3>FINAL TAKEAWAY: WHY DO SOME MEN STILL DEVELOP METASTATIC PROSTATE CANCER DESPITE SCREENING AND SURVEILLANCE?</h3><ul><li>Most prostate cancers are slow growing and commonly outlived without testing or treatment, while only an estimated 10–15% appear biologically aggressive and potentially lethal — raising a difficult question: if screening and surveillance are intended to identify dangerous cancers early, why do some men still later develop metastatic cancer?</li><li>The tests used for prostate cancer screening and active surveillance — PSA blood testing, MRI imaging, prostate examination, and needle biopsy — each have severe limitations, particularly for detecting some smaller high-grade cancers; some of these aggressive cancers may produce little or no PSA, some may be difficult to visualize on MRI, the prostate exam is undependable and standard biopsies sample only a tiny fraction of the prostate, leaving much room for small high-grade cancers to be missed.</li><li>Most prostate cancers are multifocal, meaning two or more lesions commonly coexist and are often of different size and grade — and because surveillance testing is inherently unreliable, so-called “progression” or “upgrading” is far more likely to reflect failure to detect pre-existing higher-grade disease rather than true biological transformation. There also remains a small but important possibility that a missed, biologically aggressive high-grade cancer may have already seeded disseminated cancer cells to the bone marrow before becoming detectable — these dormant cancer cells can remain silent for years or even decades before spreading further.</li><li>Prostate cancer is also influenced by “field effects,” meaning prostate tissue may already be biologically sensitized to develop new cancers at some future time of unpredictable grade and behavior — creating the possibility that while a known low-risk disease is being monitored, a new, small high-grade cancer may emerge elsewhere in the prostate and potentially seed cancer cells to the bone marrow before becoming detectable by PSA testing, MRI, or needle biopsy during active surveillance.</li><li>The uncomfortable takeaway is this: active surveillance represents a strategy built around a false prostate cancer narrative — because, despite years of PSA testing, MRIs, prostate exams, and repeat biopsies, some men still develop metastatic prostate cancer while under surveillance, underscoring the reality that imperfect tests, multifocal disease, field effects, biological uncertainty, and massive sampling error can miss pre-existing or newly emerging high-grade disease.</li></ul><h3>Early Critics Who Exposed the Cracks in the Prostate Cancer Story</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and the treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the Gleason 6 cancer label — he dismantled it: showing that Gleason 6 lacks the biological hallmarks of cancer, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3>The Bottom Line — A Narrative Built on Fear, Profit, and Evasion</h3><ul><li>Prostate cancer is very common and some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60%</a> of men over 65 harbor areas of prostate cancer. Most prostate cancers have very sluggish growth rates so that from mutation to about 1 cm in size takes about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">40 years</a>. Most cancers are <a href="https://www.sciencedirect.com/science/article/pii/S2468294220300605">outlived</a> and without need for detection and treatment. And, despite minor microscopic appearances of low-risk cancer the Gleason 6 lacks the ability to behave as cancerous because it <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lacks the biological</a> mechanisms to be cancerous. Physicians have been aware of this knowledge since the material was published in 2015.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://www.cochrane.org/evidence/CD004720_screening-prostate-cancer">Cochrane</a> study, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment (any treatment) — meaning they are not cured.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current culture surrounding prostate cancer awareness, screening, surveillance, and treatment is marketed as compassion and life-saving prevention, yet too often operates as a medical lie — weaponizing fear to drive diagnosis and funneling vulnerable men into repeated testing, surveillance, and treatments whose benefits remain disputed while harms are undeniable. Saturated with exaggerations, recycled misinformation to exploit doubt, uncertainty presented as certainty, and unreliable tests unable to consistently distinguish harmless disease from the minority of biologically aggressive cancers, the prostate cancer arena has exposed countless men to unnecessary anxiety, financial toxicity, and potentially life-altering complications. If most prostate cancers are commonly outlived while some dangerous cancers still evade detection despite surveillance, then difficult questions must be asked about a system that often overdetects the harmless while missing some of the truly dangerous. The disconnect between medicine’s obligation to “first do no harm” and the inadequate regulatory scrutiny of weak evidence underscores a profound failure of physicians and the American healthcare regulatory apparatus to fully protect vulnerable and unwitting healthcare consumers. What men urgently need are better tests capable of reliably identifying high-grade disease and treatments for aggressive prostate cancer that actually work — alongside a complete re-examination of prostate cancer medicine grounded in scientific rigor, reproducible evidence, transparency, and truth rather than fear, financial incentives, habit, or tradition.</li></ul><h3>Required Reading</h3><p>The Rise and Fall of the Prostate Cancer Scam by A. Horan M.D.</p><p>The Great Prostate Hoax by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/">https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D">https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p><a href="https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D">https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D">https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/">https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/</a></p><p><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/">https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/</a></p><p><a href="https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D">https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/">https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/active-surveillance-prostate-cancer-benefit-hoax-bert-vorstman-md-rbxee/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9116dc98a356" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[PROSTATE CANCER AWARENESS PROGRAMS: A PUBLIC HEALTH DANGER]]></title>
            <link>https://bvorstman.medium.com/prostate-cancer-awareness-programs-a-public-health-danger-a0fa2513e38f?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/a0fa2513e38f</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Mon, 22 Jun 2026 12:00:58 GMT</pubDate>
            <atom:updated>2026-06-22T12:00:58.070Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*EIOwGwBScMf-k5Cq" /></figure><h3>Bert Vorstman MD, Ron Piana</h3><p>Prostate cancer awareness isn’t the public health triumph it claims to be — it’s a polished campaign built on fear, not proof. Men are pushed into testing and treatment by slogans that promise life-saving benefits that remain unproven. The result isn’t better health — it’s overdiagnosis, overtreatment, and life-altering harm. Strip away the branding, and what remains looks less like awareness and more like a system that profits from panic.</p><h3>When Public Health Goes Rogue: Prostate Cancer Awareness Campaigns</h3><ul><li>Prostate cancer awareness is marketed as public health education — but operates as a persuasive campaign built on selective messaging, where awareness is mistaken for benefit.</li><li>Patients trust these programs to be grounded in science and in their best interest — but that trust is misplaced when claims lack irrefutable, reproducible evidence of safety, benefit, and life-saving impact.</li><li>Screening and treatment are aggressively promoted as life-saving, yet the central question is consistently avoided: where is the hard, reproducible proof that these interventions improve survival?</li><li>Junk science, medical groupthink, social media amplification, and unchallenged “standard of care” narratives allow misinformation to spread, often drowning out evidence-based alarms.</li><li>Corporate funding, financial conflicts, and regulatory failure turn public health into a megaphone for profit-driven messaging, exposing patients to harm while eroding trust in medicine itself.</li></ul><h3>Fear-Based Messaging: The Engine Driving The Narrative</h3><ul><li>The prostate cancer narrative is built less on evidence and more on belief, assumption, and repetition.</li><li>The shock of the cancer label and fear-based slogans (“catch it early,” “save your life”) are used to override rational decision-making.</li><li>Risk factors are amplified and repackaged as inevitabilities to create urgency.</li><li>Emotional messaging replaces scientific rigor, pushing men toward testing and treatment.</li><li>Financial incentives quietly shape the narrative, turning concern into compliance.</li></ul><h3>The Propaganda Playbook: How Awareness Becomes Marketing</h3><ul><li>Sporting events, charity runs, and social campaigns are used to normalize fear-driven messaging.</li><li>“Free screenings” act as funnels into a cascade of testing, diagnosis, and treatment.</li><li>Men’s health and Awareness months (June and September) recycle the same unproven claims under the guise of public service.</li><li>Hospital seminars and community events double as promotional platforms.</li><li>The result: a marketing ecosystem disguised as healthcare advocacy.</li></ul><h3>The “Cancer” Label: The Most Powerful Weapon</h3><ul><li>The word “cancer” triggers immediate fear, panic, and urgency — often bypassing critical thinking.</li><li>Most prostate cancers are slow-growing and commonly outlived, yet all are framed as imminent threats.</li><li>The label itself creates the crisis that the system then profits from managing.</li><li>Once labeled, men are funneled into lifelong monitoring, biopsies, and treatment decisions.</li><li>The diagnosis becomes psychological leverage — not just a medical finding.</li></ul><h3>Not All Prostate “Cancers” Are Created Equal: The Great Mislabeling</h3><ul><li>Prostate cancer is treated as a single deadly entity — but in reality, it is a spectrum of very different biological behaviors.</li><li>The so-called Gleason 6 prostate cancer lacks the defining characteristics of true cancer yet is labeled as such, triggering fear and aggressive intervention.</li><li>Most prostate cancers grow so slowly that they are commonly outlived — taking decades (often 40+ years) to reach one cm in size.</li><li>Only a small fraction — roughly 10–15% — represent high-grade, potentially lethal disease.</li><li>Lumping all prostate cancers under one alarming label fuels overdiagnosis, overtreatment, and unnecessary harm.</li></ul><h3>Anxiety As a Business Model</h3><ul><li>Screening and monitoring create cycles of fear, uncertainty, and hypervigilance.</li><li>Rising PSA levels can feel like a death sentence — regardless of clinical significance.</li><li>Patients often experience chronic anxiety similar to post-traumatic stress disorders.</li><li>Emotional distress extends beyond patients to partners, families, and relationships.</li><li>Anxiety is not accidental — it sustains the entire system of testing and intervention.</li></ul><h3>Targeting “Risk” Groups: Science Or Strategy?</h3><ul><li>Campaigns aggressively target older men, Black men, and those with family history.</li><li>These groups are told screening is essential — without definitive proof of life-saving benefit.</li><li>Occupational and genetic risks are emphasized to expand the pool of concerned individuals.</li><li>The messaging implies certainty where only statistical associations exist.</li><li>The key question remains unanswered: Does screening these groups actually save lives?</li></ul><h3>Symptom Misinformation: Manufacturing Fear From Normal Aging</h3><ul><li>Urinary and sexual symptoms are falsely promoted as early warning signs of prostate cancer.</li><li>In reality, early prostate cancer rarely affects urinary function due to its anatomical location in the outer part of the prostate away from the urinary channel.</li><li>Most symptoms are related to aging or benign prostate enlargement — not cancer.</li><li>This misrepresentation drives unnecessary testing and panic.</li><li>Normal physiology is reframed as disease risk to sustain engagement.</li></ul><h3>How The Awareness Industry Was Built — Without Proof</h3><ul><li>The movement grew from advocacy, lobbying, and messaging — not solid scientific evidence.</li><li>Governments, corporations, and institutions endorsed the cause without demanding proof.</li><li>Prostate cancer was framed as a public health emergency before evidence justified it.</li><li>Momentum replaced scrutiny — expansion occurred without accountability.</li><li>The foundation of the movement is persuasion, not proven outcomes.</li></ul><h3>Governments And Businesses: Amplifiers Of The False Narrative</h3><ul><li>Public and private institutions helped legitimize prostate cancer awareness campaigns without rigorous evaluation.</li><li>Corporate sponsorships and “health initiatives” reinforced the assumption of benefit.</li><li>Free screenings and workplace programs normalized routine testing.</li><li>Authority figures acted as if the science was settled — it wasn’t.</li><li>Public endorsement turned weak evidence into accepted truth.</li></ul><h3>Men’s Health Month: Wellness Branding With A Screening Agenda</h3><ul><li>Marketed as a broad push for prevention and wellness, but disproportionately steers men toward prostate cancer screening.</li><li>Positive messaging around fitness, mental health, and checkups masks the heavy emphasis on early prostate cancer detection narratives.</li><li>Campaigns like “Wear Blue” and community events create trust while reinforcing unproven screening benefits.</li><li>Encourages action without clearly presenting the lack of consistent, reproducible evidence for life-saving outcomes.</li><li>Beneath the surface, it operates less as balanced health advocacy — and more as an extension of the prostate cancer awareness machine.</li></ul><h3>Screening Tests: Highly Unreliable And Not Life-Saving</h3><ul><li>Digital rectal exams detect only large abnormalities and lack reliability.</li><li>PSA testing has a high false-positive rate and can miss aggressive cancers.</li><li>MRI imaging is limited by detection thresholds and observer variability.</li><li>Needle biopsies sample only ~0.1% of the prostate — leaving most tissue unexamined.</li><li>Pathology is not infallible and no screening method demonstrates reproducible life-saving benefits.</li></ul><h3>Prostate Needle Biopsy: Risky, Unreliable, And Not Benign</h3><ul><li>A positive PSA/MRI screen often leads to a prostate needle biopsy — a procedure that is inherently unreliable and exposes patients to real physical harm.</li><li>Around two-thirds of men experience complications, including bleeding (blood in semen, urine, or rectum), pain, urinary symptoms, and even temporary erectile dysfunction.</li><li>Infection is a serious risk — especially with transrectal approaches — ranging from urinary tract infections to life-threatening sepsis requiring hospitalization.</li><li>Though labeled “rare,” severe complications such as acute urinary retention, major hemorrhage, and bloodstream infections can occur — and in extreme cases, death.</li><li>The reality: a crude sampling of a tiny (about 0.1%) fraction of the prostate triggers a cascade of risks, turning a diagnostic step into a potentially dangerous medical event.</li></ul><h3>The Screening Paradox: Failing Basic Scientific Criteria</h3><ul><li>Effective screening requires accuracy, safety, and proven life extension — these criteria are not met.</li><li>False positives trigger unnecessary biopsies and treatments.</li><li>False negatives provide dangerous reassurance.</li><li>Detection does not reliably lead to better outcomes.</li><li>Screening persists despite failing the standards required of a useful medical test.</li></ul><h3>PSA Testing: A Failed Screening Tool Still Masquerading As Standard of Care</h3><ul><li>Urologists’ own studies have concluded that PSA test screening fails to save significant numbers of lives — yet the test remains widely promoted.</li><li>Despite this failure, PSA-based screening is still cleared by the U.S. Food and Drug Administration, giving it an undeserved aura of legitimacy.</li><li>The test continues to be labeled “standard of care,” not because it is proven effective — but because it is commonly practiced.</li><li>Clinical guidelines still include PSA testing, reinforcing a cycle where repetition substitutes for scientific proof.</li><li>No PSA derivatives or alternative biomarkers have demonstrated reproducible life-saving benefits — yet the system continues to ignore the risk and perpetuate the illusion.</li></ul><h3>Overtreatment: When Intervention Causes More Harm Than Disease</h3><ul><li>Many detected prostate cancers are indolent and would never cause harm.</li><li>Yet aggressive treatments are routinely applied.</li><li>Side effects include incontinence, erectile dysfunction, bowel issues, and infertility.</li><li>Complications often outweigh any potential survival benefit.</li><li>Patients — and their partners — pay the price for unnecessary intervention.</li></ul><h3>The Financial Engine: Follow The Money</h3><ul><li>The prostate cancer industry is a multi-billion-dollar market driven by detection and treatment.</li><li>Pharmaceutical and device companies fund awareness campaigns.</li><li>“Passion branding” aligns corporate profit with patient advocacy messaging.</li><li>Increased screening expands the pool of patients requiring costly interventions.</li><li>Financial incentives blur the line between education and marketing.</li></ul><h3>The “Standard Of Care” Deception</h3><ul><li>“Standard of care” reflects common practice — not proven effectiveness.</li><li>Treatments become normalized through repetition and consensus — not irrefutable and reproducible evidence.</li><li>Physicians may continue practices despite known limitations and harms.</li><li>The label shields questionable interventions from scrutiny.</li><li>Accepted practice does not equal scientific truth.</li></ul><h3>Dogma Over Data: Why The Awareness System Persists</h3><ul><li>Medical culture often prioritizes tradition, authority, and experience over evidence.</li><li>Outdated beliefs persist long after data fails to support them.</li><li>Consensus can override critical thinking and skepticism.</li><li>Systems resist change once they believe they are helping.</li><li>The result: entrenched practices that often cause more harm than benefit.</li></ul><h3>What Men Actually Need: Truth, Not Marketing</h3><ul><li>Honest, evidence-based counseling — not fear-driven persuasion.</li><li>Full disclosure of risks: overdiagnosis, overtreatment, false results, and complications.</li><li>Recognition that most prostate cancers are slow-growing and commonly outlived.</li><li>Transparency about the lack of proven life-saving benefits for many interventions.</li><li>A shift from aggressive action to informed, rational decision-making.</li></ul><h3>Governments And Businesses Must Stop Selling The Illusion</h3><ul><li>Government agencies and corporate sponsors helped turn prostate cancer awareness into an unquestioned public ritual.</li><li>They endorsed screening campaigns without demanding irrefutable proof that these programs are safe, beneficial, or life-saving.</li><li>Their sponsorship gave institutional credibility to a fear-based narrative that funnels men toward testing, biopsies, treatments, complications, and financial harm.</li><li>Public endorsement without rigorous evidence turns authority into a megaphone for medical misinformation.</li><li>Because the proof is absent, governments and businesses should stop recycling the illusion — and withdraw support from campaigns that function more like exploitation than honest public health.</li></ul><h3>Evidence Abandoned: When Prostate Cancer Claims Outrun Science</h3><ul><li>Bold medical claims about screening and treatment should stand on irrefutable, reproducible evidence proving safety, benefit, and life-saving impact — but prostate cancer messaging routinely bypasses that standard.</li><li>Widely promoted assertions like “catch it early to stop spread,” “early cancer is curable,” and “screen based on risk category” are presented as fact — despite lacking solid, reproducible proof of meaningful survival benefit.</li><li>There is no credible evidence that additional testing clarifies life-saving next steps — or that screening provides more benefit than harm.</li><li>These exaggerated claims simply misrepresent and recycle misinformation to exploit fear, doubt, and instill false hope in vulnerable and unwitting patients.</li><li>What emerges is not evidence-based care but a blueprint for medical misadventure — marked by intellectual dishonesty and a profound disconnect from the Hippocratic duty to do no harm.</li></ul><h3>When “Public Health” Becomes a Liability: Misinformation Without Accountability</h3><ul><li>Persuasive public health messaging can cross into dangerous misinformation, driving unnecessary testing and treatment that result in real harm and financial exploitation — health robbery disguised as prevention.</li><li>Patients assume protection and oversight, yet there is little accountability when harm occurs, leaving those affected with limited and uncertain paths to recourse.</li><li>Medical groupthink — built on unproven science and shielded by “standard of care” labeling — allows flawed practices to persist without meaningful challenge.</li><li>Regulatory failure enables the problem: despite initiatives from bodies like the Office of the Surgeon General (United States), enforcement is weak and misinformation continues largely unchecked.</li><li>While legal options like malpractice or personal injury claims exist, barriers such as sovereign immunity, “standard of care” and institutional protection make true accountability rare, leaving public health misinformation largely unchallenged and patients exposed.</li></ul><h3>Final Takeaway: A Program Built On Fear, Not Proof</h3><ul><li>Most prostate cancers are not life-threatening.</li><li>Fear-based messaging drives unnecessary testing and treatment.</li><li>There is no irrefutable, reproducible evidence that awareness and screening saves significant numbers of lives — the prostate cancer narrative is false.</li><li>Treatments carry substantial risks with questionable survival benefits.</li><li>Prostate cancer awareness, as currently structured, functions less as public health — and more as a global large-scale mechanism of overdiagnosis, overtreatment, and exploitation.</li></ul><h3>Early Critics Who Exposed the Cracks in the Prostate Cancer Story</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and the treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the Gleason 6 cancer label — he dismantled it: showing that Gleason 6 lacks the biological hallmarks of cancer, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3><strong>The Bottom Line — A Narrative Built on Fear, Profit, and Evasion</strong></h3><ul><li>Prostate cancer is very common and some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60%</a> of men over 65 harbor areas of prostate cancer. Most prostate cancers have very sluggish growth rates so that from mutation to about 1 cm in size takes about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">40 years</a>. Most cancers are <a href="https://www.sciencedirect.com/science/article/pii/S2468294220300605">outlived</a> and without need for detection and treatment. And, despite minor microscopic appearances of low-risk cancer the Gleason 6 lacks the ability to behave as cancerous because it <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lacks the biological</a> mechanisms to be cancerous. Physicians have been aware of this knowledge since the material was published in 2015.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://www.cochrane.org/evidence/CD004720_screening-prostate-cancer">Cochrane</a> study, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment (any treatment) — meaning they are not cured.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current prostate cancer awareness, screening and treatment culture is marketed as compassion — but in reality, it operates as a medical lie: a prescription that weaponizes fear to drive diagnosis, funnels patients into testing and treatments of unproven benefit, and converts anxiety into complications and revenue. A system of junk science, health dangers and health robbery that’s indefensible and demands a complete re-examination grounded in truth — not tradition. We need new tests and treatments for high-grade prostate cancer that actually work.</li></ul><h3><strong>Required Reading</strong></h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/">https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D">https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p><a href="https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D">https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D">https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D</a></p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/">https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/</a></p><p><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/">https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/</a></p><p><a href="https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D">https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=hoLsoALjQbuhGD%2BdPX57Cw%3D%3D</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/prostate-cancer-awareness-programs-public-health-bert-vorstman-md-dgh5e/?trackingId=nQgzODJTSbGNBKd6hjKdQg%3D%3D"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a0fa2513e38f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[ROBOTIC PROSTATE CANCER SURGERY: RISKY, INEFFECTIVE, UNPROVEN]]></title>
            <link>https://bvorstman.medium.com/robotic-prostate-cancer-surgery-risky-ineffective-unproven-f9e5c02fd835?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/f9e5c02fd835</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Sun, 14 Jun 2026 11:50:14 GMT</pubDate>
            <atom:updated>2026-06-14T11:50:14.997Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*knPyh9hTiysBygjL" /></figure><h4>Bert Vorstman MD, Ron Piana</h4><h4>You hear the words “prostate cancer” and everything detonates — fear floods in, logic shuts down, and survival mode takes control. The reflex is immediate: cut it out fast, fix it, move on. WRONG. Robotic prostate cancer surgery is one of the most complication-heavy treatments in the medical arena. And despite the marketing, there’s no irrefutable and reproducible evidence that robotic prostate cancer surgery is safe, effective or life-saving. This is not patient protection — it’s the gaming of fear for profit, especially when most prostate cancers are outlived.</h4><h3>Patients Expect Science — Not Surgical Salesmanship</h3><ul><li>Patients go to physicians expecting recommendations that are safe, beneficial, and genuinely life-saving.</li><li>They do not expect treatment advice built on tradition, dogma, financial incentives, marketing, and fear.</li><li>Robotic prostatectomy is promoted as advanced, precise, and “state of the art,” but technology does not automatically equal better medicine.</li><li>A smaller incision does not erase the serious internal damage caused by removing the prostate.</li><li>The central question is simple: Where is the irrefutable, reproducible evidence that robotic prostatectomy saves significant numbers of lives?</li></ul><h3>The “Standard of Care” Illusion</h3><ul><li>Patients hear “standard of care” and assume it means proven safe, effective, and life-saving.</li><li>In reality, standard of care often means what doctors commonly do — not what has been scientifically proven beyond doubt.</li><li>A treatment can become “standard” through repetition, institutional habit, professional consensus, and medical culture.</li><li>That does not make it scientifically sound.</li><li>It is absurd for physicians to condemn unproven alternative therapies while continuing unproven surgical treatments under the shield of “standard of care.”</li></ul><h3>Radical Prostate Surgery Began as a Belief — Not Proof</h3><ul><li>Open radical prostatectomy did not begin with irrefutable evidence of safety, effectiveness or survival benefit.</li><li>It began as a surgical idea: if cancer exists, cut it out aggressively.</li><li>That belief was shaped by the same radical thinking behind the now-discredited radical mastectomy.</li><li>Early surgeons claimed cure and effectiveness despite devastating complications and weak evidence.</li><li>Over time, belief became accepted practice, accepted practice became standard practice, and standard practice became “standard of care.”</li></ul><h3>A Century of Surgical Experimentation on Men</h3><ul><li>For decades, surgeons experimented with different ways to remove the prostate.</li><li>Perineal, suprapubic, retropubic, laparoscopic, and robotic approaches were all presented as improvements.</li><li>Yet the same core problems remained: bleeding, impotence, incontinence, scarring, recurrence, and regret.</li><li>“Nerve-sparing” surgery was promoted as progress, but it did not eliminate the limp-and-leaking consequences.</li><li>The rise of penile implants, artificial urinary sphincters, and other incontinence devices proves how much damage prostate surgery has caused.</li></ul><h3>Prostate Surgery: Grand Claims, Grim Reality</h3><ul><li>“Early diagnosis” and <a href="https://www.hopkinsmedicine.org/-/media/brady-urology-institute/documents/historical-research-papers/1905b.pdf?utm_source=chatgpt.com">“radical cure”</a> were boldly declared after experimental prostate cancer surgery — without a shred of evidence to support either claim.</li><li>Behind the claims of “simplicity” and “remarkably satisfactory results” were deaths, severe complications, and lifelong harm — not success.</li><li>Robotics was introduced off the back of a <a href="https://wayback.archive-it.org/7993/20170404123010/https:/www.fda.gov/ohrms/dockets/ac/99/transcpt/3523t1.pdf">study</a> done in Mexico City comparing laparoscopic gallbladder and Nissen fundoplication surgeries with study groups using the Intuitive instruments and robotic device.</li><li>On a majority vote, The Food and Drug Administration panel <a href="https://wayback.archive-it.org/7993/20170404123010/https:/www.fda.gov/ohrms/dockets/ac/99/transcpt/3523t1.pdf">approved</a> robotic gallbladder surgery after a single study claimed the device was “substantially equivalent” to laparoscopic instruments — deemed safe and effective not by superior outcomes, but by comparison.</li><li>When robotic gallbladder surgery failed to find a market, urologists became the new target — helping drive a flawed <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K011002">FDA 510(k)</a> clearance process for robotic prostatectomy on “substantial equivalence” to gallbladder and reflux devices — an unproven technology for prostate cancer surgery was effectively rubber-stamped and then normalized as “standard care” without irrefutable, reproducible evidence of safety, benefit, or life-saving impact.</li></ul><h3>Robotic Surgery Was Marketed Before It Was Proven</h3><ul><li>Robotic surgery entered healthcare wrapped in the language of innovation, precision, and the future.</li><li>The robot was sold as a superior tool before there was convincing proof of superior patient outcomes for gallbladder surgery.</li><li>FDA authorization did not prove that robotic prostatectomy saved lives.</li><li>“FDA approved” does not mean a procedure is proven curative, beneficial, or safer in the long term.</li><li>The robotic prostatectomy became a marketing triumph long before it became a standard of care triumph.</li></ul><h3>The Da Vinci Machine Became a Hospital Marketing Weapon</h3><ul><li>Hospitals promoted robotic prostatectomy as cutting-edge medicine to attract patients and compete with other hospitals.</li><li>The words “robotic,” “minimally invasive,” and “state of the art” were used to create trust and urgency.</li><li>Patients were led to believe the robot offered better precision, faster recovery, and fewer complications.</li><li>But the robot does not change the biological reality of prostate cancer.</li><li>Nor does it change the anatomical reality that removing the prostate can permanently damage urinary, sexual, and emotional health.</li></ul><h3>“Minimally Invasive” Is a Misleading Comfort Phrase</h3><ul><li>Robotic prostatectomy is called minimally invasive because the skin incisions are smaller.</li><li>But inside the body, the operation is still radical, destructive, and irreversible.</li><li>The prostate is still removed.</li><li>Nerves, vessels, bladder structures, urethral anatomy, and sexual function can still be damaged.</li><li>A smaller scar on the outside does not mean less devastation on the inside.</li></ul><h3>The Complication List Is Enormous</h3><ul><li>Robotic prostatectomy can cause urinary leakage, erectile dysfunction, loss of ejaculation, infertility, penile shortening, penile numbness, and orgasmic pain.</li><li>It can cause bladder neck scarring, urethral strictures, weak stream, urgency, infections, bladder stones, and chronic urinary problems.</li><li>It can cause bowel injury, vascular injury, nerve injury, hernias, infections, blood clots, pneumonia, lymphedema, depression, and even death.</li><li>Robotic positioning adds additional risks, including nerve palsies, pressure injuries, vision problems, swelling, and muscle damage.</li><li>This is not a minor procedure — it is a life-altering gamble.</li></ul><h3>The “Limp and Leaking” Reality Is Often Minimized</h3><ul><li>Men are often reluctant to admit urinary leakage or erectile dysfunction after surgery.</li><li>Shame, embarrassment, and loss of masculine identity often silence honest reporting.</li><li>A patient may minimize symptoms in front of the physician.</li><li>A wife, partner, or girlfriend may tell a very different and more honest story when asked privately.</li><li>The damage does not stop with the patient — it can injure intimacy, confidence, relationships, and marriages.</li></ul><h3>Robotic Prostatectomy Is Not Even a Reliable Cancer Operation</h3><ul><li>Positive surgical margins mean cancer is often left behind after surgery.</li><li>A rising PSA after surgery is common and means the cancer was not truly eliminated.</li><li>Many men experience biochemical recurrence years after treatment.</li><li>High-grade prostate cancer may already have spread microscopically to the bone marrow before the prostate is removed.</li><li>Cutting out the prostate does not guarantee cure — and often delivers permanent harm without clear survival gain.</li></ul><h3>Most Prostate Cancers Are Outlived</h3><ul><li>Prostate cancer is common, especially as men age.</li><li>Many prostate cancers are slow-growing and never threaten life.</li><li>Many men die with prostate cancer, not from prostate cancer.</li><li>Screening often detects low-risk disease that never needed to be found.</li><li>Once detected, the cancer label triggers fear, surveillance, biopsies, treatments, complications, and regret.</li></ul><h3>Gleason 6 Has Been Weaponized by the Cancer Label</h3><ul><li>Gleason 6 is often treated psychologically like a deadly cancer despite its lack of biological mechanisms to behave as cancerous.</li><li>The cancer label creates panic where restraint is more rational.</li><li>Men diagnosed with Gleason 6 are often pushed into a fear-driven medical conveyor belt.</li><li>Many who undergo treatment for Gleason 6 were not saved from a bogus cancer — they’re survivors of the risky unproven robotic treatment.</li><li>Calling every Gleason 6 “cancer” fuels overdiagnosis, overtreatment, and profit.</li></ul><h3>PSA Testing Feeds the Machine: It’s Not a Life Saver</h3><ul><li>PSA is not cancer-specific.</li><li>A high PSA does not automatically mean prostate cancer.</li><li>A low PSA does not guarantee absence of dangerous cancer.</li><li>PSA testing creates false alarms, anxiety, biopsies, surveillance, and treatment cascades.</li><li>If the test does not clearly lead to life-saving outcomes, then mass screening becomes a gateway to overmedicalization.</li></ul><h3>Awareness Campaigns Turn Fear Into Compliance</h3><ul><li>Prostate cancer awareness campaigns often imply that most prostate cancers are dangerous.</li><li>That message is misleading — especially in a background of financial conflicts of interest.</li><li>Celebrity diagnoses and emotional stories are used to amplify fear.</li><li>Fear-based messaging turns uncertainty into urgency.</li><li>Awareness without proven life-saving benefits becomes marketing — not public health.</li></ul><h3>Shared Decision-Making Can Become Shared Deception</h3><ul><li>Shared decision-making sounds patient-centered, but it depends on honest information.</li><li>If the evidence is weak, biased, incomplete, or exaggerated, the decision is not truly informed.</li><li>Patients may be offered options without being told that survival may be similar without aggressive treatment.</li><li>“Informed consent” becomes hollow when patients are not clearly told how uncertain the benefit really is.</li><li>Managing expectations for impotence and incontinence is not the same as proving the treatment should be done.</li></ul><h3>Rehabilitation Programs Prove the Damage Is Expected</h3><ul><li>Urologists developed preoperative counseling and postoperative rehabilitation because complications are common.</li><li>Men are prepared for urinary leakage, erectile dysfunction, and sexual loss before surgery even occurs.</li><li>After surgery, many require pads, clamps, medications, pelvic therapy, injections, devices, or implants.</li><li>Some need artificial urinary sphincters or penile prostheses.</li><li>An entire implant industry grew out of the damage caused by prostate cancer treatment.</li></ul><h3>The Prosthetic Industry Was Built on Surgical Failure</h3><ul><li>Radical prostatectomy helped create a market for incontinence and erectile dysfunction devices.</li><li>Penile implants and urinary control devices became downstream solutions for treatment-caused injuries.</li><li>These devices can fail, erode, become infected, or require revision surgery.</li><li>Some men undergo more procedures just to manage the damage from the first procedure.</li><li>That is not a triumph of cancer care — it is a cascade of medical harm.</li></ul><h3>The Survival Evidence Does Not Justify the Damage</h3><ul><li>Major long-term studies have shown low if any, prostate cancer mortality regardless of treatment choice.</li><li>Surgery, radiation, and monitoring have often produced similar survival outcomes over long follow-up.</li><li>If treated and untreated men survive at similar rates, the claimed life-saving power collapses.</li><li>The untreated man may avoid impotence, incontinence, surgical complications, and regret.</li><li>A treatment that does not save significant numbers of lives but causes major harm is medically indefensible.</li></ul><h3>Prostate Cancer Studies Are Often Deeply Flawed</h3><ul><li>Many studies mix different Gleason grades, scores, tumor volumes, and risk categories.</li><li>Low-risk and higher-risk cancers are often lumped together, muddying the results.</li><li>Follow-up periods may be too short for a slow-growing disease.</li><li>Definitions of success can be manipulated, such as calling a man “dry” while he still uses pads.</li><li>Flawed study design can make weak treatments appear beneficial.</li></ul><h3>Guidelines Can Legitimize Weak Evidence</h3><ul><li>Medical guidelines are supposed to protect patients.</li><li>But guidelines can also preserve professional dogma.</li><li>When specialty groups write or influence guidelines, conflicts of interest matter.</li><li>Recommendations can make unproven care look authoritative.</li><li>A medical guideline is not proof of cure, proof of safety, or proof of life-saving benefit.</li></ul><h3>Health Insurers Help Keep the System Alive</h3><ul><li>Insurers often cover treatments because they are labeled standard of care.</li><li>Coverage does not prove scientific validity.</li><li>Once a treatment is embedded in guidelines, billing systems, and hospital revenue models, it becomes financially protected.</li><li>The robotic prostatectomy generates enormous costs: equipment, maintenance, disposables, staffing, training, anesthesia, complications, and repeat procedures.</li><li>The healthcare system pays heavily for a treatment that still lacks irrefutable proof of meaningful life extension.</li></ul><h3>The Cost Is Financial, Physical, and Emotional</h3><ul><li>Robotic systems cost millions of dollars.</li><li>Hospitals must recover those costs by driving surgical volume.</li><li>Patients pay with premiums, deductibles, co-pays, complications, and lost quality of life.</li><li>Families pay through stress, intimacy loss, caregiver burden, and emotional strain.</li><li>Society pays by wasting healthcare dollars on treatments that may not deliver meaningful survival benefits.</li></ul><h3>Debulking and Salvage Surgery Add More Risk Without Clear Proof</h3><ul><li>Debulking surgery for advanced disease exposes men to even greater harm.</li><li>Salvage prostatectomy after radiation or other treatment is often more difficult and complication-prone.</li><li>These procedures may be justified with aggressive language but lack clear proof of significant life extension.</li><li>Combining surgery, radiation, and testosterone suppression can compound complications.</li><li>More treatment does not automatically mean better survival — it often means more damage.</li></ul><h3>The Regulatory Failure Is Enormous: Poor Accountability</h3><ul><li>The American healthcare regulatory apparatus (FDA, NIH, AHRQ and others) has failed to protect patients from weakly supported prostate cancer interventions.</li><li>FDA clearance, clinical guidelines, professional society support, and insurance coverage can create the illusion of certainty.</li><li>But none of these guarantee irrefutable and reproducible evidence of safety, benefit, or life-saving ability.</li><li>Vulnerable patients are too often pushed into irreversible treatments under the banner of medical authority.</li><li>That is not patient protection — it is institutional failure.</li></ul><h3>The Prostate Cancer Narrative Is Built on Fear</h3><ul><li>Men are told prostate cancer must be found early.</li><li>They are told rising PSA is dangerous.</li><li>They are told treatment may save their life.</li><li>They are told impotence and incontinence may be the price of survival.</li><li>But if treatment does not save significant numbers of lives, the entire fear-based narrative collapses.</li></ul><h3>What Is Wrong With Robotic Prostate Cancer Surgery? Everything.</h3><ul><li>It is built on the flawed foundation of open radical prostatectomy.</li><li>It was marketed as superior before being proven superior.</li><li>It causes life-altering complications.</li><li>It’s not even a good cancer operation.</li><li>It lacks irrefutable and reproducible evidence that it saves significant numbers of lives.</li></ul><h3>The Final Indictment: A Public Health Disaster</h3><ul><li>Robotic prostatectomy is not a miracle of modern medicine.</li><li>It is a technologically polished version of an old, radical, unproven surgical belief.</li><li>Like radical mastectomy and lobotomy, it may one day be remembered as a brutal “standard of care” that medicine defended long after the evidence failed it.</li><li>The tragedy is not only that men were harmed.</li><li>The tragedy is that the harm was predictable, profitable, and preventable.</li></ul><h3>What Men Actually Need: Intellectual Honesty</h3><ul><li>Men need honest information, not fear-based awareness campaigns.</li><li>They need reliable tests that identify truly dangerous high-grade disease.</li><li>They need treatments proven by irrefutable and reproducible evidence to save lives.</li><li>They need physicians willing to say, “We do not know,” instead of selling certainty where none exists.</li><li>Until then, robotic prostatectomy remains what it has always been: unproven, risky, ineffective, and medically indefensible.</li></ul><h3>Early Critics Who Exposed the Cracks in the Prostate Cancer Story</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and the treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the Gleason 6 label — he dismantled it: showing that Gleason 6 lacks the biological hallmarks of cancer, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3>The Bottom Line — A Narrative Built on Fear, Profit, and Evasion</h3><ul><li>Prostate cancer is very common and some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60%</a> of men over 65 harbor areas of prostate cancer. Most prostate cancers have very sluggish growth rates so that from mutation to about 1 cm in size takes about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">40 years</a>. Most cancers are <a href="https://www.sciencedirect.com/science/article/pii/S2468294220300605">outlived</a> and without need for detection and treatment. And, despite minor microscopic appearances of low-risk cancer the Gleason 6 lacks the ability to behave as cancerous because it <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lacks the biological</a> mechanisms to be cancerous. Physicians have been aware of this knowledge since the material was published in 2015.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment — meaning they are not cured.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current prostate cancer awareness, screening and treatment culture is marketed as compassion — but in reality, it operates as a medical lie: a prescription that weaponizes fear to drive diagnosis, funnels patients into testing and treatments of unproven benefit, and converts anxiety into complications and revenue. A system of junk science, health dangers and health robbery that’s indefensible and demands a complete re-examination grounded in truth — not tradition. We need new tests and treatments for high-grade prostate cancer that actually work.</li></ul><h3>Required Reading</h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p>Prostate Cancer Treatment Complications: The Hidden Harm Behind “Standard of Care”</p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/">https://www.linkedin.com/pulse/prostate-cancer-treatment-complications-hidden-harm-care-vorstman-md-1sqje/</a></p><p>The Great Prostate Cancer Active Surveillance Illusion</p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D">https://www.linkedin.com/pulse/great-prostate-cancer-active-surveillance-illusion-bert-vorstman-md-wxxie/?trackingId=ApdCGT2bRyyAVn9fd3FkWA%3D%3D</a></p><p>How Governments and Businesses Were Sold the Prostate Cancer Awareness Myth</p><p><a href="https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D">https://www.linkedin.com/pulse/how-governments-businesses-were-sold-prostate-cancer-myth-bert-beaue/?trackingId=uP%2B7lUuSQvidz7OUGaQgJw%3D%3D</a></p><p>WHAT’S NOT TRUE ABOUT PROSTATE CANCER? ALMOST EVERYTHING YOU’VE BEEN TOLD</p><p><a href="https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D">https://www.linkedin.com/pulse/whats-true-prostate-cancer-almost-everything-youve-been-vorstman-md-ouo3e/?trackingId=8GGLDO4oSM%2BH6rwuK38nfQ%3D%3D</a></p><p>THE GREAT PROSTATE CANCER AWARENESS AND SCREENING SCAM</p><p><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/">https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/</a></p><p>THE GLEASON 6 PROSTATE “CANCER” HOAX</p><p><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/">https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/robotic-prostate-cancer-surgery-risky-ineffective-bert-vorstman-md-zve2e/?trackingId=8ESmFbR%2BSheis3%2BdWblptg%3D%3D"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f9e5c02fd835" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[THE GLEASON 6 PROSTATE “CANCER” HOAX]]></title>
            <link>https://bvorstman.medium.com/the-gleason-6-prostate-cancer-hoax-6ccecb7d45d9?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/6ccecb7d45d9</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Tue, 09 Jun 2026 11:44:11 GMT</pubDate>
            <atom:updated>2026-06-09T11:44:11.287Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*hAl3NdMLGwMs44Lf" /></figure><h3>Bert Vorstman MD, Ron Piana</h3><p>Men are told they have “prostate cancer” — a diagnosis that detonates fear and drives them into a pipeline of testing and treatment — yet for many, it rests on a fundamental medical mislabeling. Gleason 6 does not behave like cancer, but it is deliberately branded as one, unleashing anxiety, unreliable evaluations, and interventions that can leave lifelong harm. This is not a nuance — it is a systemic deception that has turned an indolent condition into a multi-billion-dollar engine of unnecessary testing and treatment. The real threat isn’t the so-called Gleason 6 “cancer” — it’s the narrative built around it.</p><h3>The Foundational Deception: A “Cancer” That Behaves Like None</h3><ul><li>Prostate cancer is extremely common, especially with age, yet most cases are slow-growing and commonly outlived without detection or treatment.</li><li>Despite this, the medical system presents prostate cancer as universally dangerous, requiring vigilance, testing, and intervention.</li><li>At the center of this distortion is Gleason 3+3=6, widely labeled as “cancer” despite failing to behave like a true malignancy.</li><li>This label triggers fear, anxiety, and urgency — driving patients into unnecessary testing and treatment pathways.</li><li>The result is a manufactured crisis built on misrepresentation and not biology.</li></ul><h3>The Pseudo-Cancer Reality of Gleason 6: It’s a bogus cancer</h3><ul><li>Gleason 6 is best described as a pseudo-cancer, lacking the biological machinery required for true cancer behavior.</li><li>It does not possess the genetic pathways necessary for invasion, metastasis, or sustained malignant growth.</li><li>When <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">compared</a> to higher-grade disease (Gleason 4 and above), the biological differences are profound and undeniable.</li><li>Yet physicians knowingly retain the cancer label, despite understanding the fear it provokes.</li><li>This is not a scientific necessity — it is a strategic choice that fuels overdiagnosis and overtreatment.</li></ul><h3>How The Cancer Label Became a Weapon</h3><ul><li>The word “cancer” is one of the most powerful psychological triggers in medicine.</li><li>Applying this label to an indolent condition guarantees fear-driven decision-making.</li><li>Patients are pushed toward intervention not because of risk, but because of the emotional weight of the diagnosis.</li><li>Physicians are fully aware of this psychological impact, yet continue to use this shocking label.</li><li>The cancer designation is not just descriptive — it is a tool that drives the entire fear-based prostate cancer industry.</li></ul><h3>A Diagnosis Built on Appearance, Not Biology</h3><ul><li>Gleason 6 was originally classified as cancer based solely on low-power microscopic appearance.</li><li>Pathologists judged glandular patterns that “looked like” cancer, without evidence of malignant behavior.</li><li>These cells resemble cancer under the microscope but lack the ability to spread or threaten life.</li><li>This classification relied heavily on subjective interpretation rather than biological validation.</li><li>In essence, Gleason 6 was labeled cancer based on how it looked — not what it does.</li></ul><h3>The Gleason System: A Subjective and Misleading Framework</h3><ul><li>The Gleason grading system evaluates prostate tissue based on visual patterns under a microscope.</li><li>Pathologists assign grades (3–5) to the two most common growth patterns seen on a slide under low power microscopy and combine them into a score.</li><li>A Gleason score of 6 (3+3) is the lowest score typically assigned, yet patients perceive it as “mid-range.”</li><li>This creates confusion and unnecessary alarm, driving treatment decisions based on fear and misunderstanding.</li><li>The system is built on interpretation — not objective, reproducible biological truth.</li></ul><h3>The Critical Failures of the Gleason System</h3><ul><li>Subjectivity: Significant disagreement exists between pathologists interpreting the same tissue.</li><li>Poor reproducibility: Studies show only moderate agreement between biopsy and final surgical specimens.</li><li>Sampling error: Biopsies examine only ~0.1% of the prostate, missing most of the organ.</li><li>Overdiagnosis: Difficulty distinguishing grades leads to labeling benign or indolent tissue as aggressive.</li><li>Patient confusion: A misleading scoring scale drives anxiety and unnecessary treatment decisions.</li></ul><h3>The Biological Truth: Gleason 6 Lacks the Hallmarks of Cancer</h3><ul><li>True cancer requires specific biological capabilities — known as the hallmarks of cancer.</li><li>These include invasion, metastasis, angiogenesis, immune evasion, and uncontrolled replication.</li><li>Gleason pattern 3 (the basis of Gleason 6) lacks these mechanisms.</li><li>The molecular pathways that drive cancer are inactive in <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">the grade 3</a> within the Gleason 6 disease.</li><li>By definition, a disease without these hallmarks does not behave as cancer.</li></ul><h3>The Case Against the Cancer Label</h3><ul><li>There is no reproducible evidence that Gleason 6 alone causes death.</li><li>There is no evidence that Gleason 6 transforms into higher-grade cancer.</li><li>Features used to “justify” the cancer label — minor structural changes, basal cell layer loss, minor molecular changes and perineural invasion — also occur in benign prostate tissue.</li><li>The classification persists despite contradicting biological evidence.</li><li>The label is not maintained for scientific accuracy, but for institutional and systemic reasons.</li></ul><h3>Why the Label Persists Despite the Evidence</h3><ul><li>Physicians argue that labeling Gleason 6 as cancer prevents missed diagnoses and legal risk.</li><li>In reality, this argument collapses under scrutiny since most prostate cancers are non-lethal.</li><li>The continued use of the label drives:</li><li>The system benefits from maintaining the illusion of danger.</li><li>Truth is sacrificed to preserve the false prostate cancer narrative.</li></ul><h3>What Patients Need to Know About Prostate Cancer</h3><ul><li>Up to 60% of men over 65 harbor microscopic prostate cancer.</li><li>The vast majority of these cancers are slow-growing and harmless.</li><li>Most men die <em>with</em> prostate cancer, not <em>from</em> it.</li><li>Generally, detection does not equate to danger.</li><li>Only 10–15% are high-grade and potentially life-threatening.</li></ul><h3>The Myth of “Early Warning Signs”</h3><ul><li>Awareness campaigns claim urinary and sexual symptoms indicate prostate cancer.</li><li>This is highly misleading.</li><li>Most prostate cancers develop in areas that do not affect urinary function.</li><li>Symptoms are typically related to aging or benign prostate enlargement.</li><li>The symptom narrative is another fear-based construct, not scientific fact.</li></ul><h3>The Testing Illusion: Unreliable Tools, False Confidence</h3><h3>Digital Rectal Exam (DRE)</h3><ul><li>Highly subjective and dependent on examiner experience.</li><li>Detects only larger, superficial abnormalities.</li><li>Most detected nodules are benign.</li><li>No evidence it saves significant numbers of lives.</li></ul><h3>PSA Testing</h3><ul><li>Not prostate-specific and not cancer-specific.</li><li>False positive rate ~78%.</li><li>Fluctuates due to benign conditions like enlargement or inflammation.</li><li>Many aggressive cancers produce little or no PSA and are missed.</li><li>A “normal” PSA does not rule out cancer; an elevated PSA does not confirm it.</li></ul><h3>Imaging and Biopsy: Precision That Isn’t</h3><ul><li>MRI cannot reliably detect cancers smaller than ~5 mm.</li><li>False negatives are common; some aggressive cancers are invisible.</li><li>Most cancers are multifocal — meaning two or more areas of cancer.</li><li>Biopsies sample only ~0.1% of the prostate. A tiny sample is treated as representing the entire organ — a deeply flawed assumption.</li><li>Field effects (or field cancerization) in the prostate can result in new, independent cancers of unpredictable grade in the future.</li></ul><h3>The Illusion of Progression: Missing Disease That’s Already There</h3><ul><li>“Upgrading” of Gleason scores is often misinterpreted as disease progression.</li><li>In reality, it usually reflects:</li><li>Slow growth rates of low-grade disease make rapid progression biologically highly unlikely.</li><li>What appears to be progression is often simply better detection of what was already there.</li></ul><h3>Treatment: High Harm, Questionable Benefit</h3><ul><li>Prostate cancer treatments frequently cause:</li><li>These complications can be permanent and life-altering.</li><li>Yet many treated cancers would never have caused harm.</li><li>Patients often trade a non-lethal condition for lifelong disability.</li></ul><h3>Active Surveillance: A Quiet Admission of Failure</h3><ul><li>Active surveillance acknowledges that many prostate cancers do not require treatment.</li><li>It involves repeated testing and monitoring for “progression.”</li><li>However, it lacks irrefutable evidence of life-saving benefit.</li><li>It keeps patients trapped in anxiety while delaying inevitable intervention.</li><li>It exposes the contradiction at the heart of prostate cancer management.</li></ul><h3>“Standard of Care” — A Misleading Label</h3><ul><li>“Standard of care” is a legal concept, not proof of effectiveness.</li><li>It reflects what most doctors do — not what works.</li><li>Treatments can be standard without being safe, beneficial, or life-saving.</li><li>Prostate cancer testing and treatment fall into this category.</li><li>Consensus and dogma are not evidence.</li></ul><h3>The High-Grade Problem Remains Unsolved</h3><ul><li>Only 10–15% of prostate cancers are truly dangerous.</li><li>Yet there is no reproducible evidence that current treatments save significant numbers of lives even in this group.</li><li>Like pancreatic cancer and glioblastoma, effective solutions remain elusive.</li><li>The system compensates by over-treating low-risk disease.</li><li>It solves the wrong problem while failing to solve the real one.</li></ul><h3>The False Narrative: Fear, Profit, and Misinformation</h3><ul><li>The prostate cancer industry is a multi-billion-dollar enterprise.</li><li>It is sustained by:</li><li>Awareness campaigns amplify anxiety to drive participation.</li><li>The narrative persists because it is profitable — not because it is accurate.</li></ul><h3>Herd Mentality in Medicine</h3><ul><li>Physicians often follow established practices rather than evolving evidence.</li><li>Social pressure, habit, and cognitive bias reinforce outdated approaches.</li><li>Fear of litigation discourages deviation from accepted norms.</li><li>Information overload limits critical reassessment.</li><li>The result is a system that continues ineffective practices long after evidence undermines them.</li></ul><h3>The Hard Fact: Gleason 6 Is Not Cancer</h3><ul><li>Gleason 6 lacks the biological hallmarks of cancer.</li><li>There is no verifiable evidence of death.</li><li>It does not require detection or treatment.</li><li>It is a pseudo-cancer mislabeled to sustain a flawed system.</li><li>Patients treated for Gleason 6 are not cancer survivors — they are survivors of unnecessary, harmful treatment.</li></ul><h3>Final Reckoning: A Manufactured Disease, A Public Health Disaster</h3><ul><li>The Gleason 6 “cancer” label represents one of the most consequential misclassifications in modern medicine.</li><li>It has driven decades of unnecessary fear, testing, and treatment.</li><li>It has harmed countless men — physically, psychologically, and financially.</li><li>The Gleason 6 label persists as “cancer” despite overwhelming evidence to the contrary — a deliberate misrepresentation that betrays the Hippocratic duty to do no harm and subjects patients to unnecessary fear, intervention, and injustice.</li><li>This is not just a scientific failure — it is a systemic, ethical breakdown that demands correction.</li></ul><h3>Early Critics Who Exposed the Cracks in the Prostate Cancer Story</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz didn’t just question the label — he dismantled it: showing that Gleason 6 lacks the biological hallmarks of cancer, exposing the diagnosis as a misrepresentation that fuels unwarranted fear, a false sense of danger, and a cascade of unnecessary aggressive treatments.</li></ul><h3><strong>The Bottom Line — A Narrative Built on Fear, Profit, and Evasion</strong></h3><ul><li>Prostate cancer is very common and some <a href="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html">60%</a> of men over 65 harbor areas of prostate cancer. Most prostate cancers have very sluggish growth rates so that from mutation to about 1 cm in size takes about <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4086477/">40 years</a>. Most cancers are <a href="https://www.sciencedirect.com/science/article/pii/S2468294220300605">outlived</a> and without need for detection and treatment. And, despite minor microscopic appearances of low-risk cancer the Gleason 6 lacks the ability to behave as cancerous because it <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">lacks the biological</a> mechanisms to be cancerous. Physicians have been aware of this knowledge since the material was published in 2015.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment — meaning they are not cured.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current prostate cancer awareness and screening culture is marketed as compassion — but in reality, it operates as a medical lie: a prescription that weaponizes fear to drive diagnosis, funnels patients into testing and treatments of unproven benefit, and converts anxiety into complications and revenue. A system of junk science, health dangers and health robbery that demands a complete re-examination grounded in truth — not tradition. We need new tests and treatments for high-grade prostate cancer that actually work.</li></ul><h3><strong>Required Reading</strong></h3><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment Complications: The Hidden Harm Behind “Standard of Care”</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/gleason-6-prostate-cancer-hoax-bert-vorstman-md-qkfve/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6ccecb7d45d9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[THE GREAT PROSTATE CANCER AWARENESS AND SCREENING SCAM]]></title>
            <link>https://bvorstman.medium.com/the-great-prostate-cancer-awareness-and-screening-scam-5a1e0b91f305?source=rss-cf8cbd15bcb6------2</link>
            <guid isPermaLink="false">https://medium.com/p/5a1e0b91f305</guid>
            <dc:creator><![CDATA[bert vorstman]]></dc:creator>
            <pubDate>Mon, 01 Jun 2026 14:29:03 GMT</pubDate>
            <atom:updated>2026-06-01T14:29:03.795Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*yMFr7xE8CxBCOuDW" /></figure><h4>Bert Vorstman MD, Ron Piana</h4><h4>Men are told prostate cancer awareness and screening save lives — but the reality is a fear-driven narrative built on weak evidence, over-diagnosis, over-treatment, and life-altering harm. The true scandal isn’t just bad science — it’s the relentless promotion of a false promise of rescue that instead seeds doubt, fuels anxiety, and delivers complications, false hope, and broken promises.</h4><h3>What Men Expect — And What They Are Rarely Told</h3><ul><li>Men who see a physician with concerns about prostate cancer expect empathy, honesty, and advice grounded in hard evidence.</li><li>They expect recommendations that honor the Hippocratic Oath: first, do no harm.</li><li>They assume that screening and treatment programs are supported by reproducible science, not slogans, beliefs, or institutional momentum.</li><li>But when <a href="https://theincidentaleconomist.com/wordpress/half-of-medical-treatments-of-unknown-effectiveness/">roughly half of medical treatments</a> are of unknown benefit, a basic medical question becomes unavoidable.</li><li>Is the prostate cancer narrative truly evidence-based, or is it a well-marketed program built on fear, assumptions, and junk science?</li></ul><h3>The Seductive Power of Awareness Slogans</h3><ul><li>Prostate cancer awareness campaigns rely on simple, emotionally persuasive slogans that sound responsible and lifesaving.</li><li>Phrases like “Early detection saves lives,” “Get your prostate checked,” and “Know the score, check your score” are crafted to sound rational and urgent.</li><li>During campaigns such as Blue September and Movember, these slogans are repeated until they are accepted as truth rather than tested as claims.</li><li>The public is led to believe that screening is automatically wise, brave, and protective.</li><li>But a slogan is not evidence, and repetition is not proof.</li></ul><h3>Fear Is the Engine of the Prostate Cancer Awareness Campaign</h3><ul><li>Awareness programs do not merely inform men; they alarm them.</li><li>They amplify age, race, family history, genetics, urinary symptoms, and sexual symptoms as possible warning signs that demand testing.</li><li>Prostate cancer awareness groups exploit celebrity diagnoses to amplify fear — sensationalizing cases, exaggerating risks, and weaponizing high-profile stories to push an already distorted, fear-driven narrative even further.</li><li>Fear-based messaging transforms uncertainty into urgency and suspicion into compliance.</li><li>It sells the idea that doing something is automatically better than doing nothing, even when the benefits remain unproven. Yet the central question is ignored: where is the irrefutable and reproducible evidence that screening and treatment save lives in these groups?</li></ul><h3>Symptoms Are Used as a Scare Tactic</h3><ul><li>Men are often told that urinary or sexual symptoms may be early warning signs of prostate cancer.</li><li>But this claim is presented as settled truth when it is often used more as a fear trigger than an evidence-based explanation.</li><li>The narrative ignores the fact that prostate cancer typically arises in the outer portion of the prostate, away from the urinary channel.</li><li>Common urinary symptoms are far more often related to aging and benign prostatic enlargement than to prostate cancer.</li><li>This is not careful medical reasoning; it is anxiety marketing dressed up as prevention.</li></ul><h3>The Awareness Industry Knows Anxiety Is the Outcome</h3><ul><li>Prostate cancer campaigns create psychological distress and then act as though that distress is merely an unfortunate side effect.</li><li>Anxiety in prostate cancer patients is well recognized during diagnosis, surveillance, PSA monitoring, and treatment.</li><li>The very process of screening, retesting, waiting, and monitoring can trap men in cycles of dread and hypervigilance causing symptoms similar to post traumatic stress disorder (PTSD).</li><li>A rising PSA can become a psychological death sentence in the patient’s mind long before it means anything clinically meaningful.</li><li>The damage easily spreads beyond the patient, affecting wives, partners, families, intimacy, and relationships.</li></ul><h3>Anxiety Becomes Part of the Business Model: Exploiting Patients</h3><ul><li>Once fear is planted, every next step appears justified.</li><li>A worried man is easier to test, easier to biopsy, easier to monitor, and easier to treat.</li><li>Awareness campaigns exploit the emotional power of the cancer label to turn healthy men into frightened patients.</li><li>They manufacture a sense of imminent danger even when most prostate cancers are slow growing and commonly outlived.</li><li>Anxiety is not incidental to this system. It is one of the forces that awareness programs use to keep it moving.</li></ul><h3>Screening Is Marketed as Safe and Effective Without Proof</h3><ul><li>Awareness organizations promote the prostate exam and the PSA blood test as reliable screening tools.</li><li>They present screening as safe, responsible, and potentially lifesaving.</li><li>But these claims are often delivered with far more confidence than the evidence warrants. PSA testing <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">fails</a> to save significant numbers of lives.</li><li>The public is encouraged to believe that early detection is inherently beneficial, even when no reproducible proof of meaningful life-saving benefit is established.</li><li>This is not scientific humility. It is a marketing certainty.</li></ul><h3>Follow the Money Behind “Awareness”</h3><ul><li>Many prostate cancer awareness groups, support networks, foundations, and screening campaigns are financially connected to those who profit from prostate cancer testing and treatment.</li><li>That creates a conflict of interest at the very center of the awareness message.</li><li>The same industries that benefit from more diagnosis, more procedures, and more treatment help fund the campaigns urging men to get screened.</li><li>Fear, hope, and commercial opportunity become tightly intertwined.</li><li>A program claiming to protect men is often financially sustained by the business of prostate cancer itself.</li></ul><h3>How the Awareness Machine Was Built</h3><ul><li>Prostate cancer awareness did not emerge from rock-solid evidence proving screening and treatment saved lives.</li><li>It grew from grassroots patient groups, philanthropic foundations, political lobbying, and strategic public messaging in the late 1980s and 1990s.</li><li>It gained legitimacy by framing prostate cancer as a national public health emergency.</li><li>Governments, corporations, sports organizations, and advocacy groups joined the cause without first demanding the most basic scientific proof.</li><li>The movement expanded first, and the hard questions were never asked with equal force.</li></ul><h3>Governments and Businesses Were Swept Into the Story</h3><ul><li>Awareness campaigns secured proclamations, partnerships, sponsorships, and legislation by appealing to emotion, urgency, and masculine responsibility.</li><li>Businesses sponsored free screening events and awareness promotions as if the benefits of screening were already beyond dispute.</li><li>Pharmaceutical alliances and corporate campaigns helped normalize the idea that more testing meant better care.</li><li>Major institutions acted as though medical truth had already been settled.</li><li>But no one stopped to ask: where is the reproducible evidence that these programs are safe, beneficial, and life-saving?</li></ul><h3>Most Prostate Cancers Are Not the Monster Men Are Told to Fear</h3><ul><li>Awareness campaigns imply that prostate cancer is a lurking killer that must be hunted early and treated aggressively.</li><li>But prostate cancer is not one disease with one destiny.</li><li>It is a spectrum, and most prostate cancers are slow growing and commonly outlived without detection or treatment.</li><li>Many men die with prostate cancer, not from it.</li><li>The fear campaign depends on flattening this distinction and treating all prostate cancer as though it carries the same threat.</li></ul><h3>The Cancer Label Itself Is Doing Heavy Lifting</h3><ul><li>The word “cancer” carries enormous emotional force, and awareness programs exploit that force relentlessly.</li><li>Once a man hears the cancer word, calm judgment often gives way to panic and urgency.</li><li>That panic then fuels testing, biopsies, treatment, and lifelong surveillance.</li><li>Yet much of what is labeled prostate cancer does not behave like a lethal disease.</li><li>The label creates the crisis that the industry then claims to manage.</li></ul><h3>The Gleason 6 Problem</h3><ul><li>Gleason 6 is often presented as a low-risk cancer, but the argument here is more radical: it is not truly cancer or even a low-risk cancer.</li><li>It is labeled “cancer,” yet it lacks the hallmarks of cancer because <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4708232/">it lacks</a> the biological mechanisms to behave as cancerous.</li><li>Men diagnosed with it are often driven into a psychological and therapeutic trap by a label that overstates danger. There’s no verifiable evidence it causes death.</li><li>They are then called survivors, not because they escaped a proven killer, but because they endured risky treatment.</li><li>In that sense, many are not survivors of cancer, but survivors of the treatment industry built around it.</li></ul><h3>The Truly Dangerous Cancers Still Lack Proven Answers</h3><ul><li>The most meaningful threat comes from the <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4508854/">10–15%</a> of high-grade prostate cancers.</li><li>These aggressive cancers are responsible for most if not all of the 35,000 or so U.S. deaths annually.</li><li>Some men with advanced disease live for many years, showing that biology is more complicated than the awareness narrative suggests.</li><li>The harsh truth is that current medicine has not clearly solved the problem of aggressive high-grade prostate cancer as treated and untreated patients have similar survival rates.</li><li>Instead of admitting that limitation, the system oversells screening and overtreats the less dangerous disease.</li></ul><h3>Screening Only Makes Sense If Treatment Actually Saves Lives</h3><ul><li>A screening program is only rational if early detection leads to an intervention that clearly improves survival or meaningful outcomes.</li><li>If treatment does not save significant numbers of lives, then the entire logic of awareness and screening collapses.</li><li>Detecting more disease becomes little more than finding more pathology to label, monitor, and treat.</li><li>It becomes a conveyor belt into anxiety, complications, and cost.</li><li>Screening without proven benefit is not prevention. It is an expansion of the patient pool.</li></ul><h3>The Treatment Record Does Not Match the Hype</h3><ul><li>Major treatment studies are repeatedly invoked to justify aggressive intervention, yet long-term outcomes show little meaningful survival difference between treated and untreated groups.</li><li>Patients who avoid treatment usually avoid the severe complications that commonly follow intervention.</li><li>The wide range of available treatments for so-called localized prostate cancer is itself a warning sign.</li><li>When medicine truly knows what works, it converges. When it does not, it multiplies options and arguments.</li><li>The abundance of prostate cancer treatment choices reflects uncertainty, not mastery.</li></ul><h3>Standard of Care Is Not the Same as Proven Care</h3><ul><li>Patients hear the phrase “standard of care” and assume it means safe, effective, and life-saving.</li><li>It does not.</li><li>Standard of care is largely a legal and professional concept about what is commonly done, not a guarantee of true benefit.</li><li>A treatment can become standard through repetition, training, consensus, and institutional habit long before it is validated by strong reproducible evidence.</li><li>In prostate cancer, “standard of care” has too often functioned as a shield for dogma rather than a badge of scientific truth.</li></ul><h3>Prostate Cancer Surgery Rose on Belief, Not Proof</h3><ul><li>Open prostate surgery became mainstream not because it was first proven safe, beneficial, and life-saving through rigorous reproducible studies.</li><li>It spread because physicians believed it should work, then accepted it, then normalized it, then called it standard.</li><li>Robotic surgery followed the same pattern, wrapped in the glamour of technology and advancement.</li><li>Yet technological sophistication is not the same as clinical superiority.</li><li>A shiny machine can make an unproven operation look modern without making it more truthful.</li></ul><h3>Many “Localized” Cancer Treatments Are Not Even Reliably Curative</h3><ul><li>Surgical margins can be positive, meaning residual cancer remains after surgery.</li><li>Radiation and focal therapies are also followed by rising PSAs or biochemical recurrences in a substantial number of patients.</li><li>Men then move from one layer of treatment to the next, often ending with hormone suppression and its additional burdens.</li><li>The public is sold the idea of cure, yet many treatments fail even on their own terms.</li><li>This is not the clean rescue story awareness campaigns promise.</li></ul><h3>The Complications Are Not Rare — They Are Central</h3><ul><li>Urinary incontinence, erectile dysfunction, urgency, pain, bladder, bowel and penile injury are not side notes to prostate cancer treatment.</li><li>They are among the defining outcomes.</li><li>These complications are so common that entire preoperative and postoperative counseling systems were built to manage patient expectations.</li><li>The rise of prosthetic devices and implants for limp and leaking complications says the quiet part out loud.</li><li>A treatment culture does not build industries around complication management unless those complications are frequent and devastating.</li></ul><h3>Men Are Often Not Truly Informed</h3><ul><li>Shared decision-making is presented as proof of ethical practice.</li><li>But a decision is not truly informed if the lack of survival benefit is minimized, the risks are softened, and fear is amplified.</li><li>Many men consent under emotional duress created by the cancer label and reinforced by physician authority.</li><li>Only later do they realize the complications were more likely, more severe, and more permanent than they were led to believe.</li><li>Consent obtained through incomplete truth is not meaningful consent.</li></ul><h3>Quality of Life Is Often Sacrificed for Unproven Gain</h3><ul><li>Prostate cancer treatment can permanently affect continence, sexuality, body image, intimacy, confidence, and relationships.</li><li>Wives and partners often suffer alongside the patient.</li><li>Treatment <a href="https://pubmed.ncbi.nlm.nih.gov/36870852/">regret</a> is common because men realize too late that the promised benefit was uncertain while the harm was real.</li><li>Some men appear to carry a trauma-like burden after treatment, finding it difficult to speak openly about what they lost.</li><li>This is not just a medical problem. It is a human and relationship disaster.</li></ul><h3>Active Surveillance Exposes the Contradiction</h3><ul><li>If low-risk prostate cancers are commonly indolent, why call them dangerous enough to track through surveillance like a ticking bomb?</li><li>If treatments fail to save significant numbers of lives, why recommend treatment when surveillance later shows “progression” or “upgrading”?</li><li>Active surveillance may reduce overtreatment, but it also exposes a core contradiction in the system.</li><li>It acknowledges that much detected disease does not require immediate action.</li><li>Yet it keeps the patient psychologically captive inside the same cancer narrative. About 30–50% transition to active treatment within the first 5 years.</li></ul><h3>The PSA Test Became Powerful Without Becoming Reliable</h3><ul><li>Urologists continue to promote PSA (prostate specific antigen) as a key screening tool even though it is associated with about a 78% false positive rate and is neither specific for cancer or the prostate.</li><li>Elevated PSA can reflect benign enlargement, inflammation, infection, or other non-cancerous conditions.</li><li>False positives, false negatives, and arbitrary thresholds — the so-called normal level of 0–4 ng/ml was made up — undermine the test’s credibility as a population screening tool.</li><li>Yet it retains the prestige of standard practice because medicine often protects its rituals long after the evidence weakens.</li><li>The PSA test survives not because it is strong, but because the system around it is entrenched.</li></ul><h3>A Bad Test Starts a Dangerous Cascade</h3><ul><li>An abnormal PSA or suspicious prostate exam rarely ends with reassurance.</li><li>It leads to MRI, biopsy, repeat testing, pathology review, surveillance, and often treatment.</li><li>Each step is framed as prudent because the previous step generated uncertainty.</li><li>The patient moves deeper into the machine even though each stage carries its own unreliability and risks.</li><li>Screening is not one test. It is the front door to an entire cascade of interventions.</li></ul><h3>MRI Is Not the Crystal Ball It Is Sold To Be</h3><ul><li>Prostate MRI is frequently portrayed as a game-changing precision tool.</li><li>But it has observer variability, detection limits, and meaningful false-negative rates.</li><li>Smaller lesions may be missed, and some clinically significant cancers may be MRI-invisible.</li><li>The PI-RADS classification system itself requires interpretation and judgment, which means error is built into the process.</li><li>A sophisticated image is still only as good as its limits and the people reading it.</li></ul><h3>Needle Biopsy Samples Almost None of the Prostate</h3><ul><li>The standard needle biopsy takes tiny cores from a large gland.</li><li>Measured against the whole prostate, only a minuscule fraction is actually sampled — typically, only about <a href="https://www.medscape.com/viewarticle/945928#vp_2">0.1%</a> of the prostate is sampled.</li><li>That means the status of the overwhelming majority of the prostate remains unknown.</li><li>Multifocal disease, variable grade, and uneven distribution make sampling error enormous.</li><li>Yet a tiny sample is often treated as though it represents the biological truth of the entire organ.</li></ul><h3>“Upgrading” Commonly Reflects Missed Disease, Not Biological Transformation</h3><ul><li>A later biopsy that shows a worse grade is often interpreted as proof that the original cancer upgraded or progressed.</li><li>But the other possibility is far more glaring: the first biopsy sampling only a tiny fraction of tissue simply missed the higher-grade area.</li><li>Massive sampling error makes that explanation entirely plausible.</li><li>Slow tumor growth also undermines dramatic claims of rapid transformation in many cases. Most prostate cancers grow very sluggishly.</li><li>The system often calls missed disease “progression” and then uses that narrative to justify more aggressive treatment.</li></ul><h3>Some Aggressive Cancers Escape Detection Anyway</h3><ul><li>The cruel irony is that the cancers most worth finding early may still evade the system.</li><li>Some high-grade prostate cancers may be metastatic or biologically advanced when barely visible within the gland.</li><li>Some high-grade cancers produce <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.29691">little or no PSA</a> and evade blood-based screening.</li><li>Disseminated cancer cells may already be in the bone marrow long before imaging finds anything convincing.</li><li>So the system overdetects the harmless and still misses part of the truly dangerous.</li></ul><h3>Pathology Is Not Infallible Either</h3><ul><li>After biopsy, men are told the pathology report reveals the truth.</li><li>But prostate pathology is itself subjective, complex, and vulnerable to inter-observer variability.</li><li>Different pathologists may score the same tissue differently.</li><li>Overcalls, undercalls, and misclassification can profoundly alter management.</li><li>That is why second opinions are not optional luxuries. They are safeguards against a flawed interpretive system.</li></ul><h3>Overtreatment Is the Rule, Not the Exception</h3><ul><li>Once prostate cancer is diagnosed, men are psychologically steered toward intervention.</li><li>Fear of losing a window of cure overwhelms sober reflection about whether treatment will actually help.</li><li>Physicians know the emotional force of the diagnosis and how often men respond by demanding action.</li><li>The result is a system in which many men with disease they would outlive are treated as though they were facing immediate mortal danger.</li><li>Overtreatment is not an accidental excess. It is built into the way the narrative is delivered.</li></ul><h3>Dogma Keeps the Prostate Cancer Awareness Machine Running</h3><ul><li>Medicine often clings to practices long after the evidence stops justifying them.</li><li>Training, tradition, habit, anecdote, and hierarchy can overpower data.</li><li>Physicians may trust personal experience over statistics, old routines over uncomfortable uncertainty, and consensus over criticism.</li><li>Surrogate outcomes and recycled teaching can harden into pseudo-truths.</li><li>Once a system convinces itself it is helping, it becomes very hard to persuade it that it may actually be harming.</li></ul><h3>Why Ineffective Medical Practices Persist</h3><ul><li>Physicians are not immune to confirmation bias, anchoring bias, and the need to believe their work is valuable.</li><li>Patients often want action, not uncertainty.</li><li>Lawyers, institutions, guidelines, and reputational pressures favor established routines.</li><li>Industry benefits from continued testing and treatment.</li><li>Together these forces create a culture where low-value care survives by momentum even when evidence increasingly says stop.</li></ul><h3>The Market Rewards the Narrative</h3><ul><li>The prostate cancer industry is not a small side business.</li><li>It is a large and growing market involving testing, imaging, devices, surgery, drugs, surveillance, complications, and repeat interventions.</li><li>Every anxious patient, every abnormal PSA, every biopsy, every treatment, and every complication generates revenue.</li><li>That financial reality does not automatically prove fraud, but it does explain why weak evidence rarely stops the machine.</li><li>When medicine and money point in the same direction, skepticism becomes inconvenient.</li></ul><h3>The Prostate Cancer Industry Has Helped Distort the Story</h3><ul><li>PSA manufacturers and robotic surgery companies benefit from a public that believes screening and intervention are unquestionably beneficial.</li><li>Marketing highlights innovation, precision, and hope while pushing risks and limitations into the background.</li><li>Hospitals and device makers often sell technological images as though it were clinical proof.</li><li>Small advantages in process are spotlighted while long-term outcomes remain muddy.</li><li>That is how commercial storytelling replaces clinical honesty.</li></ul><h3>Medicine Has Done This Many Times Before</h3><ul><li>The history of medicine is filled with treatments once celebrated as cutting-edge, courageous, and standard, only to be later exposed as harmful, unnecessary, or ineffective.</li><li>Radical mastectomy is one of the clearest examples of destructive dogma masquerading as scientific certainty.</li><li>Many other once-routine interventions such as lobotomy for psychiatric disorders were abandoned only after evidence finally outweighed authority.</li><li>The lesson is brutal but simple: standard practice can be wrong for years.</li><li>Prostate cancer will one day be remembered as another chapter in that long history of overconfident but wrong medical care.</li></ul><h3>Early Critics Who Exposed the Cracks in the Prostate Cancer Story</h3><ul><li>Long before mainstream medicine began admitting even limited harms from prostate cancer screening, several outspoken critics challenged the prostate cancer narrative head-on. Including the United States Preventive Services Task Force (USPSTF) who determined that the potential harms of screening and treatment of screen-detected prostate cancers outweighed the perceived benefits.</li><li>Dr. Anthony Horan, a urologist, argued in <em>The Big Scare</em> and later <em>The Rise and Fall of the Prostate Cancer Scam</em> that modern prostate cancer management had become a profit-driven system of overdiagnosis and unnecessary treatment.</li><li>Dr. Richard Ablin, who discovered PSA, later condemned its use as a mass screening tool and, with Ronald Piana in <em>The Great Prostate Hoax</em>, exposed PSA screening as a deeply misused test that fueled a public health disaster.</li><li>Dr. Otis W. Brawley, former Chief Medical Officer of the American Cancer Society, repeatedly warned that routine PSA screening was overpromoted, imprecise, and often caused more harm than good through unnecessary biopsies, anxiety, and overtreatment.</li><li>Dr. Laurence Klotz challenged the labeling of Gleason 6 as cancer, arguing that its biology did not justify the fear, aggressive treatment, and false sense of danger attached to the cancer label.</li></ul><h3>When Institutions Admit Only a Little, They Still Reveal a Lot</h3><ul><li>Even establishment bodies have acknowledged that the harms of screening and treatment can outweigh the benefits.</li><li>That alone should have triggered a far more serious reckoning than it did.</li><li>Instead, any effort to restrain screening often met backlash from those whose identities, incomes, and institutions were invested in the old story.</li><li>The result is a half-admission wrapped in continued promotion.</li><li>Medicine concedes just enough to sound cautious while keeping the overall apparatus intact.</li></ul><h3>This Becomes Patient Mistreatment, Not Merely Medical Debate</h3><ul><li>When physicians know a test is unreliable, know treatment benefits are misleading, know complications are common, and still promote the system as though it were clearly lifesaving, the problem becomes ethical.</li><li>This is no longer an abstract scientific disagreement.</li><li>It becomes a matter of deceiving vulnerable patients into harm.</li><li>It also squanders enormous healthcare resources on programs that fail to deliver proportionate benefit.</li><li>A public health system that funds harm and calls it care is in moral trouble.</li></ul><h3>“Standard of Care” Cannot Excuse What Doctors Already Know</h3><ul><li>The usual defense is that physicians followed accepted practice.</li><li>But that position is indefensible when physicians have developed strategies to manage patient expectations because treatments are associated with many potentially life-altering complications and lack significant life-saving ability.</li><li>Once clinicians know the evidence does not support the promise being sold, repeating the practice becomes harder to justify ethically.</li><li>Accepted custom cannot forever excuse known weakness in benefit and known severity of harm.</li><li>There comes a point where continuing the same conduct looks less like care and more like institutional self-protection.</li></ul><h3>Governments and Businesses Should Stop Sponsoring the Illusion</h3><ul><li>Corporate sponsors and government partners helped normalize prostate cancer awareness and screening as unquestionable goods.</li><li>But institutions that support these campaigns must confront the same fundamental question physicians avoided.</li><li>Where is the irrefutable and reproducible evidence that these programs are safe, beneficial, and life-saving?</li><li>Public endorsement without rigorous proof turns authority into a megaphone for misinformation.</li><li>If the evidence is weak, support should be withdrawn rather than endlessly recycled.</li></ul><h3>What Men Actually Need</h3><ul><li>Men do not need more slogans, more panic, more ritualized screening, or more pressure to act before they understand the facts.</li><li>They need honest counseling.</li><li>They need full disclosure about uncertainty, overdiagnosis, overtreatment, false positives, false negatives, and life-altering complications.</li><li>They need to know that many prostate cancers are commonly outlived and that high-grade disease still lacks clearly proven life-saving solutions.</li><li>Most of all, they need medicine to stop confusing activity with benefits.</li></ul><h3>What Real Progress Would Look Like</h3><ul><li>Real progress would mean developing tests that can reliably identify the truly dangerous cancers.</li><li>It would mean treatments for high-grade disease that clearly demonstrate safety, benefit, and meaningful survival advantage.</li><li>It would mean abandoning the emotional manipulation of awareness culture and replacing it with medical honesty.</li><li>It would mean preventing harm instead of mass-producing patients.</li><li>And it would mean finally asking for every recommendation: where is the irrefutable and reproducible evidence that this truly helps?</li></ul><h3>The Bottom Line — A Narrative Built on Fear, Profit, and Evasion</h3><ul><li>Prostate cancer testing and treatments stand among the most complication-heavy interventions in modern medicine, leaving countless men with <a href="https://www.sciencedirect.com/science/article/pii/S0302283815001943">life-altering</a> consequences — yet instead of confronting this reality, the system hides behind “shared decision-making” and “expectation management” programs that don’t inform patients, but condition them to greet harm as acceptable, exposing the false narrative at the core of prostate cancer care.</li><li>The many “standard” procedures are not even good cancer treatments as some <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4220383/">11–48%</a> of surgical cases (open or robotic) are associated with positive margins or residual cancer while some <a href="https://www.nature.com/articles/s41391-023-00712-z">20–50%</a> of treated patients will have a rising PSA (biochemical recurrence) within 10 years of treatment — meaning they are not cured.</li><li>PSA testing fails to save significant numbers of lives, according to <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0810696">urologists’ own</a> studies, a <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2808648/"><em>JAMA</em></a> study, and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3069219/">long-term trials</a> spanning about 20 years.</li><li>Prostate cancer treatments fail to show meaningful survival benefit at <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1113162">roughly 12</a>, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214122?query=featured_home">15,</a> and even <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1615869">20 years</a> in major studies. Testosterone suppression may extend life a few years in those with metastatic disease.</li><li>The current prostate cancer awareness and screening culture is marketed as compassion — but in reality, it operates as a medical lie: a prescription that weaponizes fear to drive diagnosis, funnels patients into testing and treatments of unproven benefit, and converts anxiety into complications and revenue. A system of junk science, health dangers and health robbery that demands a complete re-examination grounded in truth — not tradition. We need new tests and treatments that actually work.</li></ul><p>Required Reading</p><p><a href="https://www.amazon.com/Rise-Fall-Prostate-Cancer-Scam/dp/1641119853/">The Rise and Fall of the Prostate Cancer Scam</a> by A. Horan M.D.</p><p><a href="https://www.amazon.com/Great-Prostate-Hoax-Medicine-Hijacked/dp/1137278749/">The Great Prostate Hoax</a> by R. Ablin and R. Piana</p><p><a href="https://www.linkedin.com/pulse/psa-testing-prostate-cancer-scam-bert-vorstman-md-rtl1e/?trackingId=tPacgq0sTWqIuy3iRdrS5Q%3D%3D">The PSA Testing For Prostate Cancer Scam</a></p><p><a href="https://www.linkedin.com/pulse/most-prostate-cancers-dont-kill-fear-driven-narrative-vorstman-md-dnjde/?trackingId=ixHDf4ocSO6baYV79yr9rQ%3D%3D">Most Prostate Cancers Don’t Kill — But the Fear-Driven Narrative Does</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-treatment-fear-fraud-health-robbery-bert-vorstman-md-vv5le/?trackingId=Xx%2FksPgBTJiAyVHpwv4Gsw%3D%3D">Prostate Cancer Treatment; Fear, Fraud and Health Robbery</a></p><p><a href="https://www.linkedin.com/pulse/prostate-cancer-narrative-false-bert-vorstman-md-zegse/?trackingId=l8P%2BxqpvQD%2BO3TwFaX9L7g%3D%3D">THE PROSTATE CANCER NARRATIVE IS FALSE</a></p><p>Discover the HEALTHdrum YouTube channel where medical fact is separated from medical fiction.</p><p><em>Originally published at </em><a href="https://www.linkedin.com/pulse/great-prostate-cancer-awareness-screening-scam-bert-vorstman-md-jeeme/"><em>https://www.linkedin.com</em></a><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5a1e0b91f305" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>